Ex-vivo lung perfusion : a platform for assessment and reconditioning of human donor lungs by Morrison, Movern Isabel
 Ex-vivo Lung Perfusion: a platform 
for assessment and reconditioning 
of human donor lungs. 
 
Dr Morvern Isabel Morrison 
 
Submitted as a Thesis for 
Degree of Doctor of Medicine 
November 2018 
 
Institute of Cellular Medicine 
Faculty of Medical Sciences, Newcastle University 
Supervisors: Professor Andrew Fisher, Professor John 
Dark and Dr William E. Scott III 
  
ii 
 
 
  
iii 
 
Abstract 
Ex-vivo Lung Perfusion: a platform for assessment and 
reconditioning of human donor lungs. 
Background: Although lung transplantation is regarded as an effective therapy for 
patients with end-stage lung disease, the demand for donor organs exceeds the 
overall donor organ supply. Ex-vivo lung perfusion (EVLP) has emerged as a 
technique to objectively assess and recondition donor lungs that have been deemed 
unsuitable for transplantation. The cellular and molecular events occurring during 
EVLP have not been well characterised, and how these processes differ between 
lungs that are deemed useable compared with those that are discarded is unknown.  
The aims of this project were three-fold. Firstly, to identify potential predictive 
biomarkers during EVLP that could distinguish donor lungs that can be 
reconditioned and predict clinical outcomes. Secondly, to investigate the differences 
in the inflammatory profiles of donor lungs following donation after brain death 
(DBD) versus donation after circulatory death (DCD). Finally, to assess EVLP as a 
therapeutic platform by examining the physiological and immunological changes in 
donor lungs undergoing EVLP supplemented with the known vasodilatory agent and 
phosphodiesterase-5 inhibitor, sildenafil.  
Methods: In retrospective studies of the DEVELOP-UK cohort and prospective 
studies using a research EVLP model, markers of inflammation, tissue injury and 
angiogenesis in perfusate, bronchoalveolar lavage (BAL), and lung tissue were 
examined. Laboratory techniques including ELISA, MSD and immunohistochemistry 
were used.  
Results: RNA-sequencing demonstrated an unbiased profile of the transcriptome of 
human donor lungs prior to, and following EVLP, comparing changes in gene 
expression between lungs deemed suitable for transplantation, and those discarded 
on the basis of standard physiological parameters. During EVLP, we observed an 
increase in a number of immune pathway genes.   
In the DEVELOP-UK sample cohort significant differences were detected in the 
inflammatory profiles prior to commencing EVLP between DBD and DCD donor 
lungs. DBD donor lungs were reported to have significantly higher concentrations of 
lung tissue C-reactive protein (CRP), IL-12p70, IL-4 and IL-6 compared with DCD 
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donor lungs. Conversely, the levels of acute phase cytokines, IL-1β and IL-1α, were 
significantly higher in the perfusate from DCD lungs during EVLP.  
EVLP was shown to be an effective and reproducible therapeutic platform which 
could allow for the testing of agents with the potential for improving the function of 
lungs turned down for transplantation. Sildenafil was hypothesised to improve 
pulmonary physiology during EVLP and lead to improved oxygenation and 
pulmonary vascular homeostasis, however this did not occur. Sildenafil did not have 
any significant effects on the physiology and immune profile of human donor lungs 
during EVLP.  
Discussion: In order for EVLP is to be effectively utilised in clinical practice as a 
platform for the assessment, reconditioning and potential treatment of donor lungs, 
an increased understanding of the cellular and molecular events occurring is 
required. In this study, we aimed to address this knowledge gap by performing an 
unbiased analysis of the lung transcriptome prior to and following EVLP. RNA-
sequencing can be used to study the pro-inflammatory changes within the lung 
transcriptome during EVLP, with subsequent correlation to potential protein 
biomarkers in perfusate. We reported significant differences in the inflammatory 
profiles of DBD versus DCD lungs. Finally, administration of sildenafil into the 
vascular compartment of the EVLP circuit failed to produce the hypothesised 
beneficial effects in human donor lung physiology and function.   
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Chapter 1. Introduction 
 
Clinical Lung Transplantation  
The History of lung transplantation 
Organ transplantation was one of the most significant medical achievements of the 
twentieth century and spans the fields of science, medicine, surgery, ethics, and law. 
Dr James Hardy reported the first successful human lung transplant, in Mississippi on 
the 11th June 1963; however, the patient died from kidney failure only eighteen days 
postoperatively[1]. The immunosuppressive regimen consisted of azathioprine, 
prednisolone, and cobalt radiation to the mediastinum and thymus.  Notably, 
cyclosporine and tacrolimus, which are the cornerstones of immunosuppression in 
modern transplantation, had not yet been discovered. The first real survivor during this 
early era of lung transplantation was a patient of Fritz Derom, in Belgium[2].This patient 
survived ten and a half months but, unfortunately, was the only patient to benefit from 
lung transplantation prior to 1980. Inadequate immunosuppression and problems with 
the bronchial anastomosis were the primary reasons for poor outcomes in the early 
cases of lung transplantation. In 1976, Jean Francoise Borel discovered cyclosporin, 
which changed the history of transplantation forever[3]. The significant improvements 
in patient survival following liver and kidney transplantation[4] due to cyclosporin led to 
a renewed interest in cardiothoracic transplantation. Bruce Reitz performed the first 
successful heart and lung transplantation in 1981[5] and research done by Joel 
Cooper's group in Toronto showed that corticosteroid use was a significant factor in 
causing the dehiscence of the bronchial anastomosis. In 1983 cyclosporin became a 
clinically approved therapy to prevent graft rejection in transplantation and 
subsequently corticosteroid use could be reduced, leading to improved bronchial 
anastomosis. In 1986, Cooper reported the first successful single-lung transplantations 
for two patients with pulmonary fibrosis[6, 7]. His team went on to perform successful 
double-lung transplants, first with an en-bloc technique, then with a bilateral-sequential 
transplantation technique which improved airway healing and had the additional benefit 
of avoiding cardiopulmonary bypass; if desired. This technique remains mostly in use 
to this day. 
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The lung transplant recipient 
Lung transplantation has evolved into a safe and effective treatment of severe 
progressive end-stage lung disease, where all medical and surgical therapies have 
been exhausted. The lung transplant waiting list contains potential recipients with a 
diverse range of lung pathologies[8]. In the United Kingdom (UK), between 1 April 2016 
and 31 March 2017, 56% of patients were male and the median age was 52 years. 
The indications for lung transplantation can be broadly separated into the following 
main categories of end-stage lung diseases: obstructive lung disease, septic lung 
disease, fibrotic lung disease, and vascular lung disease. Of these categories, chronic 
obstructive pulmonary disease (COPD), cystic fibrosis(CF), fibrosing lung disease, and 
primary pulmonary arterial hypertension (IPAH) make up the most common indication 
in each category, respectively (Table 1.1).  
Indication Percentage of all recipient diagnoses 
(%) 
Chronic obstructive pulmonary disease 
(COPD)/ emphysema  
26 
Fibrosing lung disease 26 
Cystic fibrosis (CF) and bronchiectasis 28 
Idiopathic pulmonary arterial 
hypertension (IPAH)  
3 
Other  17 
Table 1.1 Indications for lung transplantation 
Table shows the common indications for lung transplantation and the corresponding 
percentages. Adapted from NHS Blood and Transplant Cardiothoracic Report 
2016/2017[9].  
The lung transplantation procedure carries important risks to the often frail transplant 
recipient with an approximate 10% 90-day mortality risk in the UK[10]. The fatal 
complications that can occur post lung transplantation vary depending on the time 
since the transplant procedure. Whereas 30-day mortality is generally related to 
surgical issues, donor lung preservation, and primary graft dysfunction (PGD): 
infectious causes, malignancy, and bronchiolitis obliterans syndrome (BOS), a type of 
chronic rejection, predominate after the early post-transplant period. The appropriate 
selection of lung transplant recipients is an important determinant of outcomes and the 
selection process for choosing patients to go onto the waiting list is, therefore, strict[11]. 
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To address this The Pulmonary Council of the International Society for Heart and Lung 
Transplantation (ISHLT) published the Third Edition of the Consensus Report for the 
Selection of Lung Transplant Candidates[12]. The respiratory physician has a difficult 
decision to make in listing a patient on the active lung transplant waiting list. It is a 
decision that must take into account several factors including timing, treatments given 
to date, co-morbidities, frailty and the risk of surgery. By listing a patient for a lung 
transplant, both the patient and clinician recognise the limited life expectancy and poor 
quality of life associated without receiving a transplant. Patients, who are wait-listed for 
lung transplantation are at significant risk of morbidity and mortality. On the lung 
transplant waiting list, there is a 12% 1-year mortality, rising to 17 % after 3-years. On 
31st March 2017, there were 360 patients on the active UK lung transplant waiting list 
and 18 on the heart-lung list, a 32% increase since 2008[13]. Despite this, the number 
of lung or heart-lung transplants carried out between 2016 and 2017 however, fell by 
5% to 178. The national median waiting time on the lung transplant waiting list is 255 
days, and unfortunately, patients are often removed from the waiting list due to being 
too unwell for transplantation, Figure 1.1.  
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Figure 1.1  The UK adult lung transplant waiting list 
Adapted from the NHS-BT Annual Report for Cardiothoracic Activity 2016/2017. This 
bar chart shows the percentage of patients transplanted (dark blue) or still waiting 
(light blue) six months, one year, two years and three years after joining the non-
urgent lung list, respectively. It also shows the percentage of patients removed from 
the transplant list (white) and those that died (grey) whilst on the transplant list. 
Within six months of listing, 39% of lung patients had been transplanted and 12% 
had died. Three years after listing 65% have been transplanted and 21% had died. 
The patients removed from these lists may also subsequently have died[13]. 
 
Utilisation of lung from organ donors 
The number of lung transplantations that can be performed is directly related to the 
number of donor lungs available for transplantation, and a shortage of donor lungs 
restricts this. There were 1,574 actual deceased organ donors in 2017-2018, but not 
all organs from these donors were offered for transplantation. There were 955 donors 
after brain death (DBD) and 619 donors after circulatory death (DCD). Compared 
with other solid organs, lungs have a very poor conversion rate from potential donors, 
to lungs being offered, to lungs transplanted. Although a shortage of multi-organ 
donors contributes, a central concern in cardiothoracic transplantation is the high 
susceptibility of donor lungs to injury and dysfunction during the time of the donors’ 
demise and organ procurement. Many potential donor lungs are deemed unsuitable 
and excluded from use by the clinical selection criteria. During the 2017/2018 period, 
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lungs were offered for transplant in only 56.5% of DBD donors. In 20 % of donors, 
their lungs were deemed suitable for use in clinical transplantation, and subsequently 
retrieved; and only 16% transplanted, Figure 1.2[13]. In DCD donors, which make up 
~40% of all donors in the UK, only 6% result in transplantation.  Despite consent 
being given from family members and next of kin, a large number of donor lungs are 
not used for transplant.  
 
Figure 1.2 Donation and transplantation rates of organs from DBD organ 
donors in the UK 
Adapted from the NHS-BT Report “The National Organ Retrieval Service and Usage 
of Organs” 2017/2018[14]. Line graphs of the pathway for all donor organs through to 
transplantation.  The charts start at 100% for each organ, representing all organs 
from the 955 DBD and 619 DCD donors.  The proportion of these organs where any 
national donor age criteria are met is then shown, followed by the proportion with 
consent, the proportion offered, the proportion retrieved and finally the proportion 
transplanted. Comparisons can be seen between kidneys (red), livers (green), 
pancreas (blue), bowel (grey), heart (purple) and lung (pink).  Transplantation rates 
for kidneys and livers are generally high, while for lungs, even after allowing for the 
agreed age criteria, the rates are generally low.  
National publicity campaigns have yet to show any striking increase in the rates of 
organ donation and other strategies are needed to increase the number of lung 
transplantations being carried out. There have been various implementations and 
changes in the transplant culture towards expanding the lung donor pool; which 
include extending the donor criteria and using DCD donors[15, 16]. The number of 
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transplants from DBD donors has generally increased since 2007 from 111 to 146 in 
2015/2016, while the number of transplants from DCD donors has substantially 
increased from only 3 in 2006 to 33 in 2015/2016[9]. Despite increasing numbers of 
DCD donors since 2008, this resource has failed to make a significant impact on the 
overall numbers of lung donors; highlighting that further strategies to increase the 
lung donor pool are needed. 
Selection criteria for Donation – The “Ideal Donor”  
Currently, less than 20% of the DBD lungs that are offered in the UK are actually 
transplanted, while 80% of the remaining donor lungs are not accepted by the 
transplant programs primarily due to being deemed unsuitable before retrieval[9]. It is 
therefore vital to assess the way in which potential donor lungs are being evaluated 
for their function and suitability for transplantation[17]. In the UK, lungs and other 
organs intended for transplantation, are currently evaluated subjectively ‘by a trained 
eye’ alongside selection criteria, which have been shown to be poor discriminators of 
injury and infection. When donor lungs are offered to an institution, blood samples 
are obtained to check the blood group and to minimize the risk of donor-transmitted 
diseases. The size of the donor is then considered and a potential recipient is chosen 
based upon size and blood group.  A chest x-ray (CXR) is taken to exclude gross 
parenchymal or pleural abnormalities, and bronchoscopy is performed to exclude 
gross infection or anatomical abnormalities.  Finally, the gas exchange capacity of 
the donor lungs is assessed with an oxygen challenge.  At retrieval, the surgeon 
performs a gross physical evaluation by macroscopic observation and palpation to 
assess lung compliance and oedema[18].  Palpation is also used to exclude intrinsic 
lung disease, areas of contusion, pneumonic infiltrates, or nodules.  Observation of 
the ventilated lungs during deflation is used to assess pulmonary compliance. This 
crude method leads to the unavoidable exclusion of potentially useable lungs in the 
name of safety-related conservatism. The majority of organ donors arise from 
patients who have suffered severe brain injury[19]. Multi-organ donors may become 
brain dead as a result of any number of causes; head trauma, cerebrovascular 
accidents, including spontaneous intracerebral bleeding and thrombosis, anoxic, 
metabolic or toxic brain injury. Lungs from brain-dead donors are fragile and more 
sensitive to traumatic situations compared with other organs. Lungs may get injured 
in the hours leading to and after brain death resulting from direct trauma, 
resuscitation manoeuvres, neurogenic oedema, aspiration of blood or gastric content, 
ventilator-associated trauma and pneumonia, making them unsuitable for 
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transplantation. Utilising donor lungs which do not completely satisfy the criteria is an 
approach that could potentially expand the donor lung pool.  
The current International Society for Heart and Lung Transplantation (ISHLT) criteria 
outlining an ideal donor aims to establish safe, but conservative, clinical lung 
transplantation[20]. The ideal lung donor is young, previously healthy, non-smoking, 
and without impairment of lung function in the period preceding donation, Table 1.2. 
ISHLT Criteria for Lung Acceptance 
 Age <55 years 
 ABO compatibility  
 Clear chest radiograph 
 PaO2>300 on FiO2 = 1.0, PEEP 5 cm H20 
 Tobacco history <20 pack-years 
 Absence of chest trauma 
 No evidence of aspiration/sepsis 
 No prior cardiopulmonary surgery 
 Sputum gram stain – absence of organisms 
 Absence of purulent secretions at bronchoscopy 
Table 1.2 ISHLT Criteria for Lung Acceptance 
The “Ideal” Lung Donor according to ISHLT guidelines. PaO2 denotes partial 
pressure of oxygen, FiO2 fraction of inspired oxygen, PEEP peak end-expiratory 
pressure. Adapted from Orens et al.[11] 
 
The ISHLT recommended, that one must consider the individual donor to have 
several factors including age, graft ischaemic time, blood type ABO compatibility, 
sex, organ size matching, cause of death, duration of mechanical ventilation, 
radiographic findings, presence of microbial organisms, arterial blood gases, smoking 
exposure, and donor diagnoses of malignancy that may affect post-transplant lung 
function. These factors should not be viewed in isolation but rather as interacting 
variables on a spectrum of donor lung acceptability, from the ideal donor over the 
extended donor to the unusable donor. What had previously been regarded as the 
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“ideal lung donor” by the ISHLT, no longer reflects what is considered acceptable in 
most centres. Several studies in the mid to late 1990s retrospectively assessed the 
outcomes and early graft function in recipients of non-ideal or “marginal” donor lungs 
and reported no significant difference in early graft function between the two 
groups[21-23], suggesting that a large number of potential donor lungs which are 
currently excluded; may have been successfully used in lung transplantation.  Fisher 
et al. in 2004 studied 39 consecutive potential donor lungs, 14 of which were 
accepted and 25 excluded by clinical selection criteria[24]. All were evaluated 
prospectively by clinical assessment, bronchoscopy, and bronchoalveolar lavage 
(BAL) to evaluate the discrimination of pulmonary infection and injury objectively. 
Accepted donors were significantly younger than those excluded (mean (SD) age 
36.7 (15.3) years v 49.5 (13.2) years; p=0.009) and were more likely to have suffered 
traumatic brain death (50% v 20%; p=0.07, Fisher’s exact test). They found that 
positive formal BAL cultures were more frequent in accepted donors (75%) than in 
those excluded (43%). There was no significant difference in the percentage and 
concentration of neutrophils, or the concentration of inflammatory cytokines, Tumour 
Necrosis Factor-α (TNF-α) and Interleukin-8 (IL-8) in BAL fluid between accepted and 
excluded donors. This study highlighted that the current selection criteria are poor 
discriminators of pulmonary injury and infection and ultimately lead to the exclusion 
of potentially usable donor lungs. 
 
Donors that do not meet the “ideal” criteria, also called “marginal donor lungs” or 
“non-ideal donor lungs,” are not systematically used for transplantation.  However, 
these “marginal donors” are not systematically discarded either. Van Raemdonck et 
al. published in 2009, that “marginal” donor lungs are used in 33% to 77% of cases, 
as reported in published series from the U.S., Canada and Europe[25]. This study 
demonstrates the considerable variability between transplant centres internationally 
and the need for more consensus opinion.  
 
Meers et al. reported on all consecutive deceased organ donors within the Leuven 
hospital network over a 2-year period with the reasons for lung refusals and number 
of lungs transplanted being analysed[26]. Hospital outcome including early recipient 
survival was compared between standard and extended criteria donors. Out of 283 
referrals, 164 (58%) qualified as donors of any organ. The majority (65.9%) of these 
effective donors were declined for lung donation because of CXR abnormalities 
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(20%), age >70 years (13%), poor oxygenation (10%), or aspiration (9%). Out of 56 
(34.1%) accepted lung donors, 50 transplants were performed, 23 from standard 
criteria donors versus 27 from extended criteria donors. There were no significant 
differences in hospital outcome or early survival between lung recipients from both 
donor groups. This group concluded from their study that relaxing the standard lung 
donor criteria may significantly increase the reported 15% organ yield, but the 
importance of monitoring post-transplant recipient outcome should not be 
underestimated. 
 
The burden of lungs being deemed “marginal” has been emphasised by several 
groups internationally. Cypel et al. in Toronto considers that more than 80% of donor 
lungs are potentially injured and therefore not considered suitable for 
transplantation[27].  Several reports have suggested equivalent outcomes when 
standard and marginal donors are used. Ware et al. estimated that over 41% of the 
lungs rejected for transplantation could have been used[28].     
 
The ultimate judgment as to whether a donor lung is used for transplantation is made 
on the basis of donor and recipient factors in each individual case. There is a clear 
need for the extension of the traditional donor criteria to help ease the profound 
shortage of donor lungs. However, follow-up studies are necessary to validate the 
safety and efficacy of broader acceptability criteria. If we can increase the utilisation 
of currently available potential lung donors, this will have a significant impact on the 
imbalance between transplants performed and the rate of deaths while on the waiting 
list.  
 
Mechanisms of Donor Lung Injury  
Lung function is often impaired in organ donors, even in patients with previously 
healthy lungs. Several factors may contribute to this phenomenon, such as 
mechanical ventilation, aspiration, trauma, infections, and pulmonary oedema[29]. In 
DBD donors, the pathophysiology of lung injury following brain death is multifactorial, 
Figure 1.3.  
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Figure 1.3The pathophysiology of lung Injury in brainstem death 
Schematic diagram demonstrating the multifactorial pathophysiology of lung injury 
following brainstem death. ACTH: adrenocorticotropic hormone; IL: interleukin; TNF: 
tumour necrosis factor; HR: heart rate; BP: blood pressure; SVR: systemic vascular 
resistance.  
 
Brain death results from damage to the brain stem with complete, irreversible loss of 
its function.   Donors become brain dead following a rise in intracranial pressure 
(ICP) owing most commonly to either massive intracranial haemorrhage or head 
trauma[30]. This increased pressure in the skull leads to cerebral venous 
engorgement and brain swelling, which further increases ICP.  As the pressure 
increases, the brain stem is pushed through the foramen magnum, leading to arterial 
compression and brain infarction, commonly known as coning[31].  Coning results in 
even more brain swelling and increases ICP to the point of ceasing intracranial 
circulation and brain death. The autonomic response to elevated ICP triggers 
pulmonary oedema. The underlying mechanism of neurogenic pulmonary oedema is 
not completely understood but most likely depends on: a) neurocardiac effects, 
whereby massive release of catecholamine induces direct myocyte injury and fluid 
congestion in the lungs; b) neuro-haemodynamic effects as the systemic and 
pulmonary pressures increase after brain injury; and c) increased permeability of the 
capillary-alveolar membranes, caused by the increase in blood volume in the 
pulmonary vessels[32]. 
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There is an initial phase of brain stem stimulation resulting in sympathetic discharge 
producing a ‘catecholamine storm’ and hypertensive crisis. This is followed by loss of 
vasomotor tone and neurogenic hypotension. Brain death also causes significant 
endocrine changes involving the hypothalamic-pituitary axis[33]. Adrenocorticotrophic 
hormone, cortisol, triiodothyronine, thyroxine, insulin, and vasopressin plasma levels 
decrease[34]. The catecholamine storm, endocrine and hemodynamic disturbances, 
and consequential organ hypoperfusion result in metabolic derangement[35, 36]. 
There is a shift from aerobic to anaerobic metabolism, with depletion of the energy 
stores and lactic acidosis. The release of destructive enzymes such as lipases, 
proteases, endonucleases and the generation of ROS can start at this stage; leading 
to further insult. At the same time, the immune system is activated with the 
development of a profound systemic inflammatory response. Upregulation of pro-
inflammatory cytokines is observed in most organs[37-39]. Pulmonary endothelial 
activation is key in the infiltration and activation of neutrophils into the lungs, resulting 
in local tissue injury and acute lung injury (ALI). It is partly caused by the pro-
inflammatory signals as a result of brain stem death[40]. Cytokines play a crucial role 
in this inflammatory response, brain death in rats results in the up-regulation of 
interleukin- 1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), TNF-α, and interferon γ 
(IFN-γ) in multiple organs including the lungs[37]. Korovesi et al. observed both 
pulmonary and systemic inflammation in patients who required mechanical ventilation 
for severe brain injury. Brain dead patients exhaled elevated levels of interleukin-1β 
(IL-1β), IL-6, and TNF-α compared to healthy controls, with cytokine expressions 
strongly correlated to plasma IL-8 concentrations. They also had characteristic 
changes in lung mechanics suggesting subclinical pulmonary inflammation before 
they became possible organ donors[41]. De Perrot et al. showed that IL-8 levels in 
donor lung tissue before and after transplantation increased with time following 
reperfusion and that patients who developed severe primary graft dysfunction had 
significantly higher IL-8 levels during ischemia and after reperfusion[42].  
 
Similarly, Fisher et al. studied the levels of IL-8 in bronchoalveolar lavage(BAL) fluid 
from 26 donor lungs used for transplantation and showed that a high concentration of 
IL-8 in donor BAL was correlated with severe graft dysfunction and early 
postoperative deaths[43]. Kaneda et al. further studied the role of pro-inflammatory 
cytokines by using real-time reverse transcriptase polymerase chain reaction (RT-
PCR) to study the levels of IL-6, IL-1β, IL-8,  IL-10, IFN -γ, and TNF-α in the donor 
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lung at the end of cold ischemia and found that the IL-6/IL-10 ratio was predictive of 
recipient 30-day mortality[44]. ALI itself results in microvascular endothelium 
response to local production of IL-1β or TNF-α, leading to expression of endothelial 
cell-derived E-selectins and ICAM-1 in a positive feedback manner[45]. The lung is 
acutely sensitive to the above changes[19], enabling neutrophils to bind to 
endothelial cells and migrate into the interstitium and alveolar spaces of the lung, 
where they can cause further injury through the release of ROS and proteolytic 
enzymes[45].  
 
In order to maximize the utilisation of lugs from multi-organ donors and improve 
recipient outcomes, a strategy of aggressive donor management must be 
implemented[46]. The aim should be a reduction of donor lung injury and prevention 
of its amplification. Donor management measures such as protective ventilation 
adopting optimal pressure control ventilation, physiotherapy, bronchial toilet, invasive 
monitoring, hemodynamic support, judicious fluid management, maintenance of 
adequate diuresis, and antibiotics have all been shown to achieve excellent recipient 
results with lungs previously regarded as unacceptable[47-51].  
 
Primary graft dysfunction  
Following ischaemia in the donor organ and reperfusion in the recipient, inflammatory 
and immunological injury-repair responses seem to be the key pathological 
mechanisms. Primary graft dysfunction (PGD) is the syndrome that encompasses a 
spectrum of mild to severe lung injury that occurs within the first 72 hours after lung 
transplantation. PGD is a major cause of early morbidity and mortality in lung 
transplantation and is characterised by progressive hypoxaemia and alveolar 
infiltrates on a chest radiograph. PGD has significant impact on the short and longer 
term outcomes for lung transplant patients. Ex-vivo lung perfusion is one strategy to 
improve assessment of the donor organ and has the potential to act as a platform for 
implementing interventions to reduce the risk of or prevent PGD. 
 
In 2005, the International Society for Heart and Lung Transplantation (ISHLT) 
published their standardised definition for PGD[52]. In this definition, the Pa02/Fi02 
(P/F) ratio and the presence of bilateral infiltrates on a chest radiograph consistent 
with non-cardiogenic pulmonary oedema are assessed, Table 1.3. Assessment is 
carried out at specific time points after reperfusion; within the first 6 hours (T0), post 
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24 hours (T24), 48 hours (T48) and 72 hours (T72). Ideally, the P/F ratio is measured 
on a Fi02 of 1.0 and positive end expiratory pressure (PEEP) of 5 cm H20. The 
radiographic findings of PGD are non-specific and include peri-hilar ground glass 
opacities, peri-bronchial, perivascular thickening and reticular interstitial and airspace 
opacities located in a dependant fashion. Other contributory factors that can mimic, 
modify and confound the definition and grading need to be excluded, including 
cardiogenic oedema, pneumonia, hyper-acute rejection and pulmonary venous 
anastomotic obstruction. 
PGD 
Stage 
P/F ratio 
(mmHg) 
Chest radiography Updates from 2016 
Consensus Group  
0 >300 Normal Any P/F ratio  
1 >300 Diffuse allograft 
infiltration/Pulmonary 
Oedema  
No changes 
2 200-300 Diffuse allograft 
infiltration/Pulmonary 
Oedema 
No changes 
3 <200 Diffuse allograft 
infiltration/Pulmonary 
Oedema 
 
No changes 
Table 1.3 ISHLT PGD definition and severity grading 2005 and updates from 
2016 
 
A detailed review of the pathophysiology of primary graft dysfunction can be found in 
Appendix A: Morrison MI, Pither TL, Fisher AJ. Pathophysiology and classification of 
primary graft dysfunction after lung transplantation. Journal of Thoracic Disease. 
2017;9(10):4084-4097. doi:10.21037/jtd.2017.09.09. Permission from the publishers, 
the AME Group has been granted.  My contribution to this review article was in 
literature research, discussion and writing the manuscript.  
The hallmark of PGD pathophysiology is the migration of polymorphonuclear 
neutrophils (PMNs) from the pulmonary circulation into interstitium and the airways. 
These PMNs are attracted out of the circulation by chemotactic mediators such as 
CXCL8 and damage-associated molecular patterns (DAMPs) which have been 
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released from apoptotic and necrotic lung tissue following ischaemia-reperfusion 
injury (IRI). Both HMGB1 and ATP are well-renowned DAMPs, thus IRI-mediated 
damage of the pulmonary airways serves to release these into the circulation and 
facilitate attraction of neutrophils to the lungs in the case of acute pulmonary 
diseases such as PGD. 
 
Alongside neutrophil activation and migration, activation of pulmonary endothelium is 
another very important part of the pathophysiology of PGD. This activation occurs 
through the release of pro-inflammatory cytokines TNFα and IL-1β which enables up-
regulation of adhesion molecules on the surface of the endothelium[53, 54]. E-
Selectin interacts with P- and L-Selectin on the surfaces of activated endothelial cells 
to facilitate weak binding, as the latter roll along the endothelial surface through a 
cytokine ‘gradient’ before being arrested via integrin binding. Once localised to the 
lungs, transmigration of PMNs into the interstitial space and airways is facilitated by 
up-regulation of adhesion molecules, notably ICAM-1 and PECAM-1[54]. Support for 
the significance of the models is demonstrated by the study conducted by Simms et 
al, who identified heightened CD11b/CD18 cell surface expression as being 
associated with individuals who displayed acute respiratory distress syndrome 
(ARDS)[55]. Initiation of IRI provokes endothelial cells to up-regulate various 
adhesion markers on their surface, produce cytokines and begin actively contributing 
to inflammation[56-58]. ICAM-1 and PECAM-1 have both been implicated in acute 
lung injury and inflammation in general, with these facilitating leukocyte 
transmigration from the circulation into the airways[53].  
 
The other major effect that stimulation of the endothelium causes is production of 
cytokines by these cells. Endothelial cells have been shown to directly participate in 
amplifying the inflammatory response and can produce PGD-associated cytokines. 
These are detrimental to the function of the lung, with levels of both of these 
examples having been linked with worsening outcomes of PGD in patients[59-61]. 
Activation of endothelial cells primes the environment for the secondary ‘wave’ of 
leukocyte influx into the pulmonary airways. It is this secondary phase that is 
ultimately so damaging. Whilst epithelial damage is an early hallmark of primary graft 
dysfunction evidence supports the contributory role that these cells in fact have 
towards worsening of pathology in many cases.  
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Lymphocytes are typically more involved in the latter stages of PGD development. 
Once the ‘resident’ alveolar macrophages have detected and responded to IRI within 
the lungs, they can then initiate intercellular communication with donor T 
lymphocytes. CD4+ cells mediate these effects in PGD, and to a much lesser extent 
CD8+ cells.  
 
Use of alternative donor sources- DCD vs DBD   
In the first clinical lung transplantation by Hardy[1], a DCD donor who died from 
myocardial infarction was utilised.  At that time, use of DCD donors was a necessity 
as the concept of brain death was not yet legally established.  Once brain death had 
reached the status of general acceptance in the 1970s, the majority of organs were 
retrieved from brain-dead donors with intact circulation.  In the early nineties, Egan et 
al. carried out a number of experiments in dogs which caused a resurgent interest in 
the potential use of lungs from DCD donors. His group demonstrated that lung cells 
remain viable for a certain period after circulatory arrest[15]. The lung is the sole solid 
organ that is not dependent on perfusion for aerobic metabolism but rather uses a 
mechanism of passive diffusion through the alveoli for substrate delivery. Numerous 
experimental studies continued to investigate the possibility of using lungs from 
DCDs for transplantation[62, 63]. At the First International Workshop on DCDs in 
Maastricht in the Netherlands in 1995, five types of donors were identified, so-called 
Maastricht categories, Table 1.4.  
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I Dead on arrival to hospital Uncontrolled 
II Unsuccessful 
resuscitation 
Uncontrolled 
III Awaiting cardiac arrest Controlled 
IV Cardiac arrest following 
brain death 
Controlled 
V Cardiac arrest in a 
hospital inpatient 
Uncontrolled 
Table 1.4 Maastricht categories of donation after cardiac death 
Classification of donation after cardiac death (DCD). Categories I (dead on arrival) 
and II (unsuccessful resuscitation) comprise the uncontrolled donors. Categories III 
(awaiting cardiac arrest) and IV (cardiac arrest in brain-dead donor) include the 
controlled donors. A fifth category, V, cardiac arrest in a hospital inpatient, has 
recently been added[64].  
 
Clinically, the first description of the use of lungs from DCD is from Love et al. in 1995 
(n=3). This series, using lungs from category III donors, was updated in 2003 (n=20).  
In 2001, Steen reported successful lung transplantation using a category II DCD who 
died in hospital after failed resuscitation following myocardial infarction[65].  In 2004, 
the Madrid group published results from 2 successful lung transplantations from 
uncontrolled DCDs (Category I)[66]. This series has been updated more recently 
(n=17)[67].  
 
The utilisation rates of DCD donor lungs have increased steadily over the last years 
and are comparable in early survival and lung function to standard DBD donors, as 
reported by Cypel[68]. Mason et al. compared survival after lung transplantations of 
controlled DCD versus DBD in the US using the UNOS data registry from October 
1987 to May 2007[69].  During this period, 14,939 transplants were performed, 
including 36 (4%) with DCD organs (9 single, 27 double).  Three of those died during 
the first 11 days.  The 1, 6, 12, and 24- month patient survival was 94%, 94%, 94%, 
and 87%, respectively, for DCD donors versus 92%, 84%, 78%, and 69%, 
respectively for DBD (p=0.04).  The authors concluded equivalent survival among 
DCD and DBD.  
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 More recently, in May 2012, Mason et al.  published a small retrospective single 
centre experience of DCD lung transplantation[70].  From August 2004 to July 2011, 
605 patients underwent lung transplantation at the Cleveland Clinic, Cleveland, Ohio.  
32 (4.9%) received a DCD lung transplant.  The same standard donor selection, 
procurement, and preservation protocols for DBD were applied to DCD organs.  
Survival was 97% at 30 days, 91% at 1 and 2years, and 71% at 3 and 4 years.  
Mason et al. concluded that concerns over diminished organ quality are unfounded, 
and use of DCD lungs should be expanded. A meticulously performed meta-analysis 
of five studies found no difference in short or long-term survival, between transplants 
performed with DCD or DBD donors[71]. The International Society for Heart and 
Lung Transplantation Donation After Circulatory Death Registry Report published in 
2015 demonstrated excellent survival after lung transplantation using DCD donors. 
This large study of international, multi-centre experience reported; thirty-day survival 
of 96% in the DCD group and 97% in the DBD group, one-year survival 89% in the 
DCD group and 88% in the DBD group and five-year survival of 61% in both 
groups[72]. 
 
Lung Preservation  
In the current paradigm of lung transplantation, the decision to utilise an organ for 
transplantation is made at the time of organ retrieval.  Once the decision to utilise a 
donor lung is made, the lungs must be procured from the donor at which point the 
obligate ex vivo phase begins. At the time of procurement, many strategies are 
employed in an attempt to better preserve the donor lung[18].  First, a lung protective 
strategy for ventilation is utilised during procurement to avoid further injury from 
barotrauma, and full anticoagulation of the donor (300 U Heparin/kg) is achieved to 
minimise the risk of intravascular clot formation.   
 Once the assessment of the donor is complete, aortic cross-clamp of the donor can 
commence.  This arrests the heart and organ recovery can begin.  A dose of 500 μg 
of prostaglandin E1(PGE1) is given into the pulmonary artery to lower the pulmonary 
vascular resistance by dilating the pulmonary vasculature, facilitating the subsequent 
flushing of the pulmonary vasculature.  PGE1 has also been found to downregulate 
pro-inflammatory cytokine expression which may further help to reduce PGD[73].    
 The vasculature of the lung is then flushed to cool the lung tissue and to remove 
blood from the pulmonary vasculature, further minimising the potential for clot 
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formation and allowing for the removal of inflammatory and immune cells. The use of 
an extracellular type (i.e. low potassium) solution has been found to be beneficial to 
lung preservation as opposed to the intracellular type solution used in other 
organs[74].  Dextran 40 was also found to be a key ingredient in the lung flush 
solution and serves two purposes[75].  First, it acts as an oncotic agent to help keep 
fluid within the intravascular space.  Second, it has the ability to reduce the 
aggregation of erythrocytes and thrombocytes, which preserves flow through the 
microvasculature following reperfusion, particularly in the bronchial microcirculation, 
and may play a role in reducing bronchial anastomotic complications.  Another key 
ingredient in the flush solution is glucose.  Because the lungs are stored inflated with 
oxygen, a unique situation arises during storage where the lungs are ischemic but 
not hypoxic.  Glucose helps support aerobic metabolism in the lung during 
preservation.  This flush solution is administered anterograde into the pulmonary 
artery and retrograde into each of the main pulmonary veins.    
 
 Approximately 50-60 ml/kg of perfusate total is utilised for anterograde and 
retrograde flushing.  The desired flush pressure is a balance between too high a 
pressure leading to injury of the pulmonary vasculature and too low a pressure 
leading to inhomogeneous flushing.  Use of low potassium dextran-glucose flush 
solution (LPD-glucose) has improved post-transplant outcomes.  In a retrospective 
study by Oto et al., they showed that recipients of lungs stored with LPD-glucose had 
lower rates of PGD, days on ventilator, and 30-day mortality in comparison to other 
intracellular-type (high potassium) flush solutions[76].  
 
Following the flush, the lungs are removed, inflated at an airway pressure of 20 cm 
H2O with 50% oxygen gas, triple-bagged, and stored on ice.  Inflation of the lungs 
serves two purposes.  First, it provides oxygen to the lung parenchyma for aerobic 
metabolism and secondly, it preserves the alveolar structure during storage; 
preventing collapse.  Accordingly, Van Raemdonck et al. have shown that inflation 
even with nitrogen is still superior to atelectatic storage[77].  
 
 Once the lungs have been removed from the body, reduction of the metabolic rate 
by cooling of the lungs remains the cornerstone strategy for lung preservation today.  
Kayano et al. have shown in a rat model that the optimal temperature for lung 
preservation is approximately 10°C[78]. However, to simplify transport logistics, 4°C 
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is most commonly used.  Once removed from the body, transplantation into the 
recipient should occur as soon as possible.  PGD and 30-day mortality have been 
reported to increase with cold ischemic times longer than 8 h[79].  
 
The history of ex-vivo lung perfusion 
While the current cornerstone of clinical lung preservation has been to limit the 
metabolic rate by hypothermia, this strategy best serves lungs meeting ideal 
acceptance criteria.  With the current donor organ shortage, most programs now 
utilize increasing numbers of extended criteria organs where lung function is not as 
assured as in ideal lungs.  Ideally, further evaluation and even reconditioning of the 
lungs would be possible during the ex vivo phase of the organ before transplantation 
into the recipient.  The limitation of the metabolic rate by static hypothermic 
preservation, precludes the possibility of meaningful lung evaluation and recovery. 
Preservation of donor organs would, therefore, need to occur at normothermic or 
sub-normothermic conditions to achieve these goals.  One such strategy has been 
that of ex vivo lung perfusion (EVLP).  This strategy attempts to simulate the in vivo 
situation by ventilation and perfusion of the donor lung graft.  In 1935, Alexis Carrel 
and Charles Lindhbergh demonstrated that organs could remain viable for several 
days, reporting the first ex-vivo normothermic organ perfusion[80]. It would take until 
the 21st century ,however, for the first successful clinical EVLP to be reported when 
Steen et al. published their first case report in 2001, in Lund, Sweden[65]. They 
evaluated EVLP originally as a method of assessing lungs from an uncontrolled DCD 
donor prior to transplantation. They reported for the first time that lungs could be 
transplanted successfully after a period of warm ischaemia, EVLP, evaluation and 
cold storage. Steen retrieved lungs from a 54-year-old donor who had suffered a 
myocardial infarction and then had 190mins of cardiopulmonary resuscitation (CPR). 
Following this, EVLP was performed for 65mins, using the Lund protocol and resulted 
in a 54 –year old woman with COPD undergoing a single right lung transplant. The 
Lund group described their circuit which all future circuits would be based upon. The 
circuit included a pump generating a perfusate flow through an oxygenator, a 
leucocyte filter, a heater-cooler unit and gas exchange membrane before returning to 
the lungs through a cannula in the pulmonary artery. The pulmonary venous return 
was collected into a reservoir from the left atrium and then recirculated, Figure 1.4. 
Following this, several groups worldwide have investigated the role of EVLP in 
increasing the number of suitable pulmonary grafts and also in reducing the 
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incidence of primary and late graft dysfunction and overall lung transplantation 
outcomes.  
 
 
Figure 1.4 The EVLP circuit 
Line diagram of an ex vivo lung perfusion (EVLP) circuit. Demonstrates the direction 
of flow of perfusate solution into the pulmonary artery (PA), through the lung 
vasculature, out from the left atrium (LA), collecting in a reservoir, through a pump, 
oxygenator, heater cooler unit (HCU), leucocyte filter and then returning to the PA. 
Adapted from Wallinder et al.[81]  
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Professor Stig Steen was the EVLP pioneer, who focussed primarily on the 
evaluation of uncontrolled DCD lungs. Dr Shaf Keshavjee, leading the Toronto group, 
concentrated on developing a functional EVLP model for donor lung perfusions over 
longer periods of time. The development of a stable EVLP model that would work 
over several hours would provide the basis for interventional, ex vivo treatment of the 
sub-optimal donor lung. In 2007 the Toronto group presented, at the ISHLT annual 
meeting in San Francisco, the first concept and feasibility of prolonged EVLP (12h) in 
association with an active treatment strategy (IL-10 gene therapy) to repair injured 
donor lungs ex vivo[82]. Subsequent publications, demonstrated the benefits of 
having a period of normothermic EVLP during the lung preservation process and a 
seminal prospective clinical trial demonstrated the feasibility and safety of EVLP to 
assess and improve the function of injured donor lungs or lungs from donors after 
cardiac death[27]. An explosion of EVLP research has since then occurred, and 
EVLP has emerged as one of the most promising recent advances in the field of lung 
transplantation and lung donor pool expansion.  
 
Various international groups have extensively published evidence on the safety and 
effectiveness of EVLP as a way of assessment and reconditioning lungs deemed 
unsuitable for clinical transplantation. In more recent years, there has been a large 
body of work published locally in Newcastle by Andreasson et al. focussed on the 
immunological, inflammatory and tissue injury biomarkers during EVLP and the 
correlation to lung performance during assessment and after transplantation[83].  
The next chapter in the journey of EVLP is to use the pre-existing knowledge we 
have and translate this into the use novel interventions that could potentially prevent 
reperfusion injury and ischaemia and modulate the immunogenicity of the donor 
lungs to prevent rejection. The current situation of lung transplantation is such that 
the decision to utilise donor lungs is made prior to explant and the possibility to repair 
the organ is limited to the donor prior to retrieval.  With the development of EVLP, 
two new paradigms now exist.  Firstly, evaluation of the donor lung and the decision 
to utilise the organ now can occur following retrieval and at the transplant hospital.  
Secondly, during the time the lung is on EVLP, treatments individualised to identified 
lung injuries can be applied; repairing acute injury associated with the donation 
process and salvaging these lungs for utilisation. 
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The rationale of EVLP 
EVLP is a novel technique in which extended criteria donor lungs can be assessed 
objectively and potentially reconditioned for safe use in clinical lung transplantation; 
thereby safely increasing the donor pool. EVLP provides an alternative to the static 
cold preservation normally applied to organs in the period between removal from the 
donor and transplantation into the recipient. During EVLP, the lungs are not exposed 
to ischemia or the depressed metabolic state that hypothermia induces. The rationale 
for EVLP under physiologic conditions is to allow pulmonary tissue to remain 
metabolically active and viable for several hours prior to transplantation. This period 
during EVLP provides the opportunity for: prolonged lung preservation; assessment 
of the donor lungs and the re-conditioning of the organs from any damage associated 
with death and hypothermic storage. Ways in which the lungs could be reconditioned 
include but are not limited to: reduced oedema in lung tissue by the high oncotic 
pressure of the perfusate; removal of harmful and toxic waste products with filters 
and membranes within the circuit and recruitment of atelectatic areas resulting in 
improved ventilation/perfusion mismatch. There is also great potential for delivering 
therapies to the pulmonary graft and investigating and developing our understanding 
of the complex inflammatory and immune-mediated pathways and mechanisms 
involved in the ischaemic-reperfusion process.  
 
The EVLP technique and available devices  
Irrespective of the EVLP protocol or device used, the premise of EVLP always 
remains the same. The equipment always includes a pump generating a perfusate 
flow through an oxygenator, a leucocyte filter, connected to a heater-cooler unit and 
gas exchange membrane before returning to the lungs through a cannula in the 
pulmonary artery. Pulmonary venous return is collected into a reservoir from the left 
atrium and then recirculated. A ventilator is connected to the trachea allowing 
“protective” ventilation to be carefully started only after the lungs have been 
rewarmed to 32oC and steadily increased whilst approaching normothermia. 
Irrespective of the EVLP protocol used the procedure has distinct phases. The EVLP 
procedure, can be described in the following phases: 
Preparation 
The EVLP circuit is primed with 2 litres (L) of perfusate solution, most commonly 
Steen Solution™ and additive medications such as heparin, antibiotics, antifungals 
and pH buffer. When the donor lungs arrive at the operating theatre of the receiving 
24 
 
centre, they must be prepared for the EVLP procedure. Any superfluous tissue is 
trimmed off, and the lungs are weighed. An endo-tracheal tube is secured into the 
trachea, which may have been shortened. A cannula is secured into the pulmonary 
artery; this will vary depending on the specific perfusion machine being used. If the 
donated heart is favoured and the pulmonary artery is cut at or after the bifurcation, 
the artery can be elongated with a graft, consisting of a piece of the donor aorta or a 
synthetic graft. Once the cannulations are complete, a retrograde flush is performed 
using Perfadex. The lungs are connected to the EVLP unit, and a temperature probe 
is sutured to the lumen of the left atrial remnant to record the temperature of the 
perfusate leaving the lungs. Perfusion starts with a slow antegrade flow to de-air the 
circuit and the lung vasculature.  
 
Warming and reconditioning 
After the lungs are connected to the EVLP unit, they are gradually rewarmed to body 
temperature. Bronchoscopy is performed for airway control and cleaning. At 32°C, 
ventilation is initiated with small tidal volumes and at low pressure. A protective 
ventilation strategy is adopted, similar to that adopted in treating Acute Respiratory 
Distress Syndrome (ARDS) patients in the Intensive Care Unit (ICU)[84]. The 
protective strategy involves using a 7 ml/kg tidal volume, a PEEP of 5 cm H20, a 
respiratory rate of 7 breaths per minute and an oxygen concentration of 21 %. Since 
the warming of the perfusate takes place with a pre-set difference in temperature of 
8°C between the in- and out-flowing blood, the duration of the warming is dependent 
upon flow and the size of the lungs. Once the lungs begin ventilation, a gas mixture 
(86% N2,8% CO2, 6% 02) is turned on and applied at a sweep at 1 litre/min. A step-
wise increase in the perfusion flow is implemented. The perfusion flow rate is 
dependent on which protocol is being used, and this will be discussed shortly.  
 
Evaluation 
Once a temperature of 36°C is reached, the evaluation phase is started. At this point, 
the O2 supplied from the EVLP unit is discontinued. In this phase, the oxygenator is 
only used for deoxygenation and the provision of CO2, to mimic the body. 
Oxygenation and removal of CO2 from the perfusate are now dependent upon lung 
function, which can be evaluated by analysing the blood gases. The lung compliance, 
dead space fraction, respiratory pressures and peripheral vascular resistance (PVR) 
are evaluated repeatedly during this phase.  
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Cooling and storage 
If the lungs are deemed transplantable, the oxygenator is once again used as an O2 
provider. The lungs are rapidly cooled to 12°C, with ventilation terminated at 32°C.  
 
Several commercial companies have designed and marketed devices for clinical 
EVLP, Figure 1.5: 
 Organ Care System (OCS) Lung (TransMedics) 
 Vivoline LS1 (Vivoline Medical, Lund, Sweden) Vivoline has now been taken 
over by XVIVO. 
 Lung Assist (Organ Assist, Groningen) 
 XPS (XVIVO Perfusion AB) 
 XOR Labs Toronto  
 
 
 
 
 
Figure 1.5 Commercially available EVLP machines 
Semi-automated EVLP circuits used in ongoing multicentre trials investigating EVLP 
in clinical lung transplantation. (A) Vivoline® LS1, (Vivoline Medical AB), static EVLP 
with the Lund EVLP protocol. (B) XPS™, (XVIVO Perfusion AB), static EVLP with the 
Toronto EVLP protocol. (C) OCS™ Lung, (TransMedics Inc.), portable EVLP with the 
OCS EVLP protocol. Andreasson et al. [85] 
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EVLP DEVICE DEFINING DESCRIPTORS 
OCS Lung  
(Trans Medics, US) 
 Portable 
 Contains battery power, gas cylinders and 
monitoring equipment.  
 Pump has a pulsatile-type flow 
 Potential for eliminating long periods of cold 
ischaemia  
Vivoline (Lund, Sweden) 
 
 Pump has an internal roller to create 
continuous flow 
 Requires an external ventilator and gas 
cylinders to commence EVLP. 
Lung Assist (Groningen, 
Netherlands) 
 Less robust 
 Individual components mounted on a frame 
XPS (XVIVO Perfusion AB)  
 
 Fully integrated device 
 Centrifugal pump generating continuous 
flow.  
 X-ray possibilities  
Table 1.5 Comparison between commercially available EVLP devices. 
Comparison of the commercially available EVLP devices and there unique selling 
points.  
 
EVLP protocols  
Three EVLP protocols have been well examined in clinical trials: Toronto, Lund and 
Organ Care Systems. The Lund protocol, designed by Steen et al. was primarily 
designed for a shorter perfusion period and for the evaluation of initially rejected 
donor lungs and uncontrolled DCD lungs. The Lund group EVLP circuit provided the 
blueprint for all circuits currently used in clinical centres worldwide. The Lund EVLP 
protocol is designed to mimic the physiologic conditions a transplanted lung will go 
on to face after reperfusion in the recipient. It serves primarily as a thorough 
assessment of borderline lungs not meeting standard acceptance criteria to reclaim 
those demonstrating suitability for clinical transplantation on the ex-vivo circuit. 
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The Toronto protocol focused on the feasibility of prolonged EVLP to allow for an 
extended period of assessment, reconditioning and to the development of future 
treatments to be applied during extended lung perfusion.  
 
One difference between these methods is that a cellular evaluation solution is used in 
the Lund method. Also, in the Toronto method, the left atrium has a cuff attached, to 
allow a positive left atrial pressure during the perfusion, and in the Lund method, it is 
open. In the Lund method, 100% of the donor’s estimated cardiac output is circulated 
through the lungs, as compared to 40% in the Toronto method.   
 
In 2012, a third EVLP strategy was proposed, in which a portable EVLP unit allowed 
for perfusion to be instituted at the donor hospital and maintained during 
transportation and up until the transplantation. In a pilot study published in the Lancet 
2012, Warnecke et al. investigated the effect of normothermic preservation and 
transportation of standard criteria human donor lungs on a portable EVLP 
system[86]. Twelve pairs of standard criteria human donor lungs were, instead of 
transported with cold static preservation on ice, preserved by normothermic perfusion 
and ventilation on the transportable Organ Care System (OCS) Lung (TransMedics, 
Inc., Andover, MA, USA). This pioneering report of a portable EVLP system reported 
non-inferiority in short-term outcomes to controls.  
 
The Toronto method introduced the concept of extended EVLP (>12h) using an 
optimal lung protective strategy, aimed to avoid circuit-induced injuries due to 
mechanical shear stress and preserving cell homeostasis. There are three main 
differences between the Toronto method and other methods: 1) the use of an 
acellular perfusate, 2) a closed circuit with a positive left atrial pressure and 3) a 
lower perfusion flow rate. The defining differences between the three most commonly 
recognised EVLP protocols are outlined in Table 1.6. The acceptable variables that 
indicate lungs are suitable for transplantation at the end of EVLP are found in Table 
1.7.
  TORONTO LUND ORGAN CARE SYSTEM 
Application  Re-evaluation, 
reconditioning, treatment  
Re-evaluation, 
reconditioning   
Replace cold ischaemia 
Transportable No  No Yes 
Perfusate  Steen solution Steen solution OCS solution or Perfadex 
Red blood cells 
added 
NO - Acellular  YES - Cellular. 
RBC’s haematocrit 
14% 
YES – Cellular.  
RBC’s haematocrit 15-25% 
PRESSURE     
Pump Centrifugal Roller Piston (pulsatile)  
Target Flow  40% of cardiac output 100% of cardiac 
output 
2-2.5 l/min  
Target PAP <15mm Hg flow dictated  < 20 mm Hg  <20 mm Hg  
Left atrium  Closed (3-5mmHg)  Open (0 mmHg) Open(0mmHg)
  
VENTILATION    
Gas mixture 8% CO2, 6% 02, 86% N2 7% CO2, 03% N2  
Start Temp 32°C 32°C 34°C 
Tidal volume  7 ml/kg IBW 3-8 ml/kg IBW 6 ml/kg IBW 
RR 7 20 10 
PEEP 5 cm H20 5 cm H20 5-7 cm H20 
Fi02 (%) 21 50 21 
TEMPERATURE 
(°C)  
TORONTO LUND ORGAN CARE SYSTEM 
Start perfusion 25  15  32  
Start ventilation 32 32 34 
Start evaluation 37 37 37  
Time to stability  1h 1h 10-15mins 
Total time 
perfusion 
4-6 h (Up to 12 hr) 2-7 h (92-393min) Transport time (188 - 622min)  
Table 1.6 Comparison of EVLP protocols in clinical lung transplantation 
 
Direct comparisons of the three most commonly used EVLP protocols in relation to 
their haemodynamic and ventilatory settings. IBW (Ideal body weight), MIN (Minutes), 
PAP (Pulmonary artery pressure), RBCs (Red blood cells), RR (Respiratory rate), 
PEEP (Positive End-Expiratory Pressure), FiO2 (Inspired oxygen concentration), 
PO2/FiO2 ratio (Difference between inspired oxygen concentration and PO2). 
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 TORONTO LUND ORGAN CARE 
SYSTEM 
Transplant 
acceptable 
variables 
PO2/Fi02 > 
400mmHg  
Stable: PA 
pressure, PVR, 
airway pressures, 
lung compliance 
Clear chest x-ray 
Bronchoscopy  
PO2/Fi02 > 
300mmHg  
Stable: PA 
pressure, PVR, 
airway pressures, 
lung compliance  
Absence of 
consolidated lung 
collapse test  
PO2/Fi02 ratio 
When system stable 
at donor site and 
before 
transplantation  at 
recipient site  
Table 1.7 Transplant acceptable variables at end of EVLP 
Table showing the acceptable variables that must be met in order for lungs to be 
deemed acceptable for transplantation after EVLP. PO2/FiO2 ratio (Difference 
between inspired oxygen concentration and PO2), PA (Pulmonary artery), PVR 
(Pulmonary vascular resistance).  
 
Open versus closed circuit  
EVLP systems use either an open or a closed circuit. In an open system, the heart is 
removed before the lungs are connected to the circuit and the remnant of the left 
atrium is opened to the atmosphere, leaving an atrial cuff. The alternative to this, a 
closed system involves a specially designed plastic cannula being sutured into the 
remnant of the left atrium, allowing maintenance of a positive left atrial pressure by 
adjusting the height of the reservoir. A distinctive feature of the Toronto EVLP 
protocol is the use of a closed left atrium at a pressure of 3-5 mmHg whereas the left 
atrium is open in the Lund protocol. In 2014, Linacre et al.  published a comparative 
study on pig lungs to evaluate the relative effects of open or closed left atrium[87]. 
They reported a significant advantage for the closed atrium alternative when EVLP 
exceeded 4 – 5 hours. The full 12 hours of EVLP could not be completed in 4 of 5 
open atrium cases due to pulmonary oedema: after 7 hours EVLP these lungs 
showed increases in PVR, peak inspiratory pressure and decreases in lung 
compliance and oxygenation. All lungs with closed atrium completed 12 hours EVLP. 
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Advocates of the closed method argue that by achieving left atrial pressures of 3-5 
mmHg, you can counteract oedema forming by preventing the collapse of pulmonary 
veins and alveolar wall capillaries, during ventilation and maintaining venous 
afterload and microvascular recruitment, thereby reducing vascular resistance. It has 
been argued, however, that although with an open system, there is the possibility of 
venous collapse, that the actual risk is low when a fountain of perfusate with a height 
of 2–5 cm can be observed in left atrium throughout the EVLP procedure. Venous 
collapse should not occur as long as this phenomenon is observed. When using an 
open method, attention needs to be taken whilst dissecting off the heart. One must 
remove as much tissue as possible, to avoid any obstruction to outflow from the left 
atrium. In addition, an open atrium provides the opportunity to collect blood gases 
from selected pulmonary veins, thereby allowing evaluations of the functions of 
isolated parts of the lung.  
 
Cellular versus acellular perfusate 
One important question in designing any EVLP study is to decide on using either a 
cellular or acellular perfusate. The Lund and OCS protocols use a cellular perfusate, 
whereas the Toronto method employs an acellular solution.  EVLP logistics are 
simplified and costs reduced in an acellular technique. Uniquely,  oxygen supply to 
lung cells during EVLP appears to be primarily provided by the ventilator alone 
without the need of haemoglobin as an oxygen carrier[88]. During perfusion with a 
cellular perfusate solution, there is the potential risk of haemolysis due to mechanical 
trauma to the red blood cells. During the cold portion of perfusion, low temperatures 
may cause a significant increase in viscosity with cellular perfusates, which may  
impact on mechanical stress and additionally lead to haemolysis[88].  
 
Conversely, Wallinder et al. reported good short-term outcomes after human 
transplantation with lungs assessed using a cellular perfusate for up to 9 hours[81]. A 
potential benefit of a cellular perfusate is the oxygen-binding capacity that 
erythrocytes provide and its possible advantage during lung evaluation. It is also 
argued that the presence of red blood cells provides a more physiologically relevant 
assessment of flow through the pulmonary microvasculature. Yeung et al. in a small 
animal model study demonstrated that blood gas analyses during EVLP with an 
acellular perfusate are unreliable and could disguise oxygenation deficits during 
assessment; especially in the case of a ventilation–perfusion mismatch[89]. The 
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shunting effect became obvious first when erythrocytes were added to the perfusate, 
and then vanished again when the perfusate was replaced with fresh acellular Steen 
Solution™. It has also been argued that a cellular perfusate is more physiologically 
representative. Using an acellular solution for the warming phase and then adding 
red blood cells for the remainder of the perfusion could be a possible compromise.  
 
Roman et al. demonstrated no significant difference in the physiologic, immunologic, 
or ultrastructural parameters between lungs perfused with cellular or acellular 
solutions[90]. Becker et al also demonstrated that prolonged acellular and cellular 
EVLP for 12 h are both feasible with lungs pre-challenged by ischaemic organ stress. 
They found that the physiological and ultrastructural analysis showed no superiority 
of either acellular or cellular perfusate composition[91]. 
 
Low versus high flow  
During EVLP, the intrinsic pulmonary vascular resistance (PVR) often regulates the 
flow. This is especially true during the re-warming phase of EVLP when the flow is 
always limited by the high PVR in the cold and rigid lung. The approaches taken 
towards flow rates, by the Toronto and Lund groups are different. Cypel et al. and the 
Toronto group have advocated for a maximum EVLP flow rate of approximately 40% 
of the estimated cardiac output[88]. Low flow has been argued to protect the 
pulmonary microvasculature against mechanical injury of the endothelium, 
maintaining the integrity of the alveolar-capillary barrier and preventing the effusion of 
fluid from blood vessels, thereby decreasing oedema formation. The Toronto group 
relies on an EVLP technique with low Pulmonary artery (PA) flow (40% of the 
estimated cardiac output), low PA pressure (PAP; 10–15 mmHg), and advocates a 
careful perfusion strategy with initially very low PA pressures. A low flow strategy is 
thought to facilitate perfusion over longer time periods. The low flow approach has 
the potential to avoid haemodynamic stresses due to the reperfusion of a previously 
hypothermic lung. Those advocating a low flow approach stress that it is vital to 
monitor mean PAP and aim to keep this below 15-20mmHg to avoid the development 
of hydrostatic pulmonary oedema.  
 
The theoretical disadvantage with the low-flow regime is that a low pressure level 
could be insufficient for perfusion of the non-dependent parts of the lung, e.g., West 
zone 1. In an uncontrolled DCD situation with a lung that has impaired peripheral 
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circulation, the use of too careful of a perfusion regime may result in only a portion of 
the lungs being perfused. There is also concern that a reduced flow approach is less 
representative of the post-transplant load on the lung circulation.  
 
In contrast, the full-flow evaluation with the Lund protocol uses a pre-set pressure 
limit of 20 mmHg from the start to the end of the perfusion. Thus, the flow is more 
dependent upon the PVR. A high flow approach aims to test lung function during 
EVLP, and simulate the conditions under which the lungs will subsequently be 
required to function. This may provide the assessor confidence in making a quick 
prediction of the organ’s transplant suitability.  
 
Perfusate solutions 
The perfusate used in the EVLP circuit must meet some basic criteria. The colloid 
osmotic, or oncotic pressure, must be equal to or higher than the oncotic pressure in 
the blood. An oncotic pressure of about 25 mmHg exists typically in the capillaries. 
The hydrostatic pressure in the arterial end of the capillaries is normally about 30 
mmHg, and the hydrostatic pressure in the venous end of the capillaries is 
approximately 10-15 mmHg. This pressure gradient causes water to leave at the 
arterial end and return at the venous end of the capillaries.  
 
The commercially available solution that is currently used almost exclusively for 
EVLP in both laboratory and clinical settings is Steen Solution™ (XVIVO Perfusion 
AB). As the name implies, Stig Steen and colleagues developed this solution. This 
fluid has a high oncotic pressure (25–30 mmHg), which the manufacturer described 
as optimal for mobilisation of interstitial oedema often found in donor lungs. Steen 
Solution™ is an extra-cellular electrolyte composition (low K+) with the addition of 
human albumin to maintain optimal colloid pressure and dextran 40, a mild ROS 
scavenger which coats and protects endothelium from subsequent excessive 
platelet/leucocyte interaction, complement, cell-mediated injury and to inhibit 
coagulation and platelet aggregation thrombogenesis. 
 
In the Lund model, the EVLP procedure is performed with a mixture of Steen solution 
and washed erythrocytes to reach a haematocrit of 15% whereas, in the Toronto 
protocol, the EVLP procedure is carried out with an “acellular” Steen Solution™. In 
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the OCS model, OCS solution is used, made by the manufacturer and essentially a 
low potassium dextran solution with added glucose. 
 
In an attempt to produce an alternative perfusate solution for EVLP, Fernandes et al. 
in a Brazilian study of 16 EVLPs compared Steen solution with an alternative solution 
made by a Brazilian pharmaceutical company[92]. From 16 lungs tested, they found 
no difference on weight after EVLP: Steen group (SG) = 1,097±526g; Alternative 
Perfusion Solution (APS) = 743±248g, p=0.163. Oedema formation, assessed by 
Wet/dry weigh ratio, was however, statistically higher on the Alternative Perfusion 
Solution group (APS = 3.63 ± 1.26; SG = 2.06 ± 0.28; p = 0.009). Steen Solution™ 
remains the main reconditioning solution for EVLP used both in clinical and 
experimental fields.  
 
EVLP assessment and parameters  
EVLP allows for a period of assessing donor lungs and provides more information for 
decision making. Oxygenation capacity is traditionally considered to be the most 
crucial parameter for the evaluation of donor lung function. During EVLP, blood 
gases are drawn from the oxygenated blood in the left atrium. The gas exchange in 
the evaluated lung at a certain fraction of inspired oxygen is dependent upon the 
following factors: a) the ventilation of the alveoli; b) the diffusion capacity of the 
blood-gas barrier; c) the amount of shunted blood; d) the ventilation/perfusion 
relationship.  The prognostic value of the oxygenation capacity of the lung during 
EVLP has been questioned by the Toronto group[89]. Gradually decreasing dynamic 
compliance over time is instead suggested as the best indicator of inferior lung 
function.  
 
In both animal and human EVLP, irrespective of the EVLP protocol employed, the 
PVR is higher than what would be expected for normal in vivo physiology[27]. This 
may be explained in part by the difference between the physiologic flow in vivo and 
the artificial flow generated by the pump in the EVLP unit.  
 
The compliance of the lung reflects the change in lung volume for an applied 
pressure. Static compliance is calculated during an inspiratory hold manoeuvre 
(static condition). Compliance is calculated as the inspired tidal volume is divided by 
the insufflation pressure at the end of inspiration (plateau pressure) minus the 
 34 
 
positive end-expiratory pressure. Compliance, and especially changes in compliance 
over time, has been suggested as important parameters for evaluating donor lung 
function during EVLP[89].  
  
Despite being the organ with the highest oxygen concentration in the body, about 
40% of the glucose that is metabolised in the lung becomes lactate.  As the EVLP 
circuit is closed and the lungs’ ability to consume lactate is limited, the lactate level in 
the lung increases during EVLP. The level of lactate during EVLP has however been 
found to be unrelated to the function of the perfused lung[93].   
 
A high rate of glucose consumption during EVLP has been suggested as a marker of 
graft quality. In a group of animals with high glucose consumption, pulmonary 
oedema was more pronounced than in the controls. However, gas exchange capacity 
and hemodynamic parameters showed no association with the rate of glucose 
consumption[94].  
 
Oedema of the donor lung is a frequent cause of impaired function; and in the 
laboratory setting, a resected part of the lung can be weighed and then dried in an 
oven until no further weight loss is recorded. The wet to dry weight ratio is then a 
measure of tissue oedema and is often demonstrated in studies. The parameters 
which can be assessed during EVLP are summarised in Table 1.8. 
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ASSESSMENT PARAMETER 
HAEMODYNAMIC  Pulmonary artery pressure (PAP) mmHg) 
 Peripheral vascular resistance (PVR)  
 Flow rate (RPM) 
VENTILATORY  Compliance  
 Peak Airway Pressure 
 Visual inspection of consolidation and 
atelectasis 
OXYGENATION   Pa02/Fi02 ratio 
 Arterial blood gases: p02, PC02 
 
BACTERIAL LOAD  Bronchoalveolar lavage (BAL): gram stain 
and culture 
LUNG OEDEMA 
FORMATION 
 Wet/Dry ratio 
 Chest radiograph (CXR) 
 Visual inspection of pulmonary oedema 
INFLAMMATORY 
RESPONSE 
 Cytokine analysis 
Table 1.8 Summary of the parameters that can be measured, monitored and 
assessed during EVLP. 
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EVLP Clinical Trials  
Several prospective studies of various EVLP techniques have been completed in 
Europe and North America. A summary of recent clinical trials is given in Table 1.9. 
These include the HELP trial (Toronto; sponsor XVIVO Perfusion), the NOVEL trial 
(USA; sponsor XVIVO Perfusion), the INSPIRE and EXPAND trial (Europe and USA; 
sponsor TransMedics), the Develop UK (UK; sponsor Vivoline), the Vienna trial 
(Vienna, sponsor XVIVO), and the Perfusix Trial (USA; sponsor Perfusix).  
 
Name of 
clinical 
trial 
Centre Primary endpoint  Sponsor Method 
HELP Toronto  
(Cypel et al) 
2011  
PGD scores in the first 72 
hrs, 30 day mortality  
Vitrolife Toronto 
NOVEL Multicentre 
(US) 
30 day mortality  XVIVO US 
DEVELOP UK 12-month survival  
Cost effectiveness  
Vivoline Lund 
EXPAND Multicentre 
(International)  
PGD scores in the first 72 
hrs, 30 day  mortality  
Transmedics OCS 
INSPIRE  Multicentre 
(International)  
PGD scores in the first 72 
hrs, 30 day  mortality 
Transmedics OCS 
Table 1.9 Summary Table of Recent EVLP Trials 
 
HELP Trial  
The Toronto EVLP method represents arguably the most extensive clinical 
experience of EVLP. The Toronto General Hospital Transplant Program EVLP 
experience has been routinely published and updated every year.  In 2011, Cypel et 
al. published their experience from September 2008 through January 2010[27].  
During the study period, 23 donors met the inclusion criteria that defined potential 
donors as “high risk” for not having acceptable lungs.  Those 23 donor lungs 
underwent EVLP.  One hundred and sixteen standard lungs transplanted during the 
same period preserved with static cold storage constituted the control group.  The 
primary endpoint was PGD of Grade 2 (PaO2/FiO2 of 200 to 300 mm Hg) or Grade 3 
(PaO2/FiO2 <200 mm Hg), according to ISHLT[95].  Secondary endpoints were 30-
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day mortality, bronchial complications, duration of mechanical ventilation, and length 
of stay in the intensive care unit (ICU) and hospital. Out of 23 high-risk donors who 
underwent EVLP, 20 were deemed appropriate for transplantation. The lungs were 
transferred to Toronto General Hospital according to standard practice and placed in 
the EVLP system (XVIVO™, Vitrolife) and perfused at 37°C with STEEN Solution™ 
(Vitrolife, Inc.) for four hours.  After four hours of EVLP, the donor lungs were 
evaluated for delta PO2 ≥ 350 mm Hg and stable pulmonary vascular resistance 
(PVR), peak airway pressure (PawP), and lung compliance. Criteria regarding the 
termination of perfusion and non-transplantability consisted of a PVR, dynamic 
compliance, peak inspiratory pressure decline by more than 15%, and FiO2 less than 
350 mmHg. By comparing the EVLP group to contemporary transplants utilising 
standard criteria organs, no noteworthy dissimilarities could be found with respect to 
PGD rates, days of mechanical ventilation after transplant, lengths of ICU and 
hospital stays or 30-day mortality. 
 
In 20 of 23 EVLP lungs, the physiological function remained stable during EVLP and 
the median PaO2/FiO2 ratio increased from 335 mm Hg in the donor lung to 414 and 
443 mm Hg at 1 hour and 4 hours of perfusion, respectively (p<0.001). The incidence 
of PGD Grades 2 and 3 at 72 hours after transplantation was 15% in the EVLP group 
and 30% in the control group (p=0.11).  Severe PGD (Grade 3) in the EVLP group 
was 0%, and 9.4% in the control group (p=0.36).  No significant differences were 
observed for any secondary endpoints, and the 1-year post transplant survival rate 
was 80% for EVLP lungs and 83.6% for control lungs (p=0.54).  They concluded that 
4 hours of EVLP led to immediate and one-year post-transplant outcomes similar to 
those obtained with conventionally selected lungs 
 
The latest update of the Toronto General Hospital EVLP Transplant Program 
experience was published by Cypel et al. in 2012[96]. This update included lung 
transplants with high risk DBD and DCD donor lungs. During the study period of 39 
months, a total of 317 lung transplants were carried out.  58 EVLP procedures, 
durations of between 4-6 hours, were performed in high risk DBD and DCD donor 
lungs, resulting in 50 transplants (86% use).  Lungs that achieved stable airway and 
vascular pressures and PaO2 /FiO2 greater than 400 mm Hg during ex vivo lung 
perfusion were transplanted.  
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The incidence of PGD Grade 3 at 72 hours was 2% in the EVLP group and 8.5% in 
the control group (p=0.14). Thirty-day mortality (4% in the EVLP group and 3.5% in 
the control group, p=1.00) and 1-year survival (87% in the EVLP group and 86% in 
the control group, p=1.00) were similar in both groups.  The authors concluded that 
transplantation of high-risk donor lungs after 4 to 6 hours of EVLP is safe, and 
outcomes are similar to those of conventional transplants. Prior to the use of EVLP, 
Toronto General Hospital used approximately 25% of available donor lungs.  After 
initiating the HELP study and using EVLP lungs, the overall lung utilisation rate 
increased to 36%. 
 
NOVEL Trial   
The NOVEL trial was a prospective, controlled, non-randomized, multicentre (6 US 
centres), open label, non-inferiority study; including patients transplanted with 
“extended criteria lungs,” (as defined by the inclusion criteria for EVLP), compared to 
standard lung transplant recipients[97]. The primary study endpoint was 30-day 
mortality. The secondary study endpoints included 72-hour PGD, length of ICU stay 
and ventilator or extra-corporeal membrane oxygenator (ECMO) usage. During the 
period of May 2011 to May 2014, 54 lung donors met the criteria and underwent 
EVLP, using the Toronto method and XPS system.  From this group, 29 (54%) were 
transplanted into 31 recipients.  15 recipients received double lung transplants and 
16 recipients received single lung transplants, with 12 single lungs discarded.  
Additionally, 25 donor lung pairs (46%) were discarded after EVLP and not 
transplanted.  For the control group, 62 standard criteria lungs were transplanted into 
31 recipients, with 19 (61%) receiving double lung transplants and 12 (39%) 
receiving single lung transplants. At the end of EVLP, the median PaO2/FiO2 was 
500 and 375 mm Hg in the in the EVLP transplanted and EVLP-non-transplanted 
groups, respectively. 30-day survival was 97% vs.100% in the EVLP and control 
arms, respectively.  1-year survival was comparable across EVLP (87%) and control 
group (93%). The incidence of PGD Grade 3 at 72 hours was 10% and 3% in the 
EVLP and control groups, respectively.    
 
DEVELOP- UK 
The objective of the Donor Ex Vivo Lung Perfusion in UK lung transplantation: 
DEVELOP-UK study was to evaluate the clinical and cost-effectiveness of EVLP 
towards increasing UK lung transplant activity[98]. It was a multicentre, un-blinded, 
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non-randomised, non-inferiority observational study to compare transplant outcomes 
between EVLP-assessed and standard donor lungs, involving all five UK officially 
designated National Health Service (NHS) adult lung transplant centres. Patients 
aged ≥18 years with advanced lung disease accepted onto the lung transplant 
waiting list could participate. The primary outcome measure was survival during the 
first 12 months following lung transplantation. Secondary outcomes were patient-
centred metrics, influenced by the effectiveness of lung transplantation and that 
contribute to the overall health-care costs. Lungs from 53 donors found unsuitable for 
standard transplant were assessed with EVLP, of which 18 (34%) were subsequently 
transplanted. A total of 184 participants received standard donor lungs. Patients in 
the EVLP arm required ventilation for a longer period and stayed longer in an ICU 
than patients in the standard arm, but the duration of overall hospital stay was similar 
in both groups. There was a higher rate of very early grade 3 PGD in the EVLP arm, 
but rates of PGD did not differ between groups after 72 hours. The requirement for 
ECMO support was higher in the EVLP arm (7/18, 38.8%) than in the standard arm 
(6/184, 3.2%). The Kaplan–Meier estimate of survival at 12 months was 0.67 [95% 
confidence interval (CI) 0.40 to 0.83] for the EVLP arm and 0.80 (95% CI 0.74 to 
0.85) for the standard arm. There were no significant differences in rates of chest 
radiograph abnormalities, infection, lung function or rejection by 12 months. The cost 
of EVLP transplants was found to be approximately £35,000 higher than the cost of 
standard transplants, as a result of the cost of the EVLP procedure, and the 
increased ECMO use and ICU stay. The study had important limitations including 
small numbers in the EVLP arm due to the early study termination, limiting the 
analysis to descriptive statistics and the EVLP protocol change during the study. The 
reason for the increased PGD rates, ECMO requirement and possible differences in 
lung injury between EVLP protocols all need further evaluation. 
 
INSPIRE  
The INSPIRE trial aimed to assess the impact of ischaemia on short and long term 
outcomes in standard criteria double lung transplants[99]. The trial involves 21 
centres across Europe and the United States and aims to compare standard cold 
storage versus preservation by the portable OCS Lung perfusion and ventilation 
system in standard criteria donor lungs. The primary end-points were 30-day survival 
and severe PGD-3 at 72 hours. Those in the OCS arm had significantly shorter 
periods of cold ischaemic time, and this has been shown to be the most significant 
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predictor for developing PGD-3 within 72 hours. The authors also concluded that 
there was a strong correlation between ischaemic time and the development of BOS 
at 2 years’ post-transplantation.  
 
EXPAND 
The OCS Lung EXPAND trial was a prospective, multi-centre, international trial to 
assess the short and one year clinical outcomes after lung transplantation of 
Extended Criteria Donor (ECD) lungs that were preserved and assessed using the 
OCS portable lung perfusion and ventilation system. The results of the this trial were 
presented at the ISHLT 38th Annual Meeting in Nice, April 2018[100]. The inclusion 
criteria included double lung donors that met any of the following criteria: age > 55 
years, P/F ratio less or equal to 300mmHg, expected ischaemic time >6hours or DCD 
donation. Seventy-nine out of 91 eligible donor lungs were successfully transplanted, 
a utilisation rate of 87%. The incidence of PGD-3 at 72 hours was 6.4%. 30-day, 6-
month and 1-year survival rates were 99%, 93% and 91% respectively.  
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EVLP as platform for assessment and treatment  
Recent work has focussed on targeting the inflammatory and immunological 
pathways involved in ischaemic-reperfusion injury and several studies have 
investigated the main culprit pathways involved in this process. EVLP has been used 
as a platform for not only assessing the physiology of the donor lung but also the 
inflammatory and immunological status of the organ.  
  
Krishnadasan et al. investigated the role of TNF- α and IL-1β in regulating the 
development of lung ischaemia-reperfusion injury[101]. They appear to promote 
injury by altering the expression of pro- and anti-inflammatory cytokines and 
influencing tissue neutrophil recruitment. Animals receiving anti-tumour necrosis 
factor- α and anti-interleukin-1β demonstrated reduced injury compared with that 
seen in positive control animals (vascular permeability of 48.7% and 29.4% lower, 
respectively; (p <.001). Vascular injury was reduced by 71% when antibodies to TNF- 
α and IL-1β were administered together. Lung neutrophil accumulation was markedly 
reduced among animals receiving anti- TNF- α and anti- IL-1β. BAL leukocyte 
content was also reduced by treatment with, anti- TNF- α and anti- IL-1β and 
combination treatment. Reductions in permeability, myeloperoxidase, and BAL 
leukocyte content also resulted in a decrease in lung injury assessed histologically. 
Finally, anti- TNF- α and anti- IL-1β treatment resulted in decreased messenger RNA 
expression for many early response and regulatory cytokines. 
 
Following brain death, a systemic inflammatory response known as a 'cytokine storm' 
transpires.  Increased circulating pro-inflammatory cytokines results in the induction 
of cell adhesion molecules on pulmonary endothelial and epithelial surfaces and 
leads to the recruitment of neutrophils and monocytes to the lung causing 
inflammatory lung injury.   
 
Fisher et al. studied the levels of IL-8 in BAL fluid from 26 donor lungs used for 
transplantation and showed that a high concentration of IL-8 in donor BAL was 
correlated with severe graft dysfunction and with early postoperative deaths[43].  
 
Similarly, De Perrot et al. showed that interleukin IL-8 levels in donor lung tissue 
before and after transplantation increased with time after reperfusion and that 
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patients who developed severe primary graft dysfunction had significantly higher IL-8 
levels during ischaemia and after reperfusion[42].  
 
 Andreasson et al. have recently investigated the role of interleukin-1β as a predictive 
biomarker and potential therapeutic target during clinical ex-vivo lung perfusion, 
analysing EVLP samples from DEVELOP-UK[83]. The protein markers with the ability 
to differentiate declined lungs from the survival group after 30 minutes of perfusion 
were IL-1β and TNF-α in perfusate, p=0.004 and p=0.001 respectively. The most 
effective markers to differentiate recipient in-hospital mortality (non-survival group) 
from those successfully discharged (survival group) were similarly perfusate IL-1β 
p<0.001 and TNF-α p=0.003 after 30 min of perfusion. With a TLC scaled cut-off 
value of 0.1 pg/ml, perfusate IL-1β after 30min of EVLP had a sensitivity and 
specificity of 100% to diagnose non-survival lungs. The predictive value of perfusate 
IL-1β and TNF-α after 30 min of EVLP remained robust when applied to the primary 
study endpoint of 1-year post-transplant survival. With a TLC scaled cut-off value of 
0.1 pg/ml, perfusate IL-1β after 30min of EVLP had a diagnostic sensitivity of 83% 
and specificity of 100% for recipient 1-year post-transplant mortality. 
 
EVLP studies worldwide are investigating the potential for EVLP as a platform for 
lung reconditioning and repair prior to implantation. There are several target areas for 
novel interventions and therapies that can be delivered during EVLP; namely 
reducing oedema and endothelial leak, inflammation, infection and thrombi.  
 
Andreasson et al.[102], demonstrated the potential EVLP holds by showing  the 
therapeutic impact of administering broad-spectrum antibiotics added to the 
perfusate and circuit during EVLP. In this study, 18 human donors deemed 
unsuitable for transplantation that underwent EVLP were examined. 13 out of 18 
lungs had positive cultures commencing EVLP with bacterial loads significantly 
decreased after EVLP. Yeast loads reduced when prophylactic anti-fungal treatment 
was added to the circuit.  
 
Nakajima et al. investigated EVLP a platform to treat infected donor lungs with 
antibiotic therapy before lung transplantation[103]. Human donor lungs that were 
rejected for transplantation because of clinical concern regarding infection were 
randomly assigned to two groups. In the antibiotic group (n=8) lungs underwent 
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EVLP for 12 h with high-dose antibiotics (ciprofloxacin, azithromycin, vancomycin, 
and meropenem). In the control group (n=7), lungs underwent EVLP for 12h without 
antibiotics. A quantitative decrease in bacterial counts in BAL was found in all 
antibiotic-treated cases but in only two control cases. Perfusate endotoxin levels at 
12 h were significantly lower in the antibiotic group compared with the control group. 
EVLP with broad-spectrum antibiotic therapy significantly improved pulmonary 
oxygenation and compliance and reduced pulmonary vascular resistance. Perfusate 
endotoxin levels at 12 h were strongly correlated with levels of perfusate TNF-α, IL-
1β and macrophage inflammatory proteins (MIP) -1α and -1β at 12 h. Nakajima et al. 
concluded that EVLP treatment of infected donor lungs with broad-spectrum 
antibiotics significantly reduces BAL bacterial counts and endotoxin levels and 
improved donor lung function.  
 
Cypel et al. investigated the potential to use gene therapy during EVLP, using 
adenoviral vector encoding human IL-10, an anti-inflammatory cytokine. After 12 
hours on EVLP, the intra-airway adenoviral vector encoding IL-10 treated lungs 
showed significant improvement in Pa02/Fi02 and pulmonary vascular resistance 
when compared to a control group. There was also a shift from pro-inflammatory 
cytokine expression[82].  
 
The use of bone-marrow-derived multipotent mesenchymal stem cells (MSCs) as 
treatment during EVLP has also been investigated. Lee et al. tested the therapeutic 
capacity of human MSCs to restore alveolar epithelial fluid transport and lung fluid 
balance from ALI in an EVLP human lung preparation injured by E. coli 
endotoxin[104]. Intra-bronchial instillation of endotoxin into the distal airspaces 
resulted in pulmonary oedema with the loss of alveolar epithelial fluid transport 
measured as alveolar fluid clearance. Treatment with allogeneic human MSCs or its 
conditioned medium given one hour following endotoxin-induced lung injury reduced 
extravascular lung water, improved lung endothelial barrier permeability and restored 
alveolar fluid clearance. They showed that instillation of bone-marrow derived 
multipotent mesenchymal stem cells resulted in decreased endothelial permeability. 
Mayes et al. investigated the role of the Human Amnion Epithelial Cell (hAECs) 
secretome a new potential treatment preventing neutrophil recruitment and 
endothelial expression during reperfusion[105]. This may decrease the risk of 
developing PGD after transplantation if treatment is prophylactically given during 
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EVLP. The hAECs were isolated from the healthy placentas from term women 
undergoing elective caesarean section. Pre-term placentas under the same ethical 
approval were collected from women undergoing planned caesarean section for 
reasons such as multiparity and placenta previa. Mayes et al. demonstrated that  
hAECs can inhibit the pro-inflammatory cytokine response and that these changes 
result in improved lung function. They demonstrated they hAECs may be able to 
inhibit neutrophil recruitment and reduce endothelial activation and showed that 
levels of TNF-α, IL-1 and IL-6 were reduced. A reduction in ICAM-1 and VCAM was 
also seen. The secreted products of hAECs reduce endothelial activation and limit 
leukocyte-endothelial interactions and may provide a therapeutic option during EVLP 
that protects against PGD. 
 
Moreover, the utilisation of EVLP as a platform to provide different medications was 
examined. Nakajima et al. added nitroglycerin and dibutyryl cyclic adenosine 
monophosphate to Steen solution during EVLP of lungs subjected to 4 hours of warm 
ischaemia[106]. Subsequent to single LTx, EVLP lungs showed improved function, 
lower histological signs of acute lung injury as well as better microvascular patency in 
comparison to standard preservation lungs. Mulloy et al., on the other hand, in a 
model of 1 hour of warm ischaemia in pigs added a selective adenosine 2A agonist 
to the perfusate[107]. Adenosine A2B receptor antagonists have been shown in 
animal studies to improve physiological lung parameters when administered during 
EVLP[108-111].  Hijiya et al. in a canine model of EVLP reported that high-dose 
nebulised procaterol, a short-acting β2-adrenergic receptor agonist, during EVLP 
ameliorated lung graft dysfunction at the early post-transplantation period without 
severe adverse effects[112, 113].  
 
Key processes of reperfusion injury include the formation of reactive oxygen species 
(ROS)/nitrogen species (RNS) and the activation of poly (adenosine diphosphate-
ribose) polymerase (PARP). Some groups have explored whether rat lungs could be 
reconditioned during EVLP using the PARP inhibitor 3-aminobenzamide (3-AB) and 
demonstrated attenuation of lung weight gain and perivascular oedema with the 
inhibitor treatment[114].  
 
Martens et al. investigated the effects of argon and xenon gases delivered during 
EVLP on porcine donor lungs and did not find any improvements[115, 116]. Haam et 
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al. did however show that hydrogen gas inhalation during EVLP improved donation 
after cardiac death lung function via reduction of inflammation and apoptosis, and 
this effect persisted after lung transplantation[117, 118]. 
 
Several animal studies have investigated the effects of surfactant as a lung 
reconditioning agent[119, 120]. Nakajima et al. showed that lung lavage, followed by 
surfactant replacement during EVLP, reduced inflammatory mediators and prevented 
hydrolysis of phosphatidylcholine, which contributed to the superior post-transplant 
function in donor lungs with aspiration injury[121]. 
 
Today, even the most aggressive lung transplant programs use at most 40% of 
offered donor lungs for transplantation.  The remainder are either felt to be or are 
actually too injured to be safely utilised for transplantation.  With the development of 
prolonged EVLP, there now exists great potential for: 1) the evaluation of 
questionable donor lungs and 2) the individualised repair of injured human lungs 
during the lung preservation phase.  Successful development of this paradigm would 
greatly increase lung transplant volumes and reduce waitlist times and mortality. The 
potential for adding medications, gene therapies and immune modulating therapies to 
the EVLP circuit is vast. EVLP as a platform for drug delivery is an exciting concept 
which will be explored in future studies internationally.  
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Aims, Objectives, and Hypotheses 
Aim 
The aim of this MD thesis is to develop and evaluate novel methods of ex vivo lung 
perfusion as an approach for assessing the function of extended-criteria organs, and 
as a strategy for delivering and evaluating novel therapeutic interventions to improve 
donor organ quality. 
Hypotheses 
Hypothesis 1: Inflammatory and tissue injury markers of ex-vivo lung perfusion and 
lung reconditioning. Using transcriptomics to generate biomarkers that identify lungs 
suitable for transplantation following ex-vivo perfusion 
I hypothesise that transcriptomic studies can be used as a method of identifying 
potential biomarkers, pro-inflammatory proteins detectable in perfusate and be able 
to predict the likelihood of human donor lungs undergoing successful ex-vivo 
reconditioning.  
Hypothesis 2: Differences in the inflammatory profiles between donor lungs following 
donation after brain-death (DBD) and donation after circulatory death (DCD)  
I hypothesise that there will be differences in the profiles of inflammatory and tissue 
injury markers between donor lungs undergoing EVLP following donation after brain-
death (DBD) and donation after circulatory death (DCD). I hypothesise that DBD 
donor lungs will express higher levels of acute inflammation and tissue injury than 
lungs from DCD donors due to the insult of brainstem death and its associated 
haemodynamic instability, vascular endothelial injury and an acute inflammatory 
response in the lungs.   
Hypothesis 3: The use of EVLP as a therapeutic platform for the reconditioning of 
human donor lungs.  
I hypothesise that EVLP can be used as a therapeutic platform to assess the effect of 
sildenafil on human donor lungs that have been turned down for immediate 
transplantation. I hypothesise that sildenafil, a well-studied vasodilator will improve 
pulmonary physiology and lung function when administered during EVLP.   
Objectives 
In order to investigate my hypotheses, I will: 
1) Analyse a panel of inflammatory markers in perfusate that have been 
identified through lung transcriptomics from clinical EVLP donor lungs and 
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investigate if a biomarker signal can be developed that distinguishes those 
donor lungs amenable to reconditioning by EVLP.  Examine laboratory 
microbiology culture results for identification and quantification of bacterial and 
fungal species to evaluate how the microbial load in BAL samples is affected 
by normothermic lung perfusion with a perfusate containing high-dose 
antibiotics. 
2) Examine a panel of inflammatory and tissue viability markers in perfusate, 
BAL, and lung tissue samples taken from clinical EVLP donor lungs and 
investigate if there are differences in the profile of markers between donor 
lungs following donation after brain death compared with those after 
circulatory death.  
3) Develop a research EVLP model to be used as a therapeutic platform for 
reconditioning donor lungs turned down for immediate transplantation.  
4) Analyse the effect of sildenafil, given during EVLP, on the pulmonary 
physiology, cytokine profiling and makers of endothelial disruption.  
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CHAPTER 2 
- 
Materials and Methods 
Chapter 2. Materials and Methods 
Introduction 
In this chapter, a detailed overview of the methodological techniques used during this 
MD project is presented. Each results chapter contains its own individual materials 
and methods section, allowing for a more detailed and specific account.  
Materials & Methods  
Porcine procurement  
As part of initial training in EVLP, I utilised 2 key streams of animal work in order to 
gain knowledge and expertise in procurement of the lungs, transportation, dissection 
and attachment of the lungs to the EVLP machine. I gained training in the procurement 
of porcine lungs from animals sacrificed under schedule 1 practices meant for the food 
chain by attending Thompson Wholesale Meat Ltd Abattoir in Bishop Auckland, United 
Kingdom. Prior to my arrival to the research group, there was already an established 
working relationship between the management at this commercial abattoir and 
experienced Cardiothoracic Surgeon; Mr. Tanveer Butt. Mr. Butt had procured porcine 
lungs for the purposes of surgical training and “wet-lab” surgical training days held at 
the Freeman Hospital, Newcastle.  The porcine model offers very appropriate size 
comparisons to humans. Because of this, comparable tidal volumes, PEEP, and 
perfusion times can be used for the EVLP. As a result, information obtained in this 
large animal model of can be rapidly and directly transferred to settings for human 
studies. Training at the abattoir alongside Mr. Butt involved dissection of a porcine 
heart-lung bloc with identification of the main blood vessels, the pulmonary artery (PA) 
and aorta. I learnt the steps involved in efficiently dissecting the lungs from a porcine 
heart – lung bloc and then carefully suturing a cannula into the pulmonary artery for 
antegrade and retrograde flushing of the lungs. I quickly became independent in the 
procurement of porcine lungs and confident in the dissection of the pulmonary vessels 
which allowed me to use these animal organs as a valuable tool for training in the set-
up and running of the EVLP circuit. Additionally, I have carried out approximately 8 
ovine EVLPs in conjunction with the Edinburgh EVLP team who procure their animals 
from the Roslin Institute, University of Edinburgh for the ENLIGHTEN project.  
All porcine procurement was carried out at Thompson Wholesale Meat Ltd Abattoir, 
Marshall Green Abattoir, Bishop Auckland DL14 0AQ. Arrival was typically ~11am in 
order to coincide with the culling of pigs. The porcine procurement kit including all 
necessary instruments can be found in Table 2.1. Both male and female pigs weighing 
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between 60 and 80 kilograms were euthanized by abattoir staff before exsanguination 
and evisceration; providing a DCD model. Lungs were removed by staff as a heart-
lung-liver block and handed over for further dissection. Dissection began with the 
removal of unnecessary tissue such as the liver, oesophagus, descending aorta, heart. 
The heart was dissected along the atrioventricular border and then along the interatrial 
septum, removing ventricles and leaving atrial walls. PA and aorta were separated, 
and aorta was dissected off but retained. The heart was then removed leaving a left 
atrial cuff and a single common pulmonary artery. Any visible thrombus was physically 
removed. After initial dissection, 2 litres of 0.9% Sodium Chloride per pair of lungs, pre 
heparinised with 2,500 units/litre of unfractionated heparin was given as an antegrade 
and retrograde flush with an aim to remove all evidence of thrombus and have the 
flushing liquid “run clear” indicating removal of donor blood from the lungs. The initial 
litre bag of fluid at room temperature and second litre at 4°C. Lungs were intubated 
with an 8.0 mm endotracheal tube (ET), and ventilated during flushing of the first two 
litres of saline using a portable Ambu bag hand ventilator. Lungs were not ventilated 
during the final litre to avoid mechanical damage associated with ventilation of cold 
lung tissue. Lungs were transported partially inflated, within an organ transport bag on 
ice back to our lab in the Transplant Regenerative Medicine Facility, NHS-BT Donor 
Centre, Holland Drive, Newcastle, for perfusion. Exclusion criteria during procurement 
were based on visual inspection of lungs. Any lungs with contusion, lacerations, signs 
of consolidation, or oedema (at any point, including during flush) were rejected. 
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Table 2.1 Porcine procurement kit  
 
Porcine Procurement Kit – replenished after each procurement 
 Protective, aseptic clothing: surgical scrubs, gloves, gowns, shoe covers 
 1 X research retrieval box filled with ice.  
 4 X litre bags of cold 0.9% Sodium Chloride   
 2,500 units of unfractionated heparin/litre of Saline prepared prior to arrival 
 Surgical instrument kit: See Figure 2.3 (2 of each surgical instrument 
shown) 
 2 X endo-tracheal tube (size 8.0) 
 Ambu bag for ventilation 
 Blood giving set 
 Pulmonary artery flushing catheter 
 2 X 10 ml and 50 ml syringes 
 Silk ties 1.0 or 2.0  
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Figure 2.1 Work station for porcine lung procurement 
Equipment used during porcine procurement. (A) 1 Litre bag of cold saline 
heparinised with 2,500 units; (B) Pulmonary artery flushing catheter; (C) Bag-mask 
ventilator (D) Needle holders (E) Forceps (F) Scissors (G) 2.0 Silk ties.  
 
Figure 2.2 Procurement instruments 
Procurement instruments: A - Mayo scissors, straight, (Precision surgical, 51-1830). 
B - Metz scissors (BOSS, 50-1751). C - Probe 180MM (Precision surgical, 13-9110). 
D - Debakey vascular tissue forceps (Precision surgical, 65-2241). E – Tissue 
forceps, 2x3 teeth (BOSS, 10-4125). F - Crile forceps, (BOSS, 14-1266). G – 
Portable Ambu bag. 
 
  
A
B
C
D
E
F
G
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There have been many learning points from repeated procurements at the abattoir. 
There are often lung contusions, lacerations and damage to the pleura visible on 
initial inspection of the lungs. This is most likely due to the method in which the 
organs are removed from the pig and it can be highly variable depending on the staff 
member responsible. Having a more experienced abattoir technician has been 
beneficial. I have found that explaining to the abattoir workers what my research 
involves and demonstrating to them the technique of flushing the lungs has helped 
build a good rapport. I have then been able to emphasise the importance of avoiding 
lacerations through the slow and careful removal of the organs from the pig. The 
lungs often show gross, frank pulmonary oedema from the outset and it is 
hypothesised that there is shear stress from the removal of the lungs from the pig 
thoracic cage which may lead to damage to the vasculature and loss of vascular 
integrity.  
 
Another problem that has been highlighted during the porcine procurements is the 
variability of the warm ischaemic times. There are also steps in the abattoir’s culling 
protocol that involves immersing the pigs in a large tank of water at 80°F. This allows 
for any debris to be removed. The pigs are then scorched with flames to singe the 
remaining hair from the carcass. This likely does not impact visceral or thoracic organ 
temperature dramatically due to skin and fat insulation; however, it undoubtedly 
results in an exaggerated warm ischaemic time and if any breathing were to occur 
may result in damage to airways and so has been taken into consideration whilst 
explaining the severe pulmonary oedema seen in some cases. Despite this, the 
porcine procurement offers a vital training opportunity. The procurement at the Roslin 
Institute allows for a more standardised protocol. It is the same individual who culls 
the animals on every occasion and more time and care is put into retrieving the lungs 
as the time allows. Experience shows that there has been less oedema seen from 
the outset in the ovine lungs versus the porcine lungs and ovine lungs have shown 
greater stability over the duration of the EVLP. Although there has not been a direct 
experimental comparison. I postulate it is a direct result of differences in the culling 
methods and warm ischaemic time.  
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Perfusion Laboratory set up  
In the initial 6 months of my research project I worked closely with the clinical 
perfusionists at The Freeman Hospital who have a wealth of experience in clinical 
EVLP following their integral role in the DEVELOP-UK study. From discussions and 
shadowing exercises I developed an appropriate list of permanent equipment, 
laboratory consumables, additive medications and required gases for establishing a 
new perfusion laboratory space for research only EVLP. I procured all necessary 
consumables and set up a functional perfusion lab with the necessary stock, 
equipment and consumables based at NHS Blood Donor Centre, Holland Drive, 
Newcastle NE2 4NQ. I received training in the priming of an EVLP circuit, setting up 
gas cylinders and attended a gas safety training course.  
I have produced the relevant risk assessments for both the animal EVLP model and 
the human research EVLPs. This involved developing BioCoSHH forms to outline the 
risks associated with the activity being carried out in the lab and a description of the 
action taken to reduce these risks and protocols in place. Risk Assessments were 
also completed for the oxygen, mixed gases and medical air.  
Developing an EVLP model  
When deciding on which EVLP model to use for prospective studies there were 
several factors that had to be considered. The Vivoline® LS1 (Vivoline Medical, Lund, 
Sweden) EVLP machine had been used during the DEVELOP-UK trial and there was 
local knowledge of its set-up, design and troubleshooting of problems.  The Vivoline 
EVLP machine was a commercially available kit with one major downfall, the cost of 
its consumables, in the context of its use within a research project. The consumable 
in which the lung is reconditioned is costed at £6963 for a non-sterile Vivoline 
disposable lung set. Following on from DEVELOP-UK, it has been well recognised 
that clinical EVLP is an expensive procedure due to the accumulative costs of staff, 
equipment, consumables, theatre usage and drug used during EVLP. The cost of the 
EVLP procedure was found to be £42,633 (mean).  When considering which kit to 
use for training and research purposes we looked to reduce these costings.  
The Vivoline LS1 is automated and has one phase for lung reconditioning and one 
for evaluation of lung function. During reconditioning, the oxygenator is supplied with 
a gas mixture of nitrogen 74%, oxygen 21% and carbon dioxide 5%. During the 
evaluation phase, the oxygen supply is disconnected, and the oxygenator is used to 
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deoxygenate the perfusate in the EVLP system with a gas mixture of 93% nitrogen 
and 7% carbon dioxide. 
In order to gain training and experience with setting up the EVLP machine, priming 
the circuit, attaching the lungs and ensuring the circuit was set-up correctly I used the 
existing research Vivoline machine at Freeman Hospital perfusion lab. In order to 
reduce the costs of purchasing new lung set inserts, we decontaminated each set 
after each porcine EVLP and reused this equipment. The machine and all 
consumables was labelled clearly for “Research Use Only”.  
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Figure 2.3 Posterior View of Vivoline Machine 
Posterior view of Vivoline machine set-up during EVLP. (A) Pulmonary artery 
pressure transducers (B) Entry port for bronchoscope (C) Temperature transducer 
line (D) Oxygenator (E) Leucocyte filter (F) Roller pump 
 
Figure 2.4 View of Vivoline Machine from above  
View of Vivoline machine from above. Lungs are placed in a lung basin and kept 
covered with a clear plastic hood in order to preserve heat and prevent drying out of 
the lungs. (A) Endo-tracheal tube clamped prior to commencing ventilation (B) 
Pulmonary artery cannula (C) Shunt in closed position.  
 
Due to cost implications it became clear that a more economical model would need 
to be sought. Liaising with the Abdominal Perfusion team at Freeman Hospital links 
were made with Medtronic™, one of the largest multi-national medical device 
companies in the world with a portfolio spanning clinical services in neuroscience, 
vascular catheters and cardio-pulmonary bypass equipment. A pre-existing design of 
an abdominal perfusion circuit was modified and additional features added, such as 
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capacity for a leucocyte filter, Appendix B. The Medtronic kit, seen in Figure 2.5, 
includes all the necessary component parts of the EVLP circuit and is also set up 
with a computer console to monitor parameters such as pulmonary artery pressure, 
flow rate and temperature during the EVLP. The Medtronic Kit comprises a reservoir, 
oxygenator, centrifugal pump with 3/8 tubing connecting the component parts. The 
Medtronic software allows for in-line pressure monitoring via transducers placed 
within the pulmonary artery. The software ensures continuous monitoring of flow 
(l/min), RPM of the centrifugal pump and PAP (mmHg). The Medtronic kit is costed at 
£680 per kit and so is 10% of the cost of the Vivoline LS1 lung insert. The costings 
breakdown and total cost for Medtronic EVLP for all human donor lungs included in 
the Novel Therapeutics study can be seen in Appendix C. 
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Figure 2.5 Medtronic EVLP circuit  
Medtronic EVLP system. (A) Touch-screen Monitor (B) Console (C) Adult reservoir 
(D) Leucocyte filter (E) Centrifugal pump head (F) Flow meter (G) 3/8"Tubing. In 
addition to these items supplied by Medtronic, the following items were used: (H) 
Ventilator (I) Vivoline LS1 lung basin and dome. (J) Medtronic Kit as packaged.  
  
J 
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Standard operating procedures for EVLP  
In conjunction with initial training using porcine lungs and developing a cost effective 
and reproducible EVLP set-up, I developed standard operating procedures for all the 
individual elements of EVLP. I designed a logistics algorithm which was presented to 
and approved by the Northern Specialist Nurse in Organ Donation (SNOD) team and 
the National Organ Retrieval Service (NORS), Appendix D. This logistics algorithm 
laid out the pathway in which lungs which had been turned down for transplantation 
would be able to be used for research purposes.  
Potential organ donors were to be identified and consented by SNODs for research 
according to the existing policies of the NHS-Blood and Transplant (NHS-BT). 
Potential organ donors are referred to SNODs by local critical care units. Once the 
suitability for organ donation is confirmed, the family is approached and consent for 
clinical and research use is obtained. Once consent is obtained and donor 
assessment performed, the patient is registered via the NHS-BT Duty Office prior to 
offering organs. The Duty Office and/or SNOD will ensure that all potential donor 
organs are offered to the recipient centre point of contact (RcPoC) at national 
transplant centres; subject to absolute contraindications. Organs may be placed into 
this research programme via 2 mechanisms:  
•  If an organ is retrieved and deemed unsuitable for clinical use upon back-bench 
inspection and the family has consented for generic research; it will be referred to the 
NHS-BT duty office for placement in a nationally registered study with appropriate 
REC approval.  
 •  If an organ is not accepted by any centres for clinical use, study specific consent 
has been obtained, and the donation occurs in a Human Tissue Authority (HTA) 
licensed facility; the organ may be procured explicitly for use in this study.   
 Once tissue has been accepted into the study, suitable licensed transport will be 
arranged and tissues transported to the designated facility. All tissue will be 
appropriately disposed of according to HTA guidelines within 7 days or sent on to a 
designated location for long term storage.  
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Figure 2.6 Schematic Timeline Summarising Key Steps for Recruitment of 
Organs to this Study 
Adapted from the BTRU Study protocol, version 1.2, 30th January 2017. An algorithm 
and timeline showing the process from when a potential donor has been highlighted.  
INCLUSION CRITERIA EXCLUSION CRITERIA  
 Patient identified as a potential organ donor by 
the NHS-BT 
 Age between 18-85 years  
 Must fall into one of the following groups: 
defined brain death or individuals who have had 
a withdrawal of care and a minimum 5-minute 
observation period to confirm cardiac death.  
 Only patients with appropriate consent reflecting 
their own and their families’ wishes will be 
considered. 
 To be eligible for recruitment into the study, the 
tissue in question will have been declined for 
clinical use by all transplant centres in the UK.        
 Under the age of 
18 or above age 
85 
 HIV, Hepatitis B, 
Hepatitis C.  
Tuberculosis 
(TB), Clostridium 
difficile (CD) 
 Methicillin 
resistant 
staphylococcus 
aureus (MRSA).  
 
 61 
 
Table 2.2 Study Inclusion/Exclusion criteria  
Retrieval Procedure  
The standard clinical lung procurement procedure was followed for donor lungs to be 
used for EVLP in the study. The Cardiothoracic Team would adopt usual practice 
when flushing the lungs on retrieval. The organs are anterogradely flushed with 
supplemented (3.6% THAM 3.3 ml, 0.6 ml CaCl +/- 2.5 ml Prostacyclin / litre) 
Perfadex®, the first one litre at room temperature, the rest at 4 °C. A minimum 
volume of 60 ml/kg will be given. After the anterograde dose, 200ml will be given 
down each pulmonary vein as a final retrograde flush. 
An adequate portion of main PA, left atrial cuff, and at least 4 cm of trachea will be 
taken by the retrieval surgeon. A segment of aorta will be required to extend a 
deficient main PA (divided in close proximity to the bifurcation) to allow for successful 
cannulation and bilateral perfusion. The lungs will be transported on ice, in the 
standard way at retrieval in a “human tissue” ice box and be transported in the organ 
courier. EVLPs were carried out in the Transplant Regenerative Medicine Laboratory 
on the 3rd level of the NHS-BT building: Newcastle Blood Donor Centre, Holland 
Drive, NE2 4NQ.  
Ex-vivo lung perfusion protocols 
This thesis contains data from three separate studies investigating the use of EVLP 
to recondition rejected donor lungs in clinical lung transplantation. The retrospective 
studies that will be described in Chapters 3 and 4 were from the national multicentre 
study DEVELOP-UK study[98]. Using the Vivoline LS1 machine, DEVELOP-UK 
started off with a Hybrid protocol, so called because of its use of mixed features from 
the established Toronto and Lund protocols. After a pause of the DEVELOP-UK 
study and suspicion of protocol related poor perfusion, concerns regarding high 
requirements for post-operative ECMO and transplantation outcomes, the 
assessment was changed to the Lund protocol for which the LS1 machine was 
originally intended. The prospective novel therapeutics study that will be reported in 
Chapter 5, utilised a bespoke Medtronic EVLP circuit and a modified Toronto 
perfusion protocol.  Below follows an outline of the three different perfusion protocols 
that will be referred to in this thesis, Table 2.3. 
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 HYBRID LUND TORONTO 
STUDY GROUP 
The DEVELOP-UK 
study 
(2012 - 2013) 
The DEVELOP-UK 
study  
(2013 - 2014) 
Prospective Novel 
therapeutics study 
(2017-2018) 
PERFUSION    
Target flow 
40-60% of cardiac 
output  
100% of cardiac 
output (70 
ml/kg/min) 
40-60% of cardiac 
output  
Pulmonary 
arterial 
pressure 
<20 mmHg <20 mmHg <15 mmHg 
Left atrial 
pressure 
0 mm Hg (Open 
LA) 
0 mm Hg (Open 
LA) 
3-5 mm Hg 
Pump Roller Roller Centrifugal 
Circuit Vivoline LS1 Vivoline LS1 In-house Medtronic 
Perfusate 
2L Steen 
SolutionTM 
2L Steen SolutionTM 
with red-cell 
concentrates 
(Haematocrit 10-
15%) 
2.5L Steen 
SolutionTM 
VENTILATION    
Mode Volume controlled Volume controlled Volume controlled 
Tidal volume 6-8 ml/kg 6-8 ml/kg 7 ml/kg 
Frequency 10-15 bpm 10-15 bpm 7 bpm 
PEEP  5 cm H2O 5 cm H2O 5 cm H2O 
FiO2 50 % 50 % 21 % 
TEMPERATURE    
Start of 
ventilation 
32oC 32oC 32oC 
Start of 
perfusion 
15oC 15oC 15oC 
Start of 
evaluation 
37oC 37oC 37oC 
Table 2.3 Ex-vivo lung perfusion protocols used over the course of this MD 
project 
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A detailed, step by step, description of the EVLP set-up for DEVELOP-UK can be 
found in Appendix E. The procedure was performed using the Vivoline LS1 system 
(Vivoline Medical AB, Lund, Sweden). The circuit was primed with 2 litres of STEEN 
Solution with or without donor blood type specific leukocyte depleted packed red 
blood cells, depending on if following a cellular or acellular protocol. A target 
haematocrit of 10-15% was achieved. 10,000 iU heparin was added and the 
perfusate was buffered to a physiological level of pH of 7.35 – 7.45 with trometamol 
(THAM, Braun or Addex-THAM). Finally, 500 mg meropenem, 10 mg amphotericin B 
and 500 mg methylprednisolone were added to the perfusate. A blend of oxygen, 
nitrogen and carbon dioxide was supplied to the membrane oxygenator and the flow 
was adjusted to achieve a physiological venous blood gas. A visual inspection was 
carried out and recorded, to assess for areas of atelectasis, contusion, lacerations, 
areas of consolidation and tracheal secretions. 
After a period of cold storage, the PA cannula (XVIVO Perfusion AB, Gothenburg, 
Sweden) was connected to the perfusion circuit with careful de-airing through the 
open bypass shunt. The left atrium was left open and visualised to ensure a smooth 
flow of perfusate. The LA temperature probe and sampling line was secured in place 
equal distance from the 4 pulmonary veins. Reperfusion was initiated at a low flow 
rate of 0.5 L/minute. The lungs were slowly re-warmed, maintaining a 8°C difference 
between lung temperature and perfusate temperature. The flow rate was increased 
whilst ensuring that PA pressure was initially maintained at 15mmHg and then if 
stable, at 20 mmHg. At 25 °C the bypass shunt was closed, diverting all of the 
perfusate through the lung vasculature. When the temperature of the lungs reached 
32 °C, protective mechanical ventilation was initiated maintaining peak airway 
pressures of less than 20 mmHg. Ventilation was gradually increased as the lungs 
continued to warm, with full ventilation achieved at 37 °C. During this time, if there 
were areas of persistent atelectasis, recruitment manoeuvres were performed 
through transient increases in PEEP. When a steady state was achieved, with stable 
perfusate flow and ventilator settings, blood gases and haemodynamic parameters 
were registered. At this point the oxygenator was disconnected from the circuit, so 
that the perfusate was representative of mixed venous blood and the functionality of 
the lungs could be assessed via the oxygenation of the blood. An arterial and venous 
blood gas was run on a fraction of inspired oxygen (FiO2) of 50%, 100% and 21%. 
Table 2.4 demonstrates the criteria for lungs to be deemed acceptable for 
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transplantation at the end of EVLP. If lungs were suitable then they were cooled, 
oxygen was reconnected, ventilation was stopped and the trachea was clamped at 
half inspiration.  
The prospective novel therapeutics study of human lungs took place at the 
designated research area at the NHS Blood Donor Centre, Holland Drive, Newcastle, 
NE2 4NQ. A Toronto method was used involving an acellular perfusate, 40% of full 
cardiac output (70 ml/kg IBW/minute) and closed left atrium.  
 
A modified, in-house assembled Medtronic circuit (bespoke design, M444426B, 
Appendix B) was used, made up of: Vivoline LS1 lung chamber, plastic hood, 
centrifugal pump, an adult oxygenator, a LeukoGuard leukocyte filter (Pall 
Corporation, Port Washington, NY), a HICO heater-cooler unit (HICO, Germany), 
Medtronic pressure sensors, and temperature probes. 
 
Parameters to be met at EVLP Evaluation Stage  
 PAP <20mmHg, whilst achieving at least a target flow of 40-60% of a 
calculated donor flow index. 
 Oxygen capacity shown by delta PO2 of >40kPa (perfusate LA PO2 – 
perfusate PA PO2) / FiO2 
 Selective PV gas > 30 kPa on 100% FiO2 and 5 cm H2O PEEP 
 Stable or improving lung compliance and stable or falling lung resistance 
 No pulmonary oedema build-up in the ET tube 
 Satisfactory assessment on inspection and palpation 
Table 2.4 Criteria for Successful EVLP Assessment 
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Sample collection and processing 
This section contains the protocols for sample collection and processing of donor 
lung samples taken from three lung compartments: vascular compartment (perfusate 
fluid), airway compartment (BAL fluid), and tissue compartment (lung biopsy). 
Perfusate 
Samples of perfusate solution were collected longitudinally during the EVLP process. 
5 ml were collected from the perfusate sampling port at the following time-points: 
All studies  
Perfusate 0 Taken from the primed EVLP circuit before 
the donor lung perfusion is started 
Perfusate 1     Taken 15 minutes after perfusion is started 
Perfusate 2     Taken 30 minutes after perfusion is started 
Perfusate 3- maximum Perfusate 8      Taken every 30 minutes during perfusion 
Perfusate X Taken at the end of the perfusion 
immediately before the perfusion is stopped 
The perfusate samples were centrifuged to remove cellular debris and aliquoted 
equally into 5 x 1 ml tubes before being frozen initially at -20oC and then transferred 
to a -80oC for longer term storage and subsequent laboratory analysis.  
Bronchoalveolar lavage fluid 
As part of the study protocol, under flexible bronchoscopic guidance a standardised 
BAL using 120 ml of sterile normal saline (0.9% sodium chloride solution) was 
performed from either the left or right lower lobe of the donor lung on two occasions 
(BAL1 and BAL2). BAL2 was performed from the same lobe as BAL1, but in a 
different segment of that lobe. The timing of each BAL is detailed below: 
BAL 1: At the beginning of the EVLP process after perfusion has commenced and 
the lung temperature has reached at least 30oC, but before ventilation of the lung is 
initiated. 
BAL 2: At the end of EVLP process once the final assessment is complete but before 
ventilation is discontinued. 
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The BAL was filtered through gauze to remove excess mucus and then centrifuged to 
separate the cellular component from the acellular supernatant. The acellular 
supernatant was divided into 1 ml aliquots in storage tubes. The storage tubes were 
then frozen initially at -20oC and then transferred to a -80oC for longer term storage 
and subsequent laboratory analysis. 
Lung tissue biopsies 
Small biopsies (approximately 3x3x1 cm) of lung tissue were taken using a Covidien 
Duet (absorbable buttressed) endo-GIA stapler from either the right middle lobe or 
lingula  
For DEVELOP-UK, at two time points:  
Biopsy Pre: Taken prior to commencement of the EVLP process  
Biopsy Post: Taken at the end of the EVLP process once perfusion has stopped 
from the same location as Biopsy 1. 
For novel therapeutic study, at four time points: 
Biopsy 1: Taken prior to commencement of the EVLP process  
Biopsy 2: 30 minutes’ post drug dosing 
Biopsy 3: 60 minutes’ post drug dosing 
Biopsy 4: Taken at the end of the EVLP process once perfusion has stopped from 
the same location as Biopsy 1. 
Biopsies were placed on sterile gauze dampened with 0.9% sodium chloride in a 
sample pot and the pot stored on ice until processing. From each of these biopsies, 2 
pieces of tissue, approximately 5-10 mm in diameter were snap frozen using dry ice 
and isopentane slurry, for subsequent mechanistic studies, stored at -80°C. The 
remaining tissue was fixed in formalin, paraffin embedded and sections cut for 
routine histological evaluation. All fixing was carried out by the Cellular Pathology 
Research Laboratory, Royal Victoria Infirmary, Newcastle upon Tyne. Tissue blocks 
were available for subsequent immune-localisation studies using 
immunohistochemistry. 
For protein analysis snap frozen lung tissue (100 mg/sample) was homogenized in 
500 μL homogenization buffer (2 tablets complete™ mini protease inhibitor (Roche 
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Diagnostics, Basel, Switzerland) in 10 ml ready-to-use Radio-Immunoprecipitation 
Assay (RIPA) Buffer (Sigma-Aldrich, St Lois, MO, USA)) using a Minilys® ceramic 
bead tissue homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France). 
Each homogenate was centrifuged twice at 13,000 g for 5 minutes, the supernatants 
decanted, and the protein concentration of each sample estimated using a Pierce™ 
BCA protein assay (Thermo Fisher Scientific Inc., Waltham, MA, USA) before storage 
at -80oC. 4 mg protein/ml diluted in 0.1% BSA in homogenization buffer was loaded 
onto protein assay plates according to manufacturers’ instructions. 
 
Sampling Protocol  
Throughout the EVLP there are samples including perfusate, BAL and tissue biopsy 
taken for future analysis. Below in Figure 2.7, the time points at which these are 
taken in relation to the stage of EVLP is shown.  
 
Figure 2.7 Flow chart for sampling protocol during EVLP. 
Bronchoscopy will be performed on 2 occasions during a standard EVLP: 1ST at the 
beginning of EVLP, perfusing the lungs but before ventilation, lung temperature 30°C.  
2ND at the end of EVLP but before ventilation stopped. The BAL samples will be 
taken from the RLL (right lower lobe) and/or LLL (left lower lobe), using up to 120 ml 
of 0.9% Saline per lavage. Lung biopsies could be taken from the RML or lingual at 
pre and post EVLP using a Covidien Gia Surgical Stapler.  
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Figure 2.8 Pair of Lungs with markers of biopsy sites 
(A) A pair of human lungs declined for transplantation prior to EVLP. Dotted circles 
indicate biopsy sites. Lung biopsies taken from the RML or lingual at pre and post 
EVLP using a Covidien Gia Surgical Stapler (B).  
 
An alternative perfusate to Steen Solution 
During all human EVLPs we used commercially available Steen Solution, a perfusate 
which is an extracellular solution with the addition of human albumin to maintain 
optimal colloid pressure and dextran 40 to protect the endothelium from complement 
and cell-mediated injury and to inhibit coagulation and platelet aggregation. A 
minimum of 2 litres of Steen is needed for each EVLP with the potential for additional 
500 ml hourly exchanges. It is produced by XVIVO Perfusion Sweden at a cost of 
€876 per 500 ml bottle. With an overall cost per experiment of €3504 without 
exchanges. Due to this cost, an alternative solution was sought which could be used 
for animal work and training purposes. I liaised with the research team at Manchester 
University, James Fildes and William Critchley who advised us on the constituents 
and procedure for producing an alternative perfusate to the commercially available 
Steen Solution. The protocol for making this alternative STEEN can be found in 
Appendix F. The cost of alternative Steen solution is £200 per 2 litres and is 
therefore far more economical for porcine and training purposes.  
Quantification of protein expressions in perfusate, bronchoalveolar lavage fluid 
and lung tissue lysates 
Enzyme-linked Immunosorbent assays 
Enzyme-linked immunosorbent assay (ELISA) is a plate-based assay technology 
used to detect and quantify substances such as proteins and hormones. In this 
project I have consistently used commercially available already optimised sandwich 
A 
 
B 
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ELISA kits, most commonly DuoSet® ELISA development systems by R&D (Bio-
techne, Minneapolis, MN). This type of ELISA assay is called a “sandwich” ELISA as 
the measured protein is bound between two primary antibodies – a capture antibody 
and a detection antibody, Figure 2.9. The basic technique of a sandwich ELISA 
consists of coating the wells of 96 well polystyrene plates with an antigen specific 
capture antibody that passively attaches to the plastic of the well. The sample is then 
added and the attached capture antibody used to immobilize any antigen that comes 
in contact with the surface of the well and its attached antibodies. After washing out 
excessive sample, separating bound from non-bound, the amount of antigen bound 
by the primary antibodies can be quantified by the addition and complex binding of 
an antigen specific detection antibody linked to an enzyme. This ability to wash away 
non-specifically bound materials and detect proteins specifically bound to the primary 
antibodies on the bottom of the well makes the ELISA a powerful tool for measuring 
specific proteins within a crude preparation, such as perfusate, BAL fluid or tissue 
lysates. Detection and quantification of proteins in the sample is accomplished by 
measuring the activity of the enzyme linked to the detection antibodies by incubating 
it with a substrate for 15-20 min to produce a light signal that can be measured with 
high sensitivity. The most commonly used enzyme label is horseradish peroxidase 
(HRP) which catalyses the conversion of tetramethylbenzidine (TMB) into a 
measurable coloured product. The final quantification of sample protein concentration 
is established by the creation of a standard curve, which is prepared by serial 
dilutions of a known quantity of the measured protein across a range of 
concentrations near the expected sample concentration. The protein content of the 
unknown perfusate, BAL or tissue lysate sample is determined by interpolation from 
the generated standard curve. Appendix G gives a detailed, step-by step description 
of the ELISA technique used in this thesis.  
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Figure 2.9 Diagram of a sandwich enzyme-linked immunosorbent assay 
(ELISA) 
Diagram of a sandwich enzyme-linked immunosorbent assay (ELISA). In the assay, 
the protein of interest is immobilized by first attaching a capture antibody to the plate 
surface. Detection and quantification of the antigen is then accomplished by using an 
enzyme-conjugated primary antibody. Adapted from LS Bio LifeSpan Biosciences, 
Inc[122]. 
Meso scale discovery multiarray 
A wide range of protein markers were analysed in perfusate, BAL, and tissue lysate 
samples with electrochemi-luminescent Meso Scale Discovery (MSD) Multi-Array® 
(Meso Scale Diagnostics, LLC, Rockville, MD). The assay was performed according 
to manufacturer’s instructions with technical support from an experienced MSD 
technician. The MSD assay follows similar procedural steps as an ELISA. Briefly, 
multiarray plates pre-coated with capture antibodies for up to ten human proteins are 
incubated with standards and samples. After two hours of incubation and passive 
complex binding of protein to the specific capture antibodies fixed to the bottom of 
the well, a detection reagent containing electrochemi-luminescent labels conjugated 
to detection antibodies is added. Electricity applied to the plate electrodes by an MSD 
instrument leads to light emission by the “SULFO-TAG” labels Light intensity is then 
measured and compared to a standard curve to quantify protein levels in the sample, 
Figure 2.10 [103]. 
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Figure 2.10 MSD assay  
High binding carbon electrodes in the bottom of the MSD microplates allow for 
attachment of biological reagents. MSD assays use electrochemi-luminescent labels 
(SULFO-TAG) that are conjugated to detection antibodies allowing ultra-sensitive 
detection. Electricity applied to the plate stimulates light emission from the labels. 
Light intensity is then measured to quantify sample protein levels [103]. 
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Immunohistochemistry staining of lung tissue 
Antibodies used for immunohistochemistry were as follows: IHC primary Ab: anti-
eNOS (ab5589, Abcam, Cambridge, MA) and Neutrophil Elastase (42 mg/L Clone 
NP57 DAKO, Glostrup, Denmark) 
Tissue from biopsies taken pre, during and post-EVLP, see sample protocol and 
collection section. Tissue was fixed in 10% neutral buffered formalin and embedded 
in paraffin. 5-μm sections were cut and mounted on Superfrost Plus glass slides 
(Thermo Fisher Scientific, USA). Following de-waxing and citrate antigen unmasking, 
eNOS and Neutrophil Elastase (NE) were detected in parallel single-stain 
experiments.  
NE antigen was retrieved using trypsin (BD, New Jersey, USA), incubated at 37.5oC 
for 20 minutes. Monoclonal mouse anti-human antibodies against NE (42mg/L Clone 
NP57 DAKO, Glostrup, Denmark), was used in 1:100 concentrations and incubated 
for 90 minutes at RT. A Dako EnVision+ System, HRP (DAKO, K4006, Glostrup, 
Denmark) was used as secondary antibody and protein visualisation.  
eNOS antigen was retrieved by incubating in boiling citrate buffered to pH6, heated in 
a microwave on full power for 10 minutes. Rabbit polyclonal to eNOS was used in 
1:50 concentrations incubated at room temperature for 1 hour and then overnight at 
4°C, in the fridge for 18 hours. A Dako EnVision+ System, HRP (DAKO, Glostrup, 
Denmark) was used as secondary antibody and protein visualisation. 
Proteins were visualized by avidin-biotin method with biotinylated secondary 
antibodies and subsequent DAB chromogen staining (Vector Labs, Burlingame, CA). 
Sections were counterstained with Mayer’s haematoxylin, dehydrated, cover slipped, 
and digitally photographed. Appendix H provides a detailed, step by step description 
of the IHC protocols used in this thesis.  
RNA Sequencing  
The RNA sequencing results shown in Chapter 3: Novel Biomarkers of Ex-Vivo Lung 
Perfusion, were carried out by our BTRU Cambridge collaborators Dr Menna 
Clatworthy and Dr John Ferdinand. RNA sequencing (RNA-Seq) uses the capabilities 
of high-throughput sequencing methods to provide insight into the transcriptome of a 
cell. A typical RNA-Seq experiment consists of isolating RNA, converting it to 
complementary DNA (cDNA), preparing the sequencing library, and sequencing it on 
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an NGS platform. The methods described below were used for the RNA-sequencing 
reported in this thesis.  
RNA extraction 
RNA was extracted from biopsies stored in RNALater (Ambion) at -80C. Biopsies were 
removed from their storage solution and placed with 1 ml Lysis Buffer (Ambion) in a 
MK28-R grinder tube (Bertin Instruments) and lysed using a Precellys 24 homogeniser 
(Bertin Instruments). Tubes were subsequently centrifuged at 1500 xg for 4 minutes, 
the supernatant removed and the RNA extraction performed using a pure link RNA 
mini kit (Ambion) as per manufacturer’s instructions. Contaminating DNA was removed 
using TURBO DNase (Ambion) as per manufacturer’s instructions. Concentration of 
RNA was assessed using a Nanodrop Spectrophotometer (Thermo Scientific). Quality 
of RNA was assessed using a RNA nano Bioanalyzer kit (Agilent) using a Bioanalyzer 
2100 (Agilent).  
RNA sequencing 
1ug of RNA was used for producing libraries for sequencing using TruSeq Stranded 
total RNA library prep kit (Illumina) as per manufactures instructions with a final PCR 
amplification of 14 cycles. Libraries were then sequenced on a Hiseq sequencer 
(Ilumina) by Eurofins.  
RNASeq analysis 
Following sequencing data was demultiplexed to give individual fastq files using 
Casava (Illumina). Fastq files were assessed for quality control purpose using 
FASTQC. The Fastq files were aligned to the human genome (Hg38) using Hisat2. 
All further analysis was carried out using the R statistical environment. A table of 
gene counts was produced using the featureCounts function within Rsubread and 
normalisation and differential gene expression analysis was carried out using 
DESeq2. For GSEA genes were ranked by the inverse of the p value with the sign of 
the log fold change and then ran against the hallmarks database within MSigDB 
using the GSEA program from the broad with the pre ranked option. 
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Chapter 3. Identifying potential predictive biomarkers of successful 
Ex-vivo Lung Perfusion 
This chapter describes our investigation into identifying potential predictive 
biomarkers of successful EVLP in donor lungs that were assessed in the DEVELOP-
UK cohort with the intent for transplantation. The multicentre study, An Observational 
Study of Donor Ex Vivo Lung Perfusion in UK lung transplantation: DEVELOP-UK 
(DEVELOP-UK) (ISRCTN 44922411), was a three-year prospective non-randomised 
nationwide clinical trial comparing standard lung transplantation with transplantation 
following lung assessment with EVLP. DEVELOP-UK was launched in 2012 across 
the five UK lung transplant centres, with the Freeman Hospital (Newcastle) being the 
lead centre. During the trial, 53 EVLP assessments were performed with 18 of those 
proceeding to clinical lung transplantation. In each set of lungs, a lung biopsy and 
standardised research BAL were taken before and after the EVLP assessment and 
additionally, perfusate samples were collected every 30 minutes during the 
assessment, Figure 2.7. The same sample collection was completed at the other 
four UK lung transplant centres, and at the end of the study, all samples were 
transferred to Newcastle for storage and further evaluation. The samples were stored 
in an HTA licenced and monitored -80 °C freezer at Newcastle University and were 
available for analysis of a range of biomarkers of lung injury, and inflammation. The 
collection and storage of samples was part of the DEVELOP-UK study and allowed 
for complementary mechanistic studies investigating cellular and molecular 
mechanisms of donor lung reconditioning to be carried out in the future. 
To further the understanding of the biology of clinically assessed EVLP lungs a 
collaboration was initiated with the Transplant Molecular Biology Group at the 
University of Cambridge specialising in transcriptome analysis. Lead by Dr Menna 
Clatworthy and Dr John Ferdinand, RNA sequencing analysis was carried out to 
assess the changes in gene signature within snap frozen tissue from ten human 
lungs assessed in the DEVELOP-UK study. Samples were obtained at the start and 
end of EVLP for each lung. The cohort contained sets of lungs that were transplanted 
(n=6) and declined (n=4) for transplantation based on physiological parameters.  
This study aimed to utilise the method of RNA sequencing to determine the genes 
differentially expressed pre- and post-EVLP, and decipher the corresponding 
immunological processes. The study also sought to compare the transcriptome 
between lungs that were transplanted and declined for transplantation in the baseline 
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samples obtained prior to EVLP. Following up on the interesting findings from the 
transcriptomic analysis, a further study was pursued to correlate the changes in gene 
expression with the expression of their corresponding proteins within perfusate.  
This chapter reports on the identification of potential biomarkers for organ suitability 
and the analysis of the corresponding lung perfusate to determine if the proteins 
associated with the genes identified are detectable and have any predictive value as 
markers of EVLP performance. 
My contribution, in collaboration with our Cambridge colleagues, was to evaluate and 
analyse the data, correlate with clinical indices and write a manuscript that is to be 
submitted for publication.  
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Introduction 
Lung transplantation is now established as an appropriate and effective treatment for 
selected patients with life-threatening end-stage lung disease. Unfortunately, a 
worldwide shortage of suitable donor organs continues to be the major limitation to the 
increased accessibility of lung transplantation for those who will benefit. Demand for 
lung transplantation exceeds the availability of donor organs, and many potential lung 
transplant candidates do not survive the wait for a suitable donor organ[13].  
One common strategy used by transplant professionals to address the challenge of 
donor shortage is to increase the donor organ pool by increasing the utilisation of lungs 
from extended criteria donors[13, 123]. These are donors that don’t fully satisfy the 
characteristics of an ideal lung donor by virtue of age, smoking history, lung function 
or co-morbidity[22-24, 47, 124, 125]. The continual push to use more extended criteria 
donors has raised concerns among both transplant teams and patients as to whether 
this approach will lead to poorer early and late outcomes after lung transplantation[126, 
127]. One potential solution to this problem is the use of ex-vivo lung perfusion (EVLP) 
as a means to test the function of extended criteria donor lungs before a decision on 
suitability[27, 65, 128]. 
Ex-vivo lung perfusion has emerged over the last ten years as a promising technique 
to objectively assess and potentially recondition donor lungs unsuitable for immediate 
transplantation with the overall aim of increasing the available donor lung pool[129]. 
The decision to accept organs for transplantation after EVLP is currently based 
predominantly around physiological parameters such as oxygenation, lung 
compliance, pulmonary vascular resistance and peak airway pressure in addition to 
the visual appearance of the organ. Reported discard rates of 10–60% of perfused 
lungs suggest that some donor lungs may be inappropriately used or inappropriately 
declined for transplant after EVLP[85].  
The cellular and molecular events that occur in the donor lung during EVLP have not 
yet been fully characterised, and there is a pressing need to identify potential predictive 
biomarkers of inflammation and tissue injury during EVLP to distinguish donor lungs 
that can be reconditioned and to predict post-transplant outcomes. Our group has 
previously demonstrated the feasibility of identifying pro-inflammatory and tissue injury 
signals in perfusion fluid during EVLP of unsuitable donor lungs[83]. Furthermore, we 
have recently demonstrated that early pro-inflammatory signals in perfusate due to 
interleukin (IL-1β) and tumour necrosis factor-α (TNF-α), after as little as 30 minutes of 
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EVLP can distinguish between lung transplant recipients surviving to hospital 
discharge and in-hospital mortality post-transplantation[83].  
Although utilising biomarkers in perfusate seems to be showing encouraging results, 
the choice of which biomarkers to evaluate in perfusate is based on previously 
published literature and therefore makes assumptions and is biased to signals reported 
in studies of primary graft dysfunction after lung transplantation[43, 130-134].   
In this study, we have utilised RNA-Seq technology to generate an unbiased profile of 
the changes in the entire transcriptome of the human donor lung tissue during EVLP. 
A comprehensive investigation of the changes in tissue RNA expression during EVLP 
of human donor lungs has not previously been carried out.  Our aim with this approach 
is to detect significant changes in transcriptional activity that might uncover potential 
biomarkers yet to be identified as playing a significant role in donor lung injury and 
tissue damage[135].  
Methods  
Study subjects and protocol  
In this study, we utilised samples of whole donor lung tissue collected from a large 
cohort of highly characterised clinical EVLP procedures performed as part of the 
DEVELOP-UK multicentre trial, which involved all five UK transplant centres[98]. 
DEVELOP-UK included 53 adult donor lungs which were deemed unsuitable for lung 
transplantation but met pre-defined criteria for EVLP. Assessments were performed 
using a Vivoline LS1 EVLP circuit (Vivoline Medical AB, Lund, Sweden) following 1 of 
2 standardised perfusion protocols: an initial Hybrid protocol featured an open left 
atrium, acellular perfusate, and perfusate flow limited to 40%–60% of donor calculated 
cardiac output (n=22). Subsequently, the perfusion strategy was changed to the Lund 
protocol with cellular perfusate (haematocrit 10%–15%) and full flow perfusion of 100% 
donor calculated cardiac output (n=31). All tissue samples were from the Lund 
protocol. Assessment methods, including sampling procedures, remained unchanged 
between the two protocols. 
Sample collection  
The DEVELOP-UK sampling protocol was followed to allow for tissue biopsy collection 
from either the right middle lobe or lingula both before and after the EVLP assessment 
using a GIA surgical stapler[98]. Biopsies were snap frozen in liquid nitrogen as soon 
as possible after collection for subsequent RNA isolation. 
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A control perfusate sample was collected from the primed EVLP circuit before donor 
lung perfusion started. Repeated perfusate samples (5 ml) were then collected at 15 
and 30 minutes after perfusion commenced and every 30 minutes thereafter. The 
perfusate samples were centrifuged at 180 xg for 6 minutes at 4oC to remove cellular 
debris and aliquoted equally into 5x1 ml tubes before being frozen initially at -20oC and 
then transferred to a -80oC for longer term storage and subsequent laboratory analysis.  
RNA extraction 
RNA was extracted from biopsies stored in RNALater (Ambion) at -80C. Biopsies were 
removed from their storage solution and placed with 1 ml Lysis Buffer (Ambion) in a 
MK28-R grinder tube (Bertin Instruments) and lysed using a Precellys 24 homogeniser 
(Bertin Instruments). Tubes were subsequently centrifuged at 1500 xg for 4 minutes, 
the supernatant removed and the RNA extraction performed using a pure link RNA 
mini kit (Ambion) as per manufacturer’s instructions. Contaminating DNA was removed 
using TURBO DNase (Ambion) as per manufacturer’s instructions. Concentration of 
RNA was assessed using a Nanodrop Spectrophotometer (Thermo Scientific). Quality 
of RNA was assessed using a RNA nano Bioanalyzer kit (Agilent) using a Bioanalyzer 
2100 (Agilent).  
RNA sequencing  
1ug of RNA was used for producing libraries for sequencing using TruSeq Stranded 
total RNA library prep kit (Illumina) as per manufactures instructions with a final PCR 
amplification of 14 cycles. Libraries were then sequenced on a Hiseq sequencer 
(Ilumina) by Eurofins.  
RNASeq analysis 
Following sequencing data was demultiplexed to give individual fastq files using 
Casava (Illumina). Fastq files were assessed for quality control purpose using 
FASTQC. The Fastq files were aligned to the human genome (Hg38) using Hisat2. 
All further analysis was carried out using the R statistical environment. A table of 
gene counts was produced using the featureCounts function within Rsubread and 
normalisation and differential gene expression analysis was carried out using 
DESeq2. For GSEA genes were ranked by the inverse of the p value with the sign of 
the log fold change and then ran against the hallmarks database within MSigDB 
using the GSEA program from the broad with the pre ranked option. 
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Enzyme-linked immunosorbent assays 
Serial perfusate samples from 44 human donor lungs undergoing clinical EVLP 
assessments were analysed retrospectively. Enzyme Linked Immunosorbent Assays 
(ELISA) were used to detect protein levels in the perfusate for specific pro-
inflammatory markers, including Monokine induced by gamma interferon (MIG), 
Macrophage Inflammatory Protein-3 beta (MIP-3 beta), Pentraxin-3 (PTX3), Human 
Alpha-1-acid (α1AGp) and Heat Shock Protein 70 (HSP-70) (R&D Systems, Inc., 
Minneapolis, MN). All protein concentrations measured in perfusate were adjusted to 
the donor predicted total lung capacity as an estimate of perfused donor lung volume 
and reported as corrected perfusate concentrations (pg/ml).  
 
Statistical Analysis  
Perfusate protein levels were analysed using GraphPad Prism 6 (GraphPad Software 
Inc., La Jolla, CA). The ability of each biomarker to discriminate between outcome 
groups (Survival, Non-survival, and Decline) was assessed with Mann-Whitney U test. 
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Results  
Between April 2012 and July 2014, 53 donor lungs, deemed unsuitable for immediate 
transplantation underwent EVLP as part of the DEVELOP-UK clinical trial. A detailed 
description of the study population can be found in the final study report[98]. Due to 
incomplete or insufficient sampling, complete perfusate samples were available from 
44 of the 53 donor lungs and both pre- and post-EVLP tissue samples from 10 of the 
53 donor lungs. Of the 44 donor lungs included, 18 (41%) underwent “successful 
EVLP” and met the criteria for transplantation, while a further 4 of those 18 met 
transplant criteria but did not proceed to transplantation due to logistical or donor 
reasons.  26 of 44 donor lungs (59%) did not satisfy criteria for transplant after EVLP. 
Of the 14 lung transplants that were carried out following EVLP, 9 of 14 recipients 
(64%) survived to 1-year. The median donor age was 49.5 years (range 16-65 years). 
There were 25 male and 19 female donors. There were 33 DBD donors and 11 DCD 
donors. The results were compared between sub-groups depending on outcome: 
Successful EVLP n=18, Unsuccessful EVLP n=26. The results were also compared 
between sub-groups depending on the EVLP protocol used: Hybrid n=15 and Lund 
n=29.   
In this study we compared the gene expression signatures in paired pre and post EVLP 
lung tissue samples to determine the changes in gene expression that occur during 
the process of EVLP. We studied the RNA-Seq profiles from 10 EVLP procedures in 
total. We further categorised them depending on whether the EVLP was deemed 
successful (“pass” n=6 or unsuccessful “fail”, n=4) using the standard donor lung 
assessment criteria defined used as part of the DEVELOP-UK trial[98]. Comparisons 
of the genetic signature in these two groups was then carried out.   
Our results illustrated that the process of EVLP alone induce a change in the gene 
expression within donor lung tissue, Figure 3.1. Perfusion itself causes changes within 
the lung transcriptome, predominantly pathways which are involved in the immune 
system. The effect of perfusion on the transcriptome is demonstrated in the volcano 
plot, Figure 3.1A showing that EVLP was associated with the significant upregulation 
of 297 and down regulation of 86 specific genes. During EVLP several cytokine genes 
were significantly upregulated Figure 3.1F, with CXCL5, TNF, CCL20 and CXCL1 all 
showing significance (padj <0.05). During the process of EVLP there are also a number 
of genetic pathways that are upregulated. The gene pathway that was most 
significantly upregulated was TNFA Signalling via NFκB. Other important pathways 
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that were highly upregulated were hypoxia, inflammatory response and oxidative 
phosphorylation Figure 3.1C.  
    
   
 
 
 
86 297 
D 
B 
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Figure 3.1 EVLP induces a large effect on the transcriptome which is 
predominated by immune pathways 
Lung tissue biopsies were collected before and after each EVLP assessment, n=10.  
Biopsies were snap frozen in liquid nitrogen for subsequent RNA extraction.  
A. shows a Volcano plot for the effect of perfusion. Number indicate the total number 
of significant genes in each direction: 86 down regulated and 297 upregulated during 
perfusion.  
B. shows a gene set enrichment analysis (GSEA) against the hallmark data set for 
perfusion demonstrating that the TNF-α signaling via NFκB pathway is the gene set 
most highly expressed.  
C. shows the heat map of the top 20 genes up and down regulated during perfusion 
with pre EVLP samples shown in the grey panel and post EVLP samples shown in 
purple panel. Range of colours (red to blue) shows the range of expression values 
(high to low).  
D. shows the enrichment plot for the gene set TNF-α signaling via NFκB by GSEA. 
Bottom, plot of the ranked list of all genes. Y axis, value of the ranking metric; X axis, 
the rank for all genes. The enrichment plot demonstrates that with a peak enrichment 
score of 0.50, the TNF-α signaling via NFκB gene set is ranked at the top of the list of 
genes found from the GSEA.  
E. shows a volcano plot for the effect of perfusion on cytokine genes 
 
 
D E 
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We demonstrated that there was a direct correlation between the cytokine level in 
perfusate with the RNA count prior to commencing perfusion, Figure 3.2.  
 
 
 
 
Figure 3.2 Cytokine levels in the perfusate correlate with the RNA count in pre 
EVLP lung tissue samples. 
Scatter plots show the correlations between the cytokine protein level (log2 pg/ml/l) in 
perfusate (Y-axis) and the RNA count (log2_normalised counts) for the 
corresponding cytokine gene detected in the pre EVLP lung tissue (X-axis).  
Correlation is for untransformed data. Liner regression line added to log transformed 
data. CCL2, P=0.01; CXCL8 P=0.044; ICAM-1 P=0.018; IL-6 P=0.049.  
 
 
 
 
 
 
CCL2 CXCL8 
ICAM-1 IL-6 
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The assessment of the transcriptome demonstrated differences in the gene profiles 
between donor lungs that performed well during EVLP (pass) compared with donor 
lungs that performed poorly and could not be transplanted (fail). Gene set enrichment 
analysis (GSEA) was used to identifying significantly enriched gene sets in pass and 
fail lungs. There is increased induction of immune activation genes and pathways 
during perfusion in fail compared to pass lungs. Figures 3.3 and 3.4 show that in lungs 
which had a poor outcome, there was an upregulation of immune pathways such as 
interferon gamma response and TNF via NFκB. Conversely the oxidative 
phosphorylation pathway was downregulated in fail lungs. 
 
Figure 3.3 There are differentially expressed gene sets in lung tissue from pass 
versus fail EVLP. 
Lung tissue biopsies were collected before each EVLP assessment. They were then 
divided into pass or fail EVLP depending on whether they met Transplant criteria at 
the end of EVLP, “pass” n=6 and “fail”, n=4.  For fail lungs the hallmarks GSEA for 
interaction can be seen above. 
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Figure 3.4 There are differentially expressed gene sets in lung tissue from pass 
versus fail EVLP. 
Top row shows the GSEA enrichment plots for the interferon gamma, TNF-α via 
NFκB and oxidative phosphorylation responses.  
Bottom row shows the volcano plots for the individual genes within each pathway 
from GSEA analysis in row above. Red triangle points are the lungs which failed 
EVLP, black circle points are those that passed. The Log fold change is for the 
comparison within groups between pre and post samples. 
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IL-1β is a powerful pro-inflammatory cytokine that is a hallmark of sterile inflammation 
occurring as a result of NLRP3 inflammasome activation. We demonstrated that 
inflammasome activation genes are enriched in pre-perfusion biopsies in fail lungs, 
Figure 3.5. 
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Figure 3.5 The effect of EVLP and outcome on IL-1β and the inflammasone 
genes 
A. shows the normalised counts of IL-1β for perfusion in all samples between pre and 
post perfusion. Higher IL-1β  counts seen in the post samples. 
B. shows the normalised counts split by time point and outcome. Prior to 
commencing perfusion, the lungs that go onto later fail have higher normalised 
counts of IL-1β.  
C. shows the correlation for the IL-1β RNA level in samples pre perfusion with the 
protein content in the perfusate, P=0.733. 
D. shows a heat map of the inflammasone related genes. All individual cases are 
seen: pre samples for the pass group shown in the grey panel; post samples of the 
pass group in the purple panel; pre samples for the fail group in the green panel and 
post samples for the fail group in the blue panel. This demonstrates that the 
inflammasone genes are upregulated during EVLP, and significantly more in lungs 
that fail.  
E. shows the GSEA of inflammasone gene in pre EVLP samples comparing pass 
versus fail, P=0.004. Inflammasone genes are significantly upregulated in pre 
samples of fail lungs.  
F. shows the Volcano plots for the individual genes within each pathway from GSEA 
analysis in D. Red triangle points are the lungs which failed EVLP, black circles are 
those that passed. The Log fold change is for the comparison within groups, between 
pre and post samples. 
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Gene transcripts of all neutrophil-recruiting chemokines were evaluated and showed 
that lungs that failed during EVLP express higher level of CXCL8 mRNA and have a 
trend towards a greater increase during perfusion and a trend towards higher CXCL8 
mRNA levels in post-perfusion samples, Figure 3.6.  
 
 
 
Figure 3.6 The effect of perfusion and outcome on the IL-8 gene set. 
A. and B. show the normalised counts for CXCL8 in the indicated comparisons. 
Higher IL-8 counts seen in the post samples. Prior to commencing perfusion, the 
lungs that go onto later fail have higher normalised counts of IL-8. 
C. shows a heat map of neutrophil chemo attractants. 
D. shows a heat map of neutrophil related adhesion proteins. 
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A subset of heat shock proteins is upregulated during perfusion in fail lungs, Figure 
3.7. Figure 3.8 demonstrates the changes in cytokine and chemokine gene expression 
when comparing pass and fail lungs, pre and post EVLP.  
  
Figure 3.7 Heat shock protein family genes are seen in higher levels in lungs 
that fail EVLP 
A. Heatmap of HSP family of proteins – many of these are increased following 
perfusion in samples which fail EVNP.  
B. Volcano plot of genes above for effect in perfusion split by outcome group. 
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Figure 3.8 Heat map of cytokines and chemokines between pass and fail EVLP 
lungs 
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Figure 3.9 Potential biomarkers in EVLP  
A volcano plot showing the logarithmic fold change (LFC) between the outcome 
groups with potential biomarkers highlighted in red, indicates which genes taken 
forward for protein validation. In lungs that passed EVLP, there were significantly 
higher levels of the genes for HSPA1A and HSPA1L. CCL19 and ORM1 were 
upregulated in lungs that failed EVLP.  
 
Perfusate  
Following this unbiased approach of identifying genes, Figure 3.9, that were only 
upregulated in fail lungs with poor outcome, we found that there were 4 genes 
significantly upregulated in only fail lungs and that these genes corresponded to pro-
inflammatory cytokines MIG and MIP-3β; the acute phase proteins PTX3 and α1AGp. 
In lungs that passed EVLP, there were significantly higher levels of the genes for 
HSPA1A and HSPA1L. We then investigated the protein expression in perfusate for 
these specific pro-inflammatory and tissue injury proteins of interest. We then 
compared the levels of cytokine expression between the clinical outcome and protocol 
groups to assess if we could determine any clinical correlations. 
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The results were compared between sub-groups depending on outcome: Successful 
EVLP (pass) n=18, Unsuccessful EVLP (fail) n=26. The results were also compared 
between sub-groups depending on the EVLP protocol used: Hybrid n=15 and Lund 
n=29.   
There were no significant differences in the levels of protein expression for the 5 
markers comparing the fail lung group compared with the pass lung group, Figure 
3.10. 
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Figure 3.10 Perfusate potential biomarker levels comparing pass and fail 
outcome groups. 
Line graphs demonstrating the logged protein biomarker concentrations measurable 
in perfusate by ELISA comparing EVLP outcomes: pass (blue) and fail (red) EVLP of 
donor lungs measurable by ELISA. Logged perfusate levels of A) MIG in pg/ml B) 
MIP-3β in pg/ml C) PTX-3 in pg/ml D) α1AGp μg/ml and E) HSP-70 in pg/ml over the 
course of the EVLP assessment separated into outcome groups (mean ± SD), Pass 
n=18, Fail n=26. There was no significant difference in perfusate expression of any of 
the 5 protein markers at any EVLP time point in pass vs. fail EVLPs. EVLP: ex vivo 
lung perfusion; MIG: Monokine induced by gamma interferon; MIP-3 Beta: 
Macrophage inflammatory protein 3 beta; PTX-3: Pentraxin-3; α1AGp: Human alpha- 
Acid Glycoprotein; HSP-70: Heat shock protein 70. 
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When we compared the protein expression of the 5 markers between Hybrid and Lund 
protocol groups there were statistically significant differences, Figure 3.11. There was 
an increase in MIG perfusate concentrations in EVLPs performed using the Hybrid 
protocol compared to Lund protocol at all time-points during EVLP. This was detected 
as early as 15 minutes from commencing EVLP, P1 (Lund: M=31.64pg/mL, Hybrid: 
M=687.1pg/mL, p=0.0263). This remained significantly different until 210 minutes of 
perfusion, P8 (Lund: M=247.6pg/mL, Hybrid: M=646.5pg/mL, p=0.0263). There was a 
statistically significant increase in MIP-3β perfusate concentration at 30 and 60 minutes 
of EVLP performed using the Hybrid protocol compared to Lund protocol, P2 (Lund: 
M=53.2pg/mL, Hybrid: M=230.1pg/mL, p<0.0074), P3 (Lund: M=78.17pg/mL, Hybrid: 
M=272.1pg/mL, p<0.0214). There were no significant differences at any time points for 
Pentraxin-3, Human alpha-1 acid Glycoprotein or HSP-70.  
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Figure 3.11 Perfusate potential biomarker levels comparing Hybrid and Lund 
protocol groups. 
Line graphs demonstrating the logged protein biomarker concentrations measurable 
in perfusate by ELISA comparing EVLP protocols: Hybrid (grey) and Lund (pink) A) 
MIG in pg/ml B) MIP-3 beta in pg/ml C) Pentraxin-3 in pg/ml D) α1AGp in μg/ml E) 
HSP-70 in pg/ml over the course of the EVLP assessment separated into outcome 
groups (mean ± SD), analysed using unpaired t-tests and Bonferroni corrections, 
*P<0.05. **P<0.01, Hybrid n=15, Lund n=29. EVLP: ex vivo lung perfusion; MIG: 
Monokine induced by gamma interferon; MIP-3 Beta: Macrophage inflammatory 
protein 3 beta; PTX-3: Pentraxin-3; α1AGp: Human alpha- Acid Glycoprotein; HSP-
70: Heat shock protein 70. 
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Discussion  
If ex-vivo lung perfusion (EVLP) is to realise its potential as an innovative platform for 
the assessment and treatment of donor lungs prior to transplantation, it’s essential that 
the cellular and molecular events that occur during EVLP are fully understood. This 
study presents an in-depth, unbiased analysis of the lung transcriptome in donor lungs 
not deemed suitable for immediate transplantation and how this changes during the 
EVLP procedure. We have shown that genes associated with a relatively small number 
of specific pathways are either upregulated or downregulated during EVLP and that 
this is affected by both the EVLP protocol followed and the performance of the organ 
during the objective assessment.  
Lungs are highly susceptible to acute injury in the critical care environment. In the 
hours or days leading up to the donor’s demise, they are often exposed to multiple 
insults including: the sequelae of brain-stem death, infection, aspiration, barotrauma, 
fluid overload or multiple transfusions[19]. The extent of donor lung injury is difficult to 
assess at the time of organ procurement, and therefore donor acceptance criteria have 
historically been conservative and act as poor discriminators of injury and infection in 
the donor lung[24].  Robust biomarkers that can stratify donor lungs during EVLP as 
being suitable for transplant or in need of additional targeted interventions would 
enhance its clinical impact. This study evaluated the feasibility of using lung 
transcriptomics to determine if specific and significant changes in the genetic profile of 
the donor lung may reveal novel potential protein biomarkers of lung performance 
during clinical EVLP.  
We have demonstrated that expression of many genes changes by either 
upregulation or downregulation during the act of perfusion itself. Furthermore, many 
of the genes and the pathways that are upregulated are immune pathways, including 
TNF-α signalling via NFκB, cytokine interaction and intracellular signalling pathways. 
Our analyses also demonstrated that there are differential changes in gene 
expression occurring during EVLP between lungs which pass and fail the 
assessment of their transplant suitability.  
Andreasson et al. demonstrated levels perfusate IL-1β is a promising predictor of 
successful EVLP as well as the post-transplant outcome during clinical perfusion of 
extended criteria donor lungs, demonstrating a measurable increase in perfusate IL-
1β at 30 min in donor lungs Declined compared to those transplanted. A TLC scaled 
cutoff value of 0.1pg/ml, perfusate IL-1β following 30 min of EVLP had a sensitivity 
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and specificity of 100% to diagnose Non-survival lungs and could be used to 
distinguish 1-year survival with similar precision.  Perfusate interleukin-1β levels were 
strongly associated with early graft performance and could in the DEVELOP-UK 
multicentre study with high sensitivity and specificity diagnose both EVLP 
assessment failure and early post-transplant mortality. This study showed that 
inflammasome activation genes are enriched in pre-perfusion biopsies in fail lungs. 
Figure 4D shows that in lungs that went on to fail, there was clearly upregulation of 
the IL-β genetic signal prior to commencing perfusion.  
Our study showed that genes associated with inflammasome activation are enriched 
in pre-perfusion biopsies in lungs that fail EVLP assessment. Increased levels of the 
neutrophil chemokine interleukin IL-8 in the lungs of patients who have suffered 
severe trauma have been shown to predict subsequent development of acute 
respiratory distress syndrome. The lungs of brain-dead organ donors can contain 
high levels of IL-8. Fisher et al.  investigated whether this may predispose to early 
graft failure in the recipient after lung transplantation and found that that increased 
levels of IL-8 in the airspaces of a donor lung are associated with the development of 
severe primary graft dysfunction (p 0.027) and with early recipient mortality (p 
0.0034)[43].  Since IL-8 is a neutrophil-recruiting chemokine, we analysed transcripts 
of all neutrophil-recruiting chemokines to see if these were increased in lungs that 
failed to improve at the start of perfusion. This shows that lungs that fail tended to 
start with a slightly higher level of CXCL8 transcripts and trended towards a greater 
increase during perfusion resulting in higher CXCL8 levels in post-perfusion samples.  
The activation of pro-inflammatory cytokines such as IL-1β has been shown to 
correlate to an increase in cell adhesion molecules and the infiltration of 
leukocytes[83]. Our pathway analysis demonstrated the enrichment of gene sets 
involved in both cell communication and adherens junctions. The upregulation of 
these pathways highlights the role that endothelial barrier integrity plays in the 
pathophysiology of ischaemia reperfusion injury and ultimately membrane 
permeability and EVLP success.  
RNA-seq allowed us to identify genes up-regulated in either pass only or fail only donor 
lungs without bias whose associated protein product might be considered to be 
potential biomarkers for predicting EVLP outcomes for validation and clinical 
correlation.  Our results demonstrate significant differences in perfusate protein 
expression between lungs that passed EVLP and were deemed transplantable 
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compared with those that failed. Significant differences were detected when comparing 
the Hybrid and Lund protocols with a clear separation in MIG and MIP-3β protein 
expression. We observed a measurable increase in perfusate MIG and MIP-3β levels 
throughout EVLP for donor lungs that underwent the Hybrid protocol compared with 
those that underwent the Lund protocol. The hybrid protocol (n=15) combined the open 
left atrium used by Steen et al. and the reduced flow rate of the Toronto method in an 
effort to reduce pulmonary vascular shear stress and oedema formation and an 
acellular perfusate. During the DEVELOP-UK study, the Hybrid protocol was 
abandoned, because of a high rate of post-operative ECMO, to the Lund protocol for 
the remainder of the study (n=29) keeping the left atrium open but changing to a cellular 
perfusate and 100% cardiac output. While RNAseq demonstrated medium and high 
levels of expression of Orosomucoid 1 and Pentraxin 3 respectively with levels 
increasing in declined lungs only, this was not reflected at a protein product level in the 
perfusate, with very similar levels of PTX-3 observed in both pass and fail lungs and 
higher levels of α1AGp identified in successful EVLPs. As the biomarkers show the 
greatest difference is between the perfusion methods may suggest one protocol is 
better/ promotes healthier lungs when compared. Further, it may suggest that as we 
cannot see the effect at the protein level across the data set, an RNA based gene-
expression test may be more appropriate. 
Immune profiling in lung transplantation has relied primarily on downstream protein 
production and cellular analysis. If the purpose of the biomarker discovery is to detect 
the onset of ischaemia reperfusion injury before an uncontrollable immune activation 
takes place, then as a method of immune profiling, RNA-Seq transcriptomic analysis 
illuminates not only individual genes, but entire pathways and upstream regulators. 
This can provide a fuller picture of the underlying pathology and allow for identification 
of potential upstream targets to prevent injury before the onset of significant 
inflammation. Several investigators have shown that brain death and ischaemia-
reperfusion injury have a significant impact on complex gene expression changes [37, 
136, 137].  
The sample size of 10 is consistent with that of other gene profile studies in the lung 
transplantation field[138, 139]. Although small, we importantly were able to use 
paired samples of lung tissue for analysis. The results of this study need further 
evaluation in a larger validation cohort of lungs exposed to EVLP but demonstrate 
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the feasibility of identifying the changes in the lung transcriptome during EVLP and 
comparing outcome groups.  
The study cohort was that of marginal lungs which had been deemed unsuitable for 
transplantation, and so they reflect a different cohort of donor lungs compared with 
those of standard criteria.  
Our unbiased and pathway focused approach has provided novel insights into the 
potential mechanisms activated before and after EVLP. Up-regulation of the genes in 
our EVLP cohort clearly illustrates the onset of an inflammatory environment. Novel 
upstream pathways associated with this inflammation could provide an early warning 
mechanism to impending lung injury and rejection and identifiable targets for 
pharmacologic intervention. Future studies will need to investigate emerging real-time 
cytokine tests, as time-sensitive assays with high sensitivity will be essential for the 
utility of any biomarker during clinical EVLP.  
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Chapter 4: A comparison of Inflammatory profiles in donor lungs 
following donation after brain-death (DBD) and donation after 
circulatory death (DCD). 
In Chapter 3, we demonstrated the feasibility of identifying pro-inflammatory signals 
in perfusate during EVLP reconditioning of initially unsuitable donor lungs. With 
access to the large DEVELOP-UK sample cohort, we pursued whether identifying 
pro-inflammatory signals could help us determine biological differences between 
DBD and DCD donor lungs.     
Given the global shortage of suitable human donor lungs available for transplantation 
and the associated waiting list morbidity and mortality, one of the main aims of the 
lung transplant community is to expand the donor lung pool. One of the approaches 
to achieve this is through the use of organs from donation after circulatory death 
(DCD) donors. Although there are several studies from multiple centres show 
comparable clinical outcomes following DBD and DCD donor lung transplantation, 
there are only a limited number of studies investigating the disparities between these 
two donor types and their characterisation at a cellular and biological level.  
This study aimed to ascertain if there are any differences in the pro-inflammatory 
profiles and expression of tissue injury markers between lungs from DBD and DCD 
donors before and during EVLP. We evaluated a panel of inflammatory mediators, 
tissue injury-associated proteins and angiogenic factors in perfusate, bronchoalveolar 
lavage fluid (BALF) and lung tissue from human donor lungs undergoing clinical 
EVLP with intent for transplant. We hypothesised that DBD lungs and their 
associated systemic inflammatory response following brain stem death would exhibit 
increased levels of pro-inflammatory and injury markers when compared to DCD 
lungs from the outset of EVLP. 
Sample processing had been previously carried out by PhD student, Mr Anders 
Andreasson before my arrival, with raw data available for analysis. My contribution 
was to analyse and evaluate the raw data along with the generating discussion, 
execution and write up.  The results of this study are presented in the original 
manuscript presently in preparation for journal submission.  
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Introduction 
Although lung transplantation is regarded as a safe and effective therapy for selected 
patients with end-stage lung disease, the demand for donor organs still exceeds the 
overall donor organ supply, and many transplant candidates do not survive long 
enough for a suitable donor to be identified[13]. One of the approaches to expand the 
donor lung pool is through the use of organs from donation after circulatory death 
(DCD) donors[15]. Early studies showed that the lung remains viable after circulatory 
arrest for a period of time[140, 141]. Several studies from both individual institutions 
and national transplant organisations and registries have reported that the outcomes 
in controlled DCD lung transplantation are comparable with those from donors after 
brain death (DBD)[16, 68] [142-147] A meticulously performed meta-analysis of five 
studies found no difference in short or long-term survival, between transplants 
performed with DCD or DBD donors[71]. Only two reports have demonstrated worse 
outcomes with respect to primary graft dysfunction (PGD) and bronchiolitis obliterans 
syndrome (BOS)[143, 148]. The use of DCD donors varies across the globe, 
accounting for less than 5% of lung transplant activity in the US[69][149]compared with 
20% in the UK[13].  
Brain death itself leads to hemodynamic, metabolic, and neuroendocrine abnormalities 
in the donor resulting in radiological and physiological abnormalities in the lungs or so-
called neurogenic pulmonary oedema[19]. Brain death generates a systemic 
inflammatory response with the release of key pro-inflammatory mediators, leading to 
upregulated expression of adhesion molecules on pulmonary endothelium and 
subsequent leukocyte tissue infiltration[19] Patients suffering irreversible catastrophic 
brain injury, resulting in a diagnosis of brainstem death, have a high incidence of 
associated pulmonary dysfunction and a much higher expression of neutrophil 
chemokines in their lungs than non-brain dead ventilated controls [43]. This initial insult 
in combination with possible airway aspiration, respiratory tract infection, atelectasis 
and pulmonary contusion, may all contribute to lung damage before donation occurs 
[85]. Previous studies have linked the acute inflammatory response seen after brain 
stem death and an increased risk of PGD and early mortality post transplantation[43]. 
PGD is a leading cause of early morbidity and mortality after lung transplantation. In 
just one study, by Sabashnikov et al., there was a higher incidence of PGD and a trend 
towards greater need for extracorporeal life support (ECMO) in a series of 60 DCD 
lung transplant recipients compared to their score matched DBD recipients[148]. 
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However, the Krutsinger meta-analysis found no difference in PGD incidence between 
lungs from DCD donors and comparator groups of DBD donated lungs. Diamond et 
al., reported in a large multicentre cohort study that the cause of donor death was not 
a risk factor for PGD[150].   
Whilst perhaps lacking the exposure to some of the sequelae of brain-stem death, the 
lungs from the DCD donor are exposed to other potential injuries. In DCD donors, there 
may be longer periods of ventilation[145], an inevitable period of warm ischaemia[62] 
and the as-yet poorly characterised agonal phase which has some features of brain-
stem death[151]. In the interval between discontinuation of support and procurement, 
organs are exposed to adverse conditions including hypoxia, hypotension and 
ischemia. White et al demonstrated that both hypoxic pulmonary vasoconstriction and 
a profound catecholamine surge occur following withdrawal of life-sustaining therapy 
(WLST) in a porcine model of DCD[152]. 
It is thus postulated that DBD donor lungs express higher levels of acute inflammation 
than lungs from DCD donors, and this offsets any injurious events around the donor’s 
death and the delayed retrieval. However, with the exception of a single study by Kang 
et al., analysing the differential gene expression profiles of DBD and DCD donor 
lungs[139];  objective supporting evidence has so far been lacking.  
Ex-Vivo Lung Perfusion (EVLP) has emerged as a technology to evaluate and 
recondition lung grafts prior to transplantation[85] and now accounts for up to 20% of 
transplants in some centres with established EVLP programs[27, 153-155]. It has been 
argued that it may have specific benefits for lungs from DCD donors[156]. 
Nevertheless, it does allow better characterisation, both in terms of physiological 
measures and potential biomarkers, of both DCD and DBD lungs 
Our group has previously demonstrated the feasibility of identifying pro-inflammatory 
signals in perfusate during EVLP of unsuitable donor lungs[83]. In this study, our 
objective was to establish if there are any differences in the pro-inflammatory profiles 
and expression of tissue injury markers between lungs from DBD and DCD donors 
before and during EVLP. We hypothesised that DBD lungs and their associated 
systemic inflammatory response following brain stem death would demonstrate 
increased levels of pro-inflammatory and injury markers when compared to DCD lungs 
from the outset of EVLP. Ischaemia reperfusion injury (IRI) and the associated excess 
risk of PGD arise not only from immunologic factors but also non-immunologic factors 
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related to the activation of a cascade of molecular events: activation of endothelial cells 
with increased expression of adhesion molecules increased adherence of leucocytes 
to the endothelium, and activation of the coagulation and complement systems. We 
evaluated a panel of inflammatory mediators, tissue injury-associated proteins and 
angiogenic factors in perfusate, bronchoalveolar lavage fluid (BALF) and lung tissue 
from human donor lungs undergoing clinical EVLP with intent for transplant. The panel 
was based on our group’s previous work and available studies of biological markers in 
standard lung transplant and preclinical and clinical observations during EVLP[44, 83, 
157, 158]. Our panel focussed on four main groups of markers to investigate specific 
pathways and processed involved; inflammation, tissue injury, endothelial barrier 
integrity and vascular remodelling.  
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Methods 
Study subjects and Ex-vivo lung perfusion (EVLP) protocol 
This was a retrospective study, performed using samples collected from a large cohort 
of clinical EVLP procedures performed as part of the DEVELOP-UK trial[98]. 
DEVELOP-UK was a multi-centre study including all 5 UK lung transplant centres. 
Fifty-three donor lungs, deemed unsuitable for immediate transplantation underwent 
EVLP. A standard lung procurement procedure was followed for donor lungs used for 
EVLP in the study[98]. EVLP assessments were performed using a Vivoline LS1 EVLP 
circuit (Vivoline Medical AB, Lund, Sweden) following 1 of 2 standardized perfusion 
protocols[98]. A standardised approach to obtaining BALF, perfusate and tissue 
specimens was followed in all cases.  
Measurement of Inflammatory and Tissue Injury Markers in Bronchoalveolar Lavage 
Fluid (BALF), Perfusate and Tissue  
BALF was collected by performing a flexible bronchoscopy in a sub-segmental 
bronchus of the right or left lower lobes. Sterile Saline 0.9% (120 ml) was instilled via 
bronchoscopy and suctioned back at the beginning of EVLP before ventilation was 
started. The procedure was repeated in the same lobe but different sub segmental 
bronchus at the end of perfusion.  
Samples of perfusate were collected at longitudinal time-points throughout the EVLP. 
A control sample was collected from the primed EVLP circuit before starting donor lung 
perfusion. Repeated perfusate samples (5 ml) were then collected at 15 and 30 
minutes after starting perfusion and every 30 minutes thereafter. The perfusate 
samples were centrifuged at 180 xg for 6 minutes at 4oC to remove cellular debris. 
Supernatants were stored at -80oC. Because priming volume was uniform, all protein 
expressions measured in perfusate were adjusted to the predicted total lung capacity 
(pTLC) of the donor as an estimate of perfused donor lung tissue volume and were 
reported as corrected perfusate concentrations (pg/ml). The pTLC was calculated 
using predicted values based on donor gender and height.  
Tissue biopsies were taken from either the right middle lobe or lingula before EVLP 
was started using a stapler. These specimens were snap frozen in liquid nitrogen for 
protein analysis. For protein analysis snap frozen lung tissue (100 mg/sample) was 
homogenized in 500 μL homogenization buffer using a Minilys® ceramic bead tissue 
homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France). Each 
homogenate was centrifuged twice at 13,000 xg for 5 minutes, the supernatants 
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decanted, and the protein concentration of each sample estimated using a Pierce™ 
BCA protein assay (Thermo Fisher Scientific Inc., Waltham, MA, USA) before storage 
at -80oC. 4 mg protein/ml diluted in 0.1% BSA in homogenization buffer was loaded 
onto protein assay plates. 
The concentrations of a panel of pro-inflammatory cytokines and tissue injury markers 
were measured. Lactate dehydrogenase (LDH) levels were measured in perfusate, 
BAL and tissue lysate as per manufacturer’s instructions (Thermo Fisher Scientific Inc., 
Rockford, IL). Perfusate and tissue lysates were analysed with a V-PLEX Human 
Biomarker 40-Plex Kit and a Human MMP 3-Plex Ultra-Sensitive Kit. BAL was 
analysed using a V-PLEX human pro-inflammatory Panel 1 Kit and a Human MMP 3-
Plex Ultra-Sensitive Kit (Meso Scale Diagnostics, Rockville, MD). Human Syndecan-1 
was measured using a sandwich ELISA (R&D Systems, Inc., Minneapolis, MN).  
Statistical analysis  
All statistics were performed using the GraphPad Prism 6 software package 
(GraphPad Software Inc., La Jolla, CA). Cytokine levels in BALF and tissue were 
compared between DBD and DCD lungs using Mann-Whitney U tests. A p-value of 
<0.05 was deemed statistically significant. Protein expressions in perfusate at each 
time-point were compared between DBD and DCD donor lungs with multiple t-tests. 
For comparisons in donor characteristics, the chi-square test or Fisher exact test were 
used for categorical variables and Mann-Whitney U tests for continuous variables.  
Results  
Study group and donor characteristics 
Between April 2012 and July 2014, 53 donor lungs deemed unsuitable for immediate 
transplantation by all UK lung transplant centres were evaluated with EVLP within the 
DEVELOP-UK study. Seven donor lungs with incomplete perfusate sampling were 
excluded, leaving 46 donor lungs (35 DBD and 11 DCD) for this study. No significant 
differences between groups were observed for any of age, gender, or the duration of 
ventilation, Table 4.1. 
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Table 4.1 Demographic Characteristics of Donor Lungs.  
P/F ratio: ratio of the partial pressure of arterial oxygen to the fraction of inspired 
oxygen, Ischaemic time: duration from circulatory arrest in the donor to start of 
pulmonary artery (PA) perfusion on the EVLP circuit. 
 
Pre-EVLP BALF samples were available from 40 donor lungs (31 DBD and 9 DCD) 
and pre-EVLP lung tissue biopsy samples from 33 donors. All available samples were 
included in this study.  
Analysis of Bronchoalveolar lavage fluid, Perfusate and Tissue  
Assessed lungs were divided into two groups based on donor type: DBD and DCD. 
Samples were analysed retrospectively for protein expressions. A total of 48 individual 
markers were detectable in perfusate.  
Bronchoalveolar lavage fluid (BALF)  
There were no significant differences observed for any of the inflammatory and injury 
marker levels investigated in BALF samples collected at the start of EVLP between 
DBD and DCD lungs, Figure 4.1.  
Donor Variable DBD (n=35) DCD (n=11) p-value  
Age (yrs.) 48 (16-65) 53 (20-61) 0.1683 
Female (%) 48.6 27.3 0.3024 
Smoker (%) 48.6 45.5 >0.999 
Optimised donor P/F 
(mmHg)  
294 396 0.0906 
Ischaemic time (min) 226 278 0.0255 
Hybrid protocol 11 5 0.4766 
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Figure 4.1 Inflammatory panel protein expression in BALF in DBD and DCD 
donor lungs prior to commencing EVLP 
For all lungs, a research BAL was performed, instilling saline (40 ml) through the 
suction channel followed by gentle aspiration with sample collection prior to 
commencing ventilation at the beginning of EVLP. The BALF samples were filtered 
through a single layer of gauze to remove excess mucus and then centrifuged at 180 
g for 6 minutes at 4 °C to separate the cellular component from the acellular 
supernatant. Supernatants were re-centrifuged at 700 g for 6 minutes at 4°C to 
remove any remaining cell debris, decanted and stored at -80 °C. Interleaved scatter 
plot with molecular marker levels expressed in (pg/ml) and black lines representing 
means. The protein expressions of a panel of pro-inflammatory cytokines detected 
using a V-PLEX human pro-inflammatory Panel 1 Kit and a Human MMP 3-Plex 
Ultra-Sensitive Kit (Meso Scale Diagnostics, Rockville, MD). DBD n=31, DCD n=9, 
analysed by Mann-Whitney U tests. There were no significant differences in the pro-
inflammatory cytokine levels detected in BALF between DBD and DCD lungs. BALF: 
bronchoalveolar lavage fluid; EVLP: ex vivo lung perfusion; IL: interleukin; TNF-α: 
tumour necrosis factor alpha; IFN-γ: interferon gamma; DBD: donation after brain 
death; DCD: donation after circulatory death. 
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Tissue and Perfusate  
There were discernible differences between DBD and DCD donor lungs detected in 
both lung tissue and perfusate samples taken during EVLP. We noted a pattern 
towards higher release of pro-inflammatory cytokines from tissue from DBD compared 
with DCD lungs. In lung tissue lysates, the levels of a large number of pro-inflammatory 
markers (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-12p40, IL-12p70, IL-13, IL-15, 
IL-16, IL-17, IFN-γ, MCP-1, MCP-4, MCD, MIP-1α, TNF-α, TNF-β, Eotaxin and GM-
CSF) were detected prior to EVLP commencing. A significant difference between the 
DBD and DCD groups was found for 4 of the proteins investigated. In 4 proteins 
measured in tissue, there was a significant difference between the groups, Figure 4.2. 
Tissue C-reactive protein (CRP) was found to be significantly higher in DBD lungs: 
median (DBD)=248,095.0 pg/ml, median (DCD)=151,905pg/ml, p=0.0077. Tissue IL-
12p70 (p=0.028), IL-4 (p=0.0106) and IL-6 (p=0.0077) were also found in higher 
concentrations in DBD lungs.  
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Figure 4.2 Inflammatory panel protein expression in lung tissue lysate in DBD 
and DCD donor lungs prior to commencing EVLP 
For all lungs, small biopsies of lung tissue (approximately 3x2x1 cm) were taken from 
either the right middle lobe or lingula just prior to the commencement of EVLP. The 
protein expressions of a panel of pro-inflammatory cytokines were detected with a V-
PLEX Human Biomarker 40-Plex Kit and a Human MMP 3-Plex Ultra-Sensitive Kit as 
per manufacturer’s instructions (Thermo Fisher Scientific Inc., Rockford, IL). 
Interleaved scatter plot with molecular marker levels expressed in (pg/ml) and black 
lines representing means. DBD n=26, DCD n=7, analysed by Mann-Whitney U tests, 
*P<0.05. **P<0.01 ***P<0.001. DBD lungs were found to express significantly higher 
levels of IL-4, IL-6, IL-12p70 and CRP in lung tissue. EVLP: ex vivo lung perfusion; 
CRP: c-reactive protein; IL: interleukin; DBD: donation after brain death; DCD: 
donation after circulatory death. 
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Differences between DBD and DCD lungs were also seen in the concentrations of pro-
inflammatory cytokines detected in perfusate. At 15 minutes into EVLP, there was a 
significant difference in Interleukin 1-beta (IL-1β) levels between DBD and DCD lungs: 
median (DBD)= 0.064 pg/ml (IQR 0.015- 1.54) and median (DCD)= 0.735 pg/ml (IQR 
0.013-5.702), p=<0.01. At 30 minutes, a significantly higher level of Interleukin 1-alpha 
(IL-1α) was detected in the perfusate from DCD lungs: median (DBD)=0.031 pg/ml 
(IQR 0.014-1.738) and median (DCD)=1.078 (IQR 0.013-6.871), p=<0.01. This 
remained significant until the end of EVLP, Figure 4.3. 
 
Figure 4.3 Perfusate protein expressions of IL-1 cytokines in DBD and DCD 
donor lungs during EVLP 
Repeated perfusate samples (5 ml) were collected before EVLP was started, after 15 
minutes, at 30 minutes, every 30 minutes during perfusion and a final sample taken 
at the end of perfusion immediately before perfusion stopped. The protein expression 
reported as corrected perfusate concentrations (pg/ml) of IL-1α (Graph A) and IL-1β 
(Graph B) were detected with a V-PLEX Human Biomarker 40-Plex Kit (Meso Scale 
Diagnostics, Rockville, MD). Data are shown mean ± SD analysed using unpaired t-
tests, DBD n=35, DCD n=11, *P<0.05. **P<0.01 ***P<0.001. Higher values of IL-1α 
and IL-1β was detected in DCD lungs compared with DBD lungs. A statistically 
significant difference was detected at the 15-minute time-point in IL-1β and from 30 
minutes of EVLP in IL-1α. EVLP: ex vivo lung perfusion; IL: interleukin; DBD: 
donation after brain death; DCD: donation after circulatory death. 
 
 
The levels of Interleukin-10 (IL-10), a well-established anti-inflammatory cytokine were 
not significantly different between groups.  
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For an initial general assessment of tissue injury, we measured LDH levels, however 
no significant differences were seen between groups.  
To assess the integrity of the pulmonary vascular compartment, we measured the 
endothelial barrier markers; soluble ICAM-1, VCAM-1 and Syndecan-1 levels as 
markers of endothelial glycocalyx disruption. There were no significant differences 
between the groups in these endothelial markers measured in tissue and perfusate 
Figure 4.4 and Figure 4.5. 
 
Figure 4.4 Protein expression of intracellular adhesion molecules in donor lung 
tissue lysates prior to commencing EVLP. 
 For all lungs, small biopsies of lung tissue (approximately 3x2x1 cm) were taken 
from either the right middle lobe or lingula just prior to the commencement of the 
EVLP process at the recipient hospital. The protein expressions of a panel of 
intracellular adhesion molecules were detected with a V-PLEX Human Biomarker 40-
Plex Kit and a Human MMP 3-Plex Ultra-Sensitive Kit as per manufacturer’s 
instructions (Thermo Fisher Scientific Inc., Rockford, IL). Interleaved scatter plot with 
molecular marker levels expressed in (pg/ml) and black lines representing means. 
DBD n=26, DCD n=7, analysed by Mann-Whitney U tests. Expression of soluble 
ICAM-1, VCAM-1 and Syndecan-1 in lung tissue lysate prior to commencing EVLP 
did not vary significantly between DBD and DCD lungs. 
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Figure 4.5 Protein expression of intracellular adhesion molecules in perfusate 
during EVLP 
Repeated perfusate samples (5 ml) were collected from the perfusate sampling port 
before EVLP was started, after 15 minutes, at 30 minutes, every 30 minutes during 
perfusion and a final sample taken at the end of perfusion immediately before 
perfusion stopped. The protein expression of soluble ICAM-1(Graph A), VCAM-
1(Graph B) and Syndecan-1 (Graph C) were detected with a V-PLEX Human 
Biomarker 40-Plex Kit (Meso Scale Diagnostics, Rockville, MD). Data are shown 
mean ± SD analysed using unpaired t-tests, DBD n=35, DCD n=11. Expression of 
soluble ICAM-1, VCAM-1 and Syndecan-1 during perfusion did not vary significantly 
between DBD and DCD lungs. EVLP: ex vivo lung perfusion; DBD: donation after 
brain death; DCD: donation after circulatory death. 
 
We measured several angiogenic factors including placenta growth factor (PIGF) and 
vascular endothelial growth factor (VEGF) and found significantly higher levels in the 
perfusate of DBD lungs, Figure 4.6. At 15 minutes into EVLP, there was a significant 
difference in PIGF levels in perfusate between DBD and DCD lungs: median (DBD)= 
1.640 pg/ml (IQR 1.002-3.090) and median (DCD)= 1.099 pg/ml (IQR 0.734-1.808), 
p=<0.01. The higher levels in DBD lungs remained significant throughout EVLP. The 
soluble portion of the fms-like tyrosine kinase (Flt-1) receptor (sFlt-1), an endogenous 
inhibitor of VEGF, thought to play an important role in endothelial dysfunction was also 
seen to be increased in DBD lungs. At 15 minutes into EVLP, there was a significant 
difference in sFlt-1 levels between DBD and DCD lungs: median (DBD)= 108.839 
pg/ml (IQR 40.978-510.367) and median (DCD)= 25.290 pg/ml (IQR 15.440-120.719), 
p=<0.01. The higher levels in DBD lungs remained significant throughout EVLP. 
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Figure 4.6 Perfusate protein expressions of angiogenic factors in DBD and 
DCD donor lungs during EVLP 
Repeated perfusate samples (5 ml) were collected from the perfusate sampling port 
before EVLP was started, after 15 minutes, at 30 minutes, every 30 minutes during 
perfusion and a final sample taken at the end of perfusion immediately before 
perfusion stopped. The perfusate samples were centrifuged at 180 g for 6 minutes at 
4 °C to remove cellular debris. Supernatants were stored at -80 °C. All protein 
expressions measured in perfusate were adjusted to the donor predicted total lung 
capacity (pTLC), as an estimate of perfused donor lung volume, and reported as 
corrected perfusate concentrations (pg/ml). The protein expression of IL-1α (Graph 
A) and IL-1β (Graph B) were detected with a V-PLEX Human Biomarker 40-Plex Kit 
(Meso Scale Diagnostics, Rockville, MD). Data are shown mean ± SD analysed using 
unpaired t-tests, DBD n=35, DCD n=11, *P<0.05. **P<0.01 ***P<0.001. In DBD 
lungs, there are significantly higher levels of PIGF and sFlt-1 throughout perfusion.  
EVLP: ex vivo lung perfusion; VEGF: vascular endothelial growth factor; PIGF: 
placental growth factor; sFlt-1: soluble Fms-like tyrosine kinase receptor 1; DBD: 
donation after brain death; DCD: donation after circulatory death. 
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Discussion  
The increasing demand for donor lungs combined with largely static organ donation 
rates has led to the relaxation of donor inclusion criteria and acceptance of more 
extended criteria donor lungs for transplantation. One area of opportunity to increase 
the donor lung pool is the use of lungs from DCD donors, which have a prolonged 
period of warm ischaemia and go through an agonal phase but have traditionally been 
thought of as not being exposed to the systemic inflammatory stresses of brain stem 
death.  
Our study aimed to investigate differences in the inflammatory profiles in the airway, 
vascular and tissue compartments between DBD and DCD lungs prior to and during 
EVLP. Our results demonstrate a difference in the pattern of pro-inflammatory protein 
and injury marker expression in tissue and perfusate samples from lungs that were 
from a DCD compared to a DBD donor. 
Marker DBD DCD 
Pro-inflammatory and 
tissue injury  
Higher levels of IL-6, IL-4, 
IL-12p70, CRP  
Higher acute phase 
cytokines: IL-1α and IL-1β  
Anti-inflammatory  No differences   
Endothelial barrier 
markers  
No differences   
Angiogenic markers  Higher levels of PIGF and 
sFlt-1  
 
Table 4.2 Summary table of the differences between DBD and DCD donor lungs 
during this study 
 
BALF samples taken at the start of EVLP did not show any differences. BAL appears 
to show a weaker signal than that seen in perfusate and tissue. The reasons for this 
are unclear; however, one has to postulate that BAL sampling is more user dependent 
than perfusate sampling or tissue biopsying and whether this effects variability within 
a multi-centre cohort.  
We have demonstrated that in extended criteria donor lungs which have been turned 
down for immediate transplantation, there are differential inflammatory and tissue 
injury marker profiles between DBD and DCD lungs. We found that IL-4, IL-6 and IL-
12 were significantly higher in tissue samples from DBD lungs but this was not reflected 
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in the perfusate concentrations. We found that IL-α and IL-1β were detected in 
significantly higher levels in the perfusate of DCD lungs at as early as 15 minutes and 
throughout reperfusion. These observations demonstrate differences in the cytokine 
expression between DBD and DCD lungs and also in the compartment from which they 
are released.   
It is generally accepted that IL-1β and TNF-α are released in the early post-injury 
phase, following acute brain injury[159]. Avlonitis et al. investigated the 
pathophysiology surrounding the events following brain stem death and the correlation 
with systemic inflammation. They demonstrated that early donor haemodynamic injury 
programs the donor lung to develop increased inflammation after reperfusion. They 
showed that it is the sympathetic discharge, so-called “catecholamine storm” and the 
hypertensive crisis following brain death that can cause neurogenic pulmonary 
oedema and reperfusion injury. They also showed that this effect could be prevented 
by donor pre-treatment with phentolamine, by preventing vasoconstriction and 
hypertension[160]. A subsequent study by the same group demonstrated that 
phentolamine pre-treatment prevented an increase in BALF cytokine levels. They 
suggested that the inflammatory lung injury observed after brain death is caused by 
haemodynamic stress produced by the catecholamine storm[161].  
 
The release of acute phase cytokines is thought to result in the increased synthesis of 
IL-6, in addition to other mediators. IL-6 may act to decrease the production of IL-1β 
and TNF-α via a negative feedback mechanism[162]. It may be that in the DBD lungs, 
we missed an early peak of production of IL-1α and IL-1β and by the point of organ 
retrieval, this had diminished. Instead, we have seen the rise in mediators, IL-4, IL-6 
and IL-12 following the stimulation of the “early response cytokines” IL-1 and TNF-α. 
Whereas due to the lung insults such as warm ischaemia occurring much closer to the 
time of retrieval in DCD lungs higher levels of the early response cytokines were 
elevated. This suggests that events surrounding death upregulate the early response 
inflammation in DCD donors. Whether the warm-ischaemic insults in DCD donors 
directly contributes to the increased IL-1β observed during EVLP requires further 
evaluation.  
We have previously shown a relationship between perfusate IL-1β levels and 
subsequent lung allograft function after EVLP. Perfusate levels of IL-1β measured 30 
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min into EVLP could distinguish subsequent in-hospital mortality with a sensitivity 
and specificity of 100% and 1-year survival with similar precision[158]. The results 
here are in keeping with that finding, with perhaps DCD lungs being in a worse 
position. This flies against the accepted wisdom that DCD lungs are in every way 
equivalent to DBD lungs. As has been described, there is just one study suggesting a 
worse outcome in this cohort[148]  
Hamill et al.  reported that in 33 patients with traumatic brain injury, the levels of 
circulating catecholamines appeared to be excellent endogenous and readily 
quantifiable markers that reflected the extent of brain injury and predicted the 
likelihood of patient recovery[163]. Studies have also shown that there are 
differences in the catecholamine surge between sudden and gradual increases in 
intracranial pressure, with a sudden rise in ICP demonstrating a hyperdynamic state 
of greater degree and this coincides with a huge peak of catecholamines[164].  
Catecholamine levels have also been shown to be important in the pathophysiology 
of DCD as well as in DBD donors. Ali et al. reported findings of a substantially more 
profound rise in catecholamines within the reperfused DCD donor compared to the 
DBD donor[165]. In the DCD donor, plasma epinephrine and norepinephrine 
concentrations began to increase after discontinuation of mechanical ventilation and 
continued to increase throughout circulatory arrest. At the end of the 15-min 
ischaemic period, the plasma norepinephrine concentration was 50-fold greater in the 
DCD donor than the peak concentration noted during brain stem death. 
Correspondingly the plasma epinephrine concentration was 30-fold greater than the 
peak value measured in the brain-dead donor. Catecholamine levels continued to 
increase during the first 5 min of extracorporeal perfusion and then began to decline. 
After 30 min of reperfusion, the norepinephrine and epinephrine concentrations in the 
DCD donor remained markedly elevated compared to baseline and were 2.5-fold and 
2-fold greater, respectively than the peak levels seen after brain stem death.  
 
Cytokine modulation during IRI and its correlation with donor parameters and graft 
function have been systematically explored in recent studies[166]. Machuca et al. 
studied the impact of EVLP on cytokines, chemokines, and growth factors and their 
correlation with graft performance; either during EVLP or post transplantation. They 
found that the best marker to differentiate declined lungs from control lungs was stem 
cell growth factor-β [P < 0.001, AUC (area under the curve) = 0.86] at 1 hour. The best 
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markers to differentiate PGD3 cases from controls were interleukin-8 (P < 0.001, AUC 
= 0.93) and growth-regulated oncogene-α (P = 0.001, AUC = 0.89) at 4 hours of 
EVLP[157]. 
Previous reports have demonstrated the detrimental effects of brain death on organs 
and the multifactorial pathophysiology, including haemodynamic, metabolic and 
inflammatory responses[37, 161, 167]. Several research groups have indicated that IL-
6[37, 39] and IL-8[161] are amongst the most elevated cytokines in brain death.  
IL-8, proposed as one of the optimum markers of EVLP transplant outcome in their 
study, has consistently shown potential in previous studies of donor lung injury from 
our group[43, 168]. De Perrot et al. also showed the importance of IL-8 in predicting 
early graft function[42]. In our study, there were no significant differences seen in the 
IL-8 expressions in perfusate and tissue between DBD and DCD lungs.  
Our study showed significant differences in the expression of angiogenic factors 
between DBD and DCD lungs. We observed significantly higher levels of Placental 
growth factor (PlGF) and soluble Fms-like tyrosine kinase receptor 1 (sFlt-1) 
expression in the perfusate of DBD compared with DCD lungs. Placental growth 
factor (PlGF) is a member of the VEGF family of angiogenic proteins and is 
expressed in placental, cardiac, and lung tissue[169, 170]. PlGF is expressed in 
numerous cell types including endothelial cells, monocytes, and renal mesangial cells 
and activates sFlt-1. sFlt-1 is a member the vascular endothelial growth factor 
(VEGF) family and is a splice variant of the VEGFR-1 (Flt-1) receptor, which acts as 
an antagonist of VEGF and placental growth factor and is thought to be an 
antiangiogenic factor[171]. The pathogenic roles of sFlt-1 have been previously 
documented in preeclampsia [172, 173]and in chronic[174]and acute[175] renal 
disease. Chapal and co-workers reported that sFlt-1 is an independent risk factor for 
delayed graft function and to an early loss of peritubular capillaries during renal 
transplantation-related ischemia-reperfusion. They concluded that an increase in the 
potent antiangiogenic factor sFlt-1, combined with the repression of the 
proangiogenic VEGF, tips the balance toward a deleterious antiangiogenic 
state[176].  
In patients with chest pain and acute coronary syndromes, higher PlGF levels are 
seen in those with myocardial infarction (MI) and are associated with an increased 
risk of short and long-term adverse outcomes[170, 177, 178]. Studies of circulating 
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sFlt-1 have demonstrated conflicting results, with some studies noting higher levels 
during acute MI compared to control patients [179] and others noting lower plasma 
levels in patients during the acute phase of MI compared to controls[180].  
Ky et al. measured plasma PlGF and sFlt-1 in 1,403 patients from the Penn Heart 
Failure Study, a multi-centre cohort of chronic systolic heart failure (HF)[181]. 
Subjects were followed for death, cardiac transplantation, or ventricular assist device 
placement over a median follow-up of 2 years. They demonstrated that sFlt-1 was 
independently associated with measures of HF severity, including NYHA Class 
(p<0.01) and BNP (p<0.01). 
One could postulate that the higher expression of angiogenic factors in DBD compared 
with DCD lung perfusate is a matter of the timing of the injury. Given that in DBD 
donors, the pathogenic process of brainstem injury has started hours if not days prior 
to organ retrieval, there has been time for the process of vascular remodelling 
endothelial dysfunction to begin. This is perhaps seen much later in DCD lungs and 
could perhaps be detected in the days following transplantation. A study measuring 
the levels of both PGIF and sFlt-1 in lung transplant recipients would help evaluate this 
further.  
Literature comparing the differences between inflammation in DBD and DCD donor 
lungs at a cellular and molecular level is limited. Kang et al.[139] studied the differential 
gene expression profiles in lungs of DCD and DBD patients and interpreted the 
differences using functional pathway analysis. Analysis of gene expression profiles 
showed distinct activation of gene pathways between pre-transplant DBD and DCD 
human lungs. They found that there were 12 gene sets highly enriched in DBD but not 
DCD lungs. The gene sets were related to pathways of innate immunity (n=3), cytokine 
interaction (n=3), intracellular signalling (n=2), cell communication (n=2), apoptosis 
(n=1) and others (n=1). Increased expression of genes such as CXCL2, NAMPT, 
THBS1 and MMP9 imply activation of inflammatory, tissue injury pathways and cell 
communication in the DBD recovered organ. They demonstrated that lungs obtained 
from DCD donors had a significantly attenuated inflammatory transcriptional response 
compared with DBD donors, concluding that this suggests safe application of lung 
transplantation in properly preserved DCD donor lungs. In pre-transplant samples, 
cytokine levels were higher in DBD than for DCD. They demonstrated statistically 
significantly higher levels of IL-6 (p=0.001) in DBD compared with DCD lungs, which 
we have re-confirmed in this study. 
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Comparison studies have been carried out in the liver transplant community, as Xu et 
al. demonstrated significantly higher levels of neutrophil, T cell infiltration, and ICAM-1 
expression detected in DBD compared to DCD donor liver prior to transplantation[182]. 
Their results demonstrated increased platelet adhesion and von Willebrand Factor 
expression prior to reperfusion in DBD livers. They concluded that as compared to 
DBD allografts, DCD grafts appear to have reduced leukocyte infiltration before and 
after transplantation. They suggested that DCD livers are prone to necrosis rather than 
inflammation. 
Limitations of the Study 
We have shown that in lungs submitted for EVLP (and therefore turned down for 
immediate transplantation) there was across a spectrum of inflammatory markers, 
specific differences in the inflammatory and tissue injury profiles comparing DBD and 
DCD lungs. A potential weakness is that these lungs come from one end of the 
spectrum of acceptability. Truly marginal donor lungs subjected to EVLP for 
reconditioning purposes form by nature a subpopulation that is likely to have a higher 
inflammatory burden than standard donor lungs. It may be that what might be termed 
“standard” as opposed to extended donors might have different inflammatory profiles.  
Another limitation of our study is its relatively small sample size, with 46 human EVLP 
assessments included; however this cohort has previously been sufficient to 
demonstrate the feasibility of using perfusate markers to classify successful EVLP[83]. 
The results of this study need further evaluation in a larger prospective validation 
cohort of lungs exposed to ex vivo perfusion and that further investigation into the 
molecular and cellular differences of DBD and DCD lungs undergoing EVLP is 
welcomed.  
In this study, we demonstrated in lungs subjected to EVLP (and therefore turned down 
for immediate transplant) that across a spectrum of markers, there are specific 
differences in the inflammatory and tissue injury profiles comparing DBD and DCD 
lungs. This study appears to be the first in-depth analysis of these inflammatory and 
injury markers in comparable groups of DCD and DBD donors and provides insight 
into the potential molecular events in the period prior to retrieval and differences 
between the two donor groups. Improved knowledge on when and how fast brain death 
related processes occur and the sequence in which these events take place, will help 
us to understand the primary triggers of DBD-associated organ injury. A greater 
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understanding of pre-donation events may inform the creation of donor management 
protocols tailored specifically to the DCD and DBD lung and evaluation strategies that 
identify organs suitable for transplantation. Further knowledge of the 
pathophysiological processes occurring in these groups may identify ways to improve 
donor management and possible therapeutic targets for improving outcomes in lung 
transplantation.  
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Chapter 5: EVLP as a platform for novel therapeutics: Sildenafil  
In the previous chapters, I have reported on Ex-vivo lung perfusion (EVLP) emerging 
over the past decade as a proficient technique to objectively assess and recondition 
organs unsuitable for immediate transplantation. In addition to its function as a donor 
lung assessment platform, the EVLP technique offers an opportunity to attenuate the 
inflammatory response and encourages the recovery of vascular integrity in the 
donor lung before implantation, with a personalised medicine approach. Better 
knowledge of the biology of these lungs and ways to favour cellular recovery may 
improve early outcomes after lung transplantation and further help to safely maximise 
lung use from the existing donor pool.  
As part of the BTRU, my prospective work concentrated on developing a robust, 
reproducible model for EVLP of donor lungs that have been turned down for immediate 
transplantation and evaluating this as a platform for therapeutic interventions. As 
described in Chapter 2, training and education in the porcine model was utilised to 
develop, optimise and establish a research EVLP model for human lungs turned down 
for transplantation and use as a platform for delivering a novel therapeutic.  
Armed with the knowledge from the literature review presented in Chapter 1, on 
primary graft dysfunction and ischaemia reperfusion injury, I wanted to investigate a 
therapy which had been presented in the literature to have potential attenuating 
effects of this pathological process. In addition, we set out to demonstrate the 
feasibility and limitations of using EVLP as a platform for therapy delivery.  
The therapeutic agent, sildenafil citrate, a selective and potent inhibitor of 
phosphodiesterase type 5 (PDE-5) targets the nitric oxide (NO)/ cyclic guanosine 
monophosphate (cGMP) pathway in the vascular endothelium. It is a vasodilator 
commonly used in pulmonary hypertension and has the potential to improve the 
physiology of donor lungs by reducing pulmonary vascular resistance and pulmonary 
artery pressure. It has also been postulated to have an immunomodulatory effect, via 
NO inhibition of adhesion molecule expression, leucocyte adhesion and platelet 
aggregation. In an effort to clarify the haemodynamic response to intravenously 
administered sildenafil citrate and investigate its potential use in the EVLP setting, we 
conducted a prospective study of 5 human donor lungs that had been turned down 
for transplantation. We aimed to study the effects of sildenafil on lung physiology 
during EVLP, in addition to its biological effect on cytokines, endothelial markers and 
angiogenic factors. The following chapter outlines this study. I was responsible for 
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the study concept, design and execution.  Laboratory analyses were performed by 
myself, with the introduction to the laboratory techniques generously provided by 
members of the Borthwick Fibrosis Research Group. I led the subsequent data 
analysis and wrote the manuscript for the study which is planned for submission for 
publication.  
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Introduction  
Despite 20 years of successful lung transplantation, primary graft dysfunction (PGD) 
remains a significant and devastating complication in the early postoperative lung 
transplant period[183, 184]. PGD, a form of acute lung injury (ALI) occurring within 72 
hours of lung transplantation, is characterised by hypoxaemia and alveolar infiltrates 
in the allograft[95]. Occurring in up to 20% of lung transplant recipients, PGD results 
in the development of progressive hypoxaemia, increased pulmonary pressures, and 
pulmonary oedema[185]. Patients in whom PGD develops have increased rates of 
graft rejection, infection, longer intensive care unit and hospital lengths of stay, and 
greater short and long-term mortality[186-188]. 
Alterations in pulmonary vascular resistance, microvascular permeability, and gas 
exchange support the belief that the injury in PGD is primarily caused by IRI[189].IRI 
refers to sterile inflammation that occurs after substrate supply is restored following a 
period of absent blood flow[190]. A long ischaemic period followed by quick 
restoration of blood and oxygen supply to the lung can lead to IRI that is 
characterised by damage to the lung structure and a decline in respiratory function. 
Lung IRI is characterised by massive pulmonary oedema and hypoxaemia, which are 
difficult to reverse and require intensive ventilator therapy. The alveolar air spaces 
which are the site of gaseous exchange are separated from the circulating blood 
volume only by the alveolar-capillary membrane, a monolayer of endothelial cells 
fused via the extracellular matrix to the alveolar epithelial cells[191]. The pulmonary 
endothelium is the most vulnerable component of this structure[192]. Permeability 
occurs predominantly via a para-cellular route between two cells, normally “zipped 
together” by junctional proteins. Several strategies have also been introduced into 
clinical morbidity and mortality after lung transplantation. Several strategies have also 
been introduced into clinical practice for the prevention and treatment of ischaemia–
reperfusion with various degrees of success. 
Several studies have suggested an important role for NO signalling pathways 
mediated by secondary messengers such as cGMP in the maintenance of vascular 
homeostasis and have been implicated in IR lung injury. cGMP is an important 
signalling molecule that stimulates smooth muscle relaxation. Models of lung IRI 
have demonstrated that reduced levels of cGMP[193] after lung reperfusion have 
been associated with the development of pulmonary hypertension,[194] reduced 
oxygenation,[195] and increased microvascular permeability[189]. 
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PDE-5 inhibitors such as sildenafil prevent the breakdown of NO driven cGMP[196]. 
Sildenafil is widely used in the treatment of pulmonary hypertension and erectile 
dysfunction[196, 197]. However, cGMP also has other regulatory roles that stimulate 
neutrophil degranulation, inhibit platelet aggregation, regulate intracellular calcium 
levels, and open the mitochondrial K+ATP channels[198, 199]. These mechanisms 
have a beneficial role in reducing the severity of IRI. Previous studies have reported 
that sildenafil can suppress multiple pro-inflammatory cytokines which play an 
important role in neutrophil and monocyte recruitment[200].  It has also been 
reported that through modulation of the NO/cGMP pathway, the interaction between 
neutrophils and endothelial cells via adhesion molecules can be attenuated[201].  
The importance of NO signalling via cGMP suggests an opportunity for 
preconditioning via modulation of this pathway. Through augmentation of cGMP 
levels, PDE inhibition may protect against the deleterious effects of IRI after lung 
transplantation. Although there have been several animal studies investigating the 
use of phosphodiesterase inhibitors as a preconditioning treatment of IRI, there is a 
limited number of studies assessing the potential therapeutic effects in human donor 
lungs. 
 
One of the major upcoming challenges will be to improve the number of donor lungs 
available for transplantation. Although the number of patients on the waiting list 
continues to increase, only 10 - 30% of the available donor lungs are clinically used. 
Hence, the development of new strategies to repair and improve the quality of the 
lungs could have a tremendous impact on the number of transplants performed. 
EVLP has emerged as a promising technique for assessing and potentially 
reconditioning unusable human donor lungs before use in clinical lung 
transplantation. More targeted interventions are now possible with the use of EVLP 
prior to transplantation. EVLP provides us with a highly unique, localised environment 
for the administration of high-dose treatments to donor lungs prior to implantation 
without fear of systemic repercussions. Given the potential therapeutic role for PDE 
inhibition in PGD, we hypothesised that administering sildenafil to human donor lungs 
during EVLP would reduce the potential for IRI and improve lung physiology during 
perfusion. The study aimed to examine the physiological, immunological and 
histological changes in donor lungs deemed unsuitable for standard transplantation 
undergoing EVLP with a perfusate supplemented with the known vasodilatory agent, 
Sildenafil.  
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Materials and Methods 
Study design 
This was a prospective observational study examining the effect of sildenafil 
administered to human donor lungs during EVLP. Ethical approval was received from 
the local Research Ethics Committee and informed consent obtained from donor 
families (REC 16/NE/0230). Inclusion and exclusion criteria are listed in Table 5.1  
INCLUSION CRITERIA EXCLUSION CRITERIA  
 Patient identified as a potential organ 
donor by the NHS-BT 
 Age between 18-85 years  
 Must fall into one of the following 
groups:  
 * defined brain death  
 * individuals who have had a withdrawal of 
care and a minimum 5-minute observation 
period to confirm cardiac death.  
 Only patients with appropriate consent 
reflecting their own and their families’ 
wishes will be considered. 
 To be eligible for recruitment into the 
study, the tissue in question will have 
been declined for clinical use by all 
transplant centres in the UK.        
 Under the age of 18 or 
above age 85 
 Presentation of blood borne 
pathogens such as HIV, 
Hepatitis B, Hepatitis C 
 Tuberculosis (TB) 
 Clostridium difficile (CD) 
 Methicillin resistant 
staphylococcus aureus 
(MRSA).  
 
Table 5.1 Study inclusion exclusion criteria 
 
Ex-vivo lung perfusion protocol 
All lungs included in this study were adult donor lungs with donor-family research 
consent deemed unsuitable for lung transplantation by all UK lung transplant centres. 
Adult donor lungs rejected for standard lung transplantation and meeting the above 
criteria were procured according to established clinical protocols, inflated with 100% 
oxygen and stored in cold PerfadexTM for transport to our institution. The standard lung 
procurement procedure can be briefly summarised as follows; lungs were 
anterogradely flushed with supplemented Perfadex® (XVIVO Perfusion AB, 
Gothenburg, Sweden) [3.3 ml of 3.6% trometamol (THAM), 0.6 ml of calcium chloride 
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(CaCl2) ± 2.5 ml of prostacyclin/l], initially at room temperature and then the remainder 
at 4°C. A minimum volume of 60 ml/kg was given. After the antegrade flush, 200 ml 
was flushed into each pulmonary vein as a final retrograde flush. The retrieved lungs 
were filled with air, the airway sealed and then sterilely bagged for transport on ice, 
during a period of cold storage.  All EVLP procedures were carried out in the Transplant 
Regenerative Medicine Facility, NHS-BT Donor Centre, Holland Drive, Newcastle, NE2 
4NQ.   
EVLP assessments were performed using a Medtronic EVLP Rig. The technique for 
EVLP followed a protocol described in detail by the Toronto group[88], which included 
a perfusate consisting of 2 litres of acellular Steen solution with 10,000 units of 
heparin. The EVLP protocol is outlined in Table 5.2. 
Table 5.2 EVLP protocol used during this study  
 
PERFUSION  
Target flow 40% of cardiac output 
Pulmonary arterial pressure <20 mmHg 
Left atrial pressure 3-5 mm Hg (Closed LA) 
Pump Roller 
Perfusate 2L Steen SolutionTM 
VENTILATION  
Mode Volume controlled 
Tidal volume 7 ml/kg 
Frequency 7 bpm 
Peak end-expiratory pressure 5 cm H2O 
Fraction of inspired oxygen 50 % 
TEMPERATURE  
Start of ventilation 32oC 
Start of perfusion 15oC 
Start of evaluation 37oC 
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Sildenafil Citrate  
In all lung pairs within the treatment group, the selective PDE-5 inhibitor sildenafil 
(Revatio; Pfizer, Sandwich, Kent) was administered at a dose of 10 mg, as a bolus 
into the arterial arm of the circuit after a period of stable normothermic perfusion, 30 
minutes of ventilation and when the lungs had reached 37 °C.  
Physiological Assessment  
Haemodynamic data was continuously monitored throughout EVLP and recorded at 
5 minute intervals prior to sildenafil delivery, at one minute intervals for the 
subsequent hour and then every 15 minutes until the end of perfusion. The aim was 
to compare the haemodynamic data before and after sildenafil was administered and 
identify any alteration to the physiological parameters. The pulmonary artery flow 
(L/min), i.e. cardiac output (CO) was measured continuously via a flow probe in the 
ex vivo model and the pulmonary artery pressure (PAP) recorded via a pressure 
transducer positioned in the PA. Temperature recordings were taken from the left 
atrium as to obtain readings of the perfusate leaving the lungs. Blood gas analyses 
using an ISTAT portable machine were carried out prior to commencing EVLP and at 
30-minute intervals during perfusion.   
Sample collection 
Lung tissue 
Small biopsies (approximately 3x3x1 cm) of lung tissue were taken using a Covidien 
Duet (absorbable buttressed) endo-GIA stapler from either the right middle lobe or 
lingula at four time points: 
Biopsy 1: Taken prior to commencement of the EVLP process  
Biopsy 2: 30 minutes’ post drug dosing 
Biopsy 3: 60 minutes’ post drug dosing 
Biopsy 4: Taken at the end of the EVLP process once perfusion has stopped  
Biopsies were placed on sterile gauze dampened with 0.9 % sodium chloride in a 
sample pot and the pot stored on ice until processing. From each of these biopsies, a 
small amount snap frozen using dry ice and isopentane slurry for subsequent 
mechanistic studies. The remaining tissue was fixed in formalin, paraffin embedded 
and sections cut for Haematoxylin and Eosin staining for routine histological 
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evaluation. Tissue blocks were available for subsequent immune-localisation studies 
using immunohistochemistry. 
 
Perfusate fluid 
Repeated perfusate samples (5 ml) were collected from the perfusate sampling port: 
- Perfusate 0: Perfusate primed EVLP circuit before the donor lung perfusion 
was started. 
- Perfusate 1: 15 minutes after perfusion start.  
- Perfusate 2: 30 minutes after perfusion start.  
- Perfusate 3 to Perfusate 8: Every 30 minutes of perfusion.  
- Perfusate X: End of perfusion immediately before perfusion stop.  
The perfusate samples were centrifuged at 180 xg for 6 minutes at 4 °C to remove 
cellular debris. Supernatants were stored at -80 °C. 
Quantification of protein expressions in perfusate and bronchoalveolar lavage fluid 
All protein expressions measured in perfusate were adjusted to the donor predicted 
total lung capacity (pTLC), as an estimate of perfused donor lung volume, and 
reported as corrected perfusate concentrations (pg/ml). The pTLC was calculated in 
a routine fashion based on donor gender and height[202].  
Meso scale discovery multiarray 
To assess the effect of sildenafil on the concentrations of pro-inflammatory cytokines 
detected during perfusion an MSD Multi-Array® U-PLEX Human Biomarker pro-
inflammatory Panel 1 Kit (K15067L-1) (Meso Scale Diagnostics, LLC, Rockville, MD) 
was used. This allowed for the detection of the specific cytokines of interest, IL-1β, 
IL-6, IL-8, TNF-α, and VEGF which have been highlighted in previous EVLP 
literature[43, 83, 157]. Perfusate samples were also analyzed with a R-PLEX Human 
Ang-2 Antibody Set (F21YR-3) (also Meso Scale Diagnostics, LLC, Rockville, MD). 
The assays were performed according to manufacturer’s instructions. Technical 
issues prevented reading of perfusate samples from donor lung EVLP03 and these 
samples were therefore excluded from the analysis.  
Enzyme-linked immunosorbent assays (ELISAs) 
To assess the effect of sildenafil on the integrity of the pulmonary vascular 
compartment, we measured a number of endothelial barrier markers, including 
junctional proteins and thrombogenic agents which are known to activate the 
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pulmonary endothelium. Solid phase sandwich ELISAs were used to assess the 
perfusate concentration of five soluble markers of: E-selection (DY724), Von 
Willebrand factor (DY2764-05), Thrombomodulin (DY3947), VE-cadherin (DY938-05) 
(all R&D Systems, Inc., Minneapolis, MN).  These were measured with commercially 
available ELISA kits according to manufacturer’s instructions.  
Griess Reagent System  
To investigate nitric oxide formation, nitrite (NO2–) was measured, one of two primary, 
stable and non-volatile breakdown products of NO. The Griess Reagent System 
(G2930 from Promega) is based on the chemical reaction which uses sulfanilamide 
and N-1-napthylethylenediamine dihydrochloride (NED) under acidic (phosphoric 
acid) conditions.  
Histology  
Lung biopsy tissue was taken from pre- and post-EVLP for all six human lungs and at 
two additional time points (30 minutes’ post sildenafil and 60 minutes’ post sildenafil) 
in H004, H005 and H006 (n=18 sections). Tissue was fixed in 10% neutral buffered 
formalin and embedded in paraffin. 5 μm sections were cut and mounted on 
Superfrost Plus glass slides (Thermo Fisher Scientific, USA). The sections are 
deparaffinised in xylene before rehydration through graded alcohol solutions. 
Endogenous peroxidase was blocked in methanol/hydrogen peroxide (1:50) and 
incubated for 30 minutes. Slides are washed in PBS between all major steps. 
Immunolocalization of neutrophil elastase (EPR7479) and e NOS (ab5589) (both 
Abcam, Inc., Cambridge, MA) was by the avidin-biotin method with biotinylated 
secondary antibodies and subsequent DAB Chromogen staining (Vector 
Laboratories, Inc., Burlingame, CA). Sections were counterstained with Mayer’s 
haematoxylin, dehydrated, cover slipped, and digitally photographed. Five fields at 
x20 magnification from each section were independently scored by two blinded 
arbiters using a semi-quantitative scoring system with 4 levels: (0 = no staining; 1 = 
weak staining, 2 = moderate staining; and 3 = strong staining). Average scores were 
compared between groups. Two independent arbiters individually counted neutrophil 
elastase positive cells and average scores were recorded. 
Statistical analysis  
All data measurements are presented as the mean ± standard error of the mean. 
Comparison of the mean values was performed by using repeated measures 
analysis of variance (ANOVA method). Differences were considered significant when 
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the p-value was less than 0.05. Donor characteristics and physiological parameters 
are expressed as medians with interquartile range. Paired samples, start-end of 
perfusion, were compared with Wilcoxon signed-ranks tests. Log protein expressions 
were compared between transplanted and non-transplanted lungs with multiple t-
tests. 
Results  
Study group  
Lungs from six UK multi-organ donors were identified as unsuitable for immediate 
standard transplantation despite extensive donor management and were assessed 
with EVLP in the study. The donor demographics and indications for EVLP are 
shown in Table 3.  
Donor characteristics 
Six donor lungs, all bilateral were recruited into the study. The EVLP assessments 
were evenly distributed between genders, 3 females (50%) and 3 males (50%). The 
median donor age was 54 years (range 28-64 years). Donor lungs came from 5 heart 
beating donors (DBD) and 1 donation after circulatory death (DCD).   
Of these six donors, two died from spontaneous intracranial haemorrhage (33.3%), 
two from hypoxic brain injury (33.3%), one from ischaemic stroke (16.6%) and one 
from meningitis (16.6%).  
Of six donors, 4 (66.6%)were never smokers, 1 ex-smoker (16.6%)and 1 current 
smoker (16.6%).  Three (50%) had an abnormal chest x-ray at the time of 
procurement, and 2 (33.3%) had airway secretions deemed prohibitive of standard 
transplantation; predominantly purulent secretions. The median ventilation time for 
the EVLP donors before procurement was 2 days (range 2 to 5 days) and 2 donors 
(33.3%) had positive microbiology cultures from either sputum, BAL or CSF. The 
median optimised PaO2:FiO2 for the 6 EVLP donors at the time of procurement on 
100% inspired oxygen and PEEP of 5 cmH2O was 56.5 kPa.  Donor characteristics 
are listed in Table 5.3.
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Variable  H001 H002 H003 H004 H005 H006 Median 
(range) 
Sex Female Male Male Female Male Female  
Age (years) 56 28 42 56 52 64 54 (28-64) 
Height (cm) 165 176 171 170 174 163 170.5 (163-
176) 
Weight (kg) 65 80 76.5 70 68 75 72.5 (70-
80) 
Blood group  A+ O+ A+ O- A+ A+  
Cause of death Hypoxic brain 
damage  
Hypoxic brain 
damage 
Intracranial 
CVA 
Intracranial 
haemorrhage 
Meningitis  Intracranial 
haemorrhage 
 
Donor type DCD DBD DBD DBD DBD DBD  
Smoking Never  Smoker  Never  Never  Never Ex-smoker  
Chest x-ray 
findings 
Right 
pneumothorax.  
Consolidation 
left base  
Bi-basal 
consolidation  
Clear  Clear Clear  
Microbiology on 
offer 
Nil Nil  Staphylococcus 
aureus in 
sputum 
Nil Neisseria 
meningitidis  
Nil  
Secretions Nil  Yes  Yes Nil Nil Nil  
Duration of 
ventilation (days) 
2 3 5 2 4 1 2.5 (1-5) 
 
Table 5.3 Donor Characteristics.  
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Variable  H001 H002 H003 H004 H005 H006 Median (range) 
Ischaemic time 
(hours) 
28 21 26 14 14 17 19 (14-28) 
EVLP time (mins) 210 225 165 160 160 155 162.5 (155-210) 
Optimised Donor P/F 
ratio (kPa) 
63.8 29.9 50.7 55.6 57.5 64 56.55 (29.9-64) 
P/F ratio after EVLP 
(kPa) 
48.3 
 
75.24 34.6 64.9 61.3 43.6 54.8 (34.6-75.24) 
Perfusion flow 
(L/min) 
3.71 1.9 1.85 1.69 2.0 1.92 1.91 (1.69-3.71) 
Pulmonary artery 
pressure (mmHg) 
15 17 17 5 7 8 11.5 (5-17) 
Left atrial pressure 
(mmHg) 
0 3 3 3 5 3 3 (0-5) 
PVR  (dyne · s/cm5) 827 507 1806 347 224 457 482 (224-1806) 
Peak airway pressure 
End (cmH2O) 
 
19 13 17 13 18 14 15.5 (13-19) 
Compliance  NA NA 46.2 48 34.6 41 43.6 (41-48)  
Table 5.4 Lung Reconditioning  
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Ex-vivo lung perfusion outcomes 
After reconditioning, the lungs from these donors produced a median PaO2:FiO2 on 
a 100% oxygen of 54.8 kPa. The median CIT from donor lung flush to start of EVLP 
was 19 hours (range 14-28 hours) and median perfusion time was 162.5 min (range 
155-225 min). The variables of the physiology achieved, hemodynamic and 
ventilatory parameters are presented in Table 5.4. 
Effect of sildenafil on ex vivo lung physiology 
Haemodynamic data including pulmonary artery flow (L/min), i.e. cardiac output (CO) 
in the ex vivo model and pulmonary artery pressure (PAP), were measured 
continuously. Pulmonary vascular resistance was calculated retrospectively, 
determined as follows:  
 flowpulmonary pressure)/ atrialleft -pressureartery pulmonary (mean 805)-cm-sec-dynes( PVR  
In the five donor lungs that received Sildenafil, changes in mean PA pressure, mean 
aortic pressure, pulmonary flow and pulmonary vascular resistance did not change 
significantly following administration of the sildenafil bolus, Figure 5.1. By analysis of 
variance with repeated measures, there were no significant differences between any 
of the time points or comparing time points following administration of the drug to the 
baseline parameters. 
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Figure 5.1 Effect of sildenafil on the physiological characteristics of EVLP 
donor lungs 
Line graphs show the physiological data over the course of EVLP; pulmonary artery 
pressure (PAP) (graph A); flow rate (graph B) and pulmonary vascular resistance 
(PVR) (graph C). The dotted black line indicates the time at which 10 mg sildenafil 
was administered. Data analysed using repeated measures ANOVA, n=5.There were 
no significant changes in physiology when comparing between each time-point or 
when using time 0 as a comparison. In PAP, there was a downward trend following 
sildenafil in H001 and H002 where there were higher pressures recorded prior to 
Time 0. EVLP denotes ex-vivo lung perfusion, Time in minutes of ex vivo lung 
perfusion prior to and after sildenafil administration. 
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In all lungs, Pa02:Fi02 remained stable and above 40kPa (300mmHg) throughout 
EVLP. No significant changes were observed following sildenafil, Figure 5.2.  
 
 
Figure 5.2 Effect of sildenafil on oxygenation during EVLP  
In all lung pairs shown, the selective PDE-5 inhibitor sildenafil (Revatio; Pfizer, 
Sandwich, Kent) at a dose of 10 mg was administered as a bolus into the arterial arm 
of the EVLP circuit after a period of stable reperfusion, 30 minutes of ventilation and 
when the lungs had reached 37°C. Line graphs show the PaO2/FiO2 ratio which 
denotes oxygenation capacity over the course of EVLP. The dotted black line 
indicates the time at which sildenafil was administered. Data analysed using 
repeated measures ANOVA, n=5.There were no significant changes in oxygenation 
when comparing between each time-point or when using time 0 as a comparison. 
EVLP denotes ex-vivo lung perfusion, Time in minutes of ex vivo lung perfusion prior 
to and after sildenafil administration. PaO2/FiO2 ratio denotes the ratio of arterial 
oxygen partial pressure to fractional inspired oxygen.  
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To investigate nitric oxide formation, NO2– was measured, a primary, stable and non-
volatile breakdown product of NO. As expected following the delivery of sildenafil to 
the perfusate, an increase in nitrite concentration was seen. There was a significant 
increase in nitrite concentration when comparing concentrations at 45 minutes 
following sildenafil administration versus baseline levels, (p=0.0261). The nitrite 
concentrations are demonstrated in Figure 5.3.  
 
Figure 5.3 Effect of sildenafil on nitrite concentration in perfusate 
In all lung pairs shown, the selective PDE-5 inhibitor sildenafil (Revatio; Pfizer, 
Sandwich, Kent) at a dose of 10 mg was administered as a bolus into the arterial arm 
of the EVLP circuit after a period of stable reperfusion, 30 minutes of ventilation and 
when the lungs had reached 37°C. The black dotted line indicates time 0, when 
sildenafil was given. Perfusate samples were collected from the circuit prior to 
commencing EVLP, at 15 minutes and then at 30 minute intervals during perfusion. 
The Griess Reagent System (G2930 from Promega) was used to detect nitrite 
concentration in each sample. By analysis of variance with repeated measures, a 
significant difference was seen at 45 minutes after sildenafil was given versus 
baseline values, P=0.0261. EVLP denotes ex-vivo lung perfusion, Time in minutes of 
ex vivo lung perfusion prior to and after sildenafil administration. 
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Effect of sildenafil on cytokine expression 
When comparing the concentrations of cytokines IL-1β, IL-6, IL-8 and TNF-α in the 
perfusate of the 5 donor lungs that received sildenafil versus the historical 
DEVELOP-UK cohort[98] significant differences were seen at the final sample time, 
with higher concentrations of TNF- α and IL-8 in the sildenafil group.  The overall 
trends for these pro-inflammatory cytokines were very similar in both groups, Figure 
5.4. The effect of sildenafil on cytokine protein levels can be seen in Figure 5.5.  
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Figure 5.4 Comparison of cytokine concentrations between sildenafil and 
DEVELOP-UK cohorts.  
Perfusate samples were collected from the circuit prior to commencing EVLP, at 15 
minutes and then at 30 minute intervals during perfusion. Perfusate concentrations in 
pg/ml of IL-1β (graph A), IL-6 (graph B), IL-8 (graph C) and TNF-α (graph D) were 
detected using a MSD Multi-Array® U-PLEX Human Biomarker pro-inflammatory 
Panel 1 Kit (K15067L-1) (Meso Scale Diagnostics, LLC, Rockville, MD), according to 
manufacturer instructions. The DEVELOP-UK historical cohort was used as a 
comparative group. Data shown as mean +/- SD, analysed by multiple unpaired t-
tests, with a post-test correction for multiple comparisons (Bonferroni) **P<0.01. 
Sildenafil group n=5, DEVELOP group n=46. There were no significant differences 
seen in IL-1β and IL-6 concentrations detected in perfusate between groups. In the 
sildenafil group there were significantly higher levels of IL-8 and TNF-alpha by the 
end of perfusion. 
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Figure 5.5 Effect of sildenafil on cytokine expression in perfusate. 
In all lung pairs shown, the selective PDE-5 inhibitor sildenafil (Revatio; Pfizer, 
Sandwich, Kent) at a dose of 10 mg was administered as a bolus into the arterial arm 
of the EVLP circuit after a period of stable reperfusion, 30 minutes of ventilation and 
when the lungs had reached 37 °C. The black dotted line indicates time 0, when 
sildenafil was given. Perfusate samples were collected from the circuit prior to 
commencing EVLP, at 15 minutes and then at 30 minute intervals during perfusion. 
Perfusate concentrations of IL-1β (graph A), IL-6 (graph B), IL-8 (graph C) and TNF-α 
(graph D) were detected using a MSD Multi-Array® U-PLEX Human Biomarker pro-
inflammatory Panel 1 Kit (K15067L-1) (Meso Scale Diagnostics, LLC, Rockville, MD), 
according to manufacturer instructions. Data analysed using repeated measures 
ANOVA, n=5. There is a linear trend for all markers, no significant differences were 
detected following sildenafil administration.  
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Effect of sildenafil on endothelial marker expression 
When comparing the concentrations of vascular endothelial markers E-selectin, 
Thrombomodulin, VE-cadherin and von Willebrand Factor in the perfusate of the 5 
donor lungs that received sildenafil versus the historical DEVELOP-UK cohort[98] 
there were significant differences seen. Using multiple t-tests and bonferroni 
corrections to compare groups at each time point, there were significantly higher 
levels of Thrombomodulin and VE-cadherin in the DEVELOP-UK cohort at all-time 
points (p<0.01). There was a higher concentration of von Willebrand Factor in the 
DEVELOP-UK group at 120 minutes, (p<0.01). The comparison of the endothelial 
marker levels between groups can be seen in Figure 5.6. The effect of sildenafil on 
endothelial marker protein levels can be seen in Figure 5.7.  
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Figure 5.6 Comparison of endothelial marker concentrations between sildenafil 
and DEVELOP-UK cohorts.  
Perfusate samples were collected from the circuit prior to commencing EVLP, at 15 
minutes and then at 30 minute intervals during perfusion. Perfusate concentrations of 
E-selectin (graph A); Thrombomodulin (graph B); VE-cadherin (graph C) and Von 
willebrand (VWF) (graph D) were detected using solid phase sandwich ELISAs (R&D 
Systems, Inc., Minneapolis, MN), according to manufacturer instructions. The 
DEVELOP-UK historical cohort was used as a comparative group. Data shown as 
mean +/- SD, analysed by multiple unpaired t-tests, with a post-test correction for 
multiple comparisons (Bonferroni) **P<0.01. Sildenafil group n=5, DEVELOP group 
n=46. There were no significant differences seen in E-selectin concentrations 
detected in perfusate between groups. In the DEVELOP-UK group there were 
significantly higher levels of THR and VE-cadherin throughout perfusion. VWF was 
significantly higher in the DEVELOP-UK group at 120 minutes. 
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Figure 5.7 Effect of sildenafil on endothelial marker expression 
In all lung pairs shown, the selective PDE-5 inhibitor sildenafil (Revatio; Pfizer, 
Sandwich, Kent) at a dose of 10 mg was administered as a bolus into the arterial arm 
of the EVLP circuit after a period of stable reperfusion, 30 minutes of ventilation and 
when the lungs had reached 37oC. The black dotted line indicates time 0, when 
sildenafil was given. Perfusate samples were collected from the circuit prior to 
commencing EVLP, at 15 minutes and then at 30 minute intervals during perfusion. 
Perfusate concentrations of E-selectin (graph A); Thrombomodulin (THR) (graph B); 
VE-cadherin (graph C) and Von Willebrand (VWF) (graph D) were detected using 
solid phase sandwich ELISAs (all R&D Systems, Inc., Minneapolis, MN).  according 
to manufacturer instructions. The dotted black line indicates the time at which 
sildenafil was administered. Data analysed using repeated measures ANOVA, n=5. 
There is a linear trend for all markers.  
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Effect of sildenafil on lung histology  
The expression of eNOS and neutrophil elastase in immunohistochemistry stained 
EVLP donor lung tissue was evaluated. Paraffin embedded lung tissue from four of 
the EVLPs at four time points (pre, 30 minutes after sildenafil, 60 minutes after 
sildenafil and post) were stained for endothelial nitric oxide synthase (eNOS)and 
neutrophil elastase (NE). We aimed to investigate if following the administration of 
sildenafil there was an increase in eNOS and a reduction in NE on parenchymal 
endothelial cells of lungs having undergone the EVLP assessments. Representative 
images of low intensity and high intensity eNOS stained pulmonary vascular 
endothelium are displayed in Figure 5.8, with individual scoring in Figure 5.9.  
Low expression                                   High expression 
 
Figure 5.8: eNOS stained lung tissue  
Representative examples of digital photos at x20, expressions of eNOS in 
immunohistochemistry stained EVLP donor lung tissue. Paraffin embedded donor 
lung sections DAB stained for eNOS expressions. Arrows marking the low intensity 
stained (A) or high intensity (B) stained pulmonary vascular endothelium.  
 
 
 
 
 
 
A B 
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Figure 5.9 Scoring of in eNOS EVLP Tissue 
Individual eNOS scores for lung tissue taken before commencing EVLP, 30 minutes 
after sildenafil was given, 60 minutes after sildenafil was given and after stopping 
EVLP. Five fields were captured at x20 magnification from each time point section 
and were independently scored. The vascular endothelial staining was graded using 
a semi-quantitative scoring system with 4 levels: (0 = no staining; 1 = weak staining, 
2 = moderate staining; and 3 = strong staining) Average scores were used and 
compared for the different time points.  There were no significant differences when 
comparing each time point using one-way ANOVA. The overall trend showed that 
eNOS staining fell during perfusion with no increase following sildenafil.  
 
There was no significant difference in eNOS expression between the time points. We 
did not see the expected increase in eNOS following the delivery of sildenafil to the 
EVLP circuit.  
Neutrophil elastase (NE) is a specific stain used in the lung biopsy samples to 
examine the numbers of neutrophils in the pulmonary vasculature. IHC staining 
demonstrated that there was a reduction in NE between the pre and post sildenafil 
biopsies, Figures 5.10 and 5.11. 
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Figure 5.10: Neutrophil elastase stained lung tissue  
Representative examples of digital photos at x20, expressions of neutrophil elastase 
(NE) in immunohistochemistry stained EVLP donor lung tissue. Paraffin embedded 
donor lung sections DAB stained for NE expression. Arrows marking neutrophil 
elastase stained cells. A. shows neutrophil elastase cells adhered to the pulmonary 
vascular endothelium. B. shows neutrophil elastase cells within a pulmonary vessel.  
 
Figure 5.11 Scoring of Neutrophil Elastase in EVLP Tissue 
Neutrophil Elastase positive cell count before and after EVLP. The overall trend 
shows a reduction in the neutrophil elastase stained cell count, however this did not 
reach statistical significance. Data analysed using Mann-Whitney U test, (p=0.1143).  
 
  
A B 
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Discussion  
In this study, we examined the effects of administering sildenafil to the vascular 
compartment of donor lungs during EVLP. We found no measurable differences in 
lung physiology after sildenafil administration.  We did, however, observe significantly 
lower expression of vascular endothelial activation markers when comparing to a 
historical control cohort.  
The principal mechanism of action of sildenafil involves modulation of NO-activated 
cGMP by directly inhibiting the PDE-5 enzyme responsible for cGMP breakdown. The 
resulting increase in cGMP leads to the activation of protein kinase G (PKG), which 
phosphorylates downstream targets including receptors, kinases, and phosphatases 
leading to a variety of cellular effects.  PKG can, in turn, phosphorylate both enzymes 
endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS), 
leading to feedback regulation of NO production[203-206]. Increased PKG leads to 
pulmonary vasodilation and to the opening of potassium channels on the inner 
mitochondrial membrane which can contribute to the cellular stabilisation. Increases 
in cGMP and eNOS may also mediate platelet aggregation, neutrophil and leucocyte 
adhesion[207-209]. Studies have also suggested that delayed protection may result 
from PDE-5 activation of the Bcl-2 gene, shown to inhibit apoptosis[204].  
NO released from endothelial cells maintains vascular homeostatic properties[210] 
by relaxing vascular smooth muscle[211], inhibiting neutrophil adhesivity[201, 212], 
platelet aggregation[213, 214]and maintaining endothelial barrier properties[209, 
215]. In the lungs, endogenously produced NO stimulates basal cGMP production 
and results in pulmonary vascular tone.  
Considerable interest has therefore been directed towards strategies that supplement 
the NO/cGMP pathway in an effort to attenuate IRI. The administration of the PDE-5 
inhibitor, sildenafil during EVLP in this study did not improve lung physiology or 
attenuate endothelial marker and cytokine expression. 
Our data indicates that although pulmonary vascular resistance was improved 
following the administration of sildenafil, there were no improvements in physiological 
parameters such as pulmonary artery pressures, pulmonary flow rates or 
oxygenation capacity.  These results are in contrast to those that have that have 
reported that endogenous NO levels plummet rapidly after reperfusion[216] and that 
exogenous NO has been reported to be protective in many models of IRI[217, 218]. 
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NO is responsible for controlling many biologic processes. NO has a key role in 
regulating blood flow and maintaining vascular tone. NO has a role in several 
important physiological processes, including vasoregulation and 
immunomodulation[219]. It is produced by a family of enzymes, i.e., NOSs that 
catalyses the conversion of L-arginine to L-citrulline with the help of five cofactors. NO 
then stimulates soluble guanylyl cyclase, which catalyses the formation of cyclic 3′-5′-
guanosine monophosphate, which in turn regulates protein phosphorylation, ion 
channel conductivity, and phosphodiesterase activity. We demonstrated that 
following the delivery of sildenafil to the EVLP circuit, increased concentrations of 
nitrite, the breakdown product of NO metabolism were detectable in the perfusate.  
Multiple approaches have been utilised to compensate for the fall in endogenous NO 
during lung transplantation. Strategies have been targeted at the donor and/or to the 
recipient and have focused on each step of the pathway described previously. 
Strategies in the literature, have included the administration of the upstream 
precursor molecule L-arginine[220], methods to increase the downstream effector 
molecule cyclic 3′-5′-guanosine monophosphate[221, 222], and the administration of 
exogenous NO. Exogenous NO has been given directly by inhalation (inhaled 
NO)[218, 223-227] or indirectly by infusion of a NO donor, such as 
nitroprusside[228], glyceryl trinitrate[229] or nitroglycerin[230-233].  
The role of NO as an anti-inflammatory and anti-adhesive modulator in post-
ischaemic venules of various organs has been studied. Kurose et al. [207]studied 
leukocyte adherence and emigration as well as albumin extravasation in single post-
capillary venules in rat mesentery subjected to 20 minutes of ischaemia followed by 
30 minutes of reperfusion. NO donors (sodium nitroprusside, spermine-NO, and 
SIN1) significantly reduced the IRI-induced leukocyte adherence, emigration and 
albumin leakage in post-capillary venules. Platelet-leukocyte aggregation and mast 
cell degranulation were also observed in the post-ischaemic mesentery, and the 
responses were also attenuated by the NO donors. NO is a homeostatic regulator of 
leukocyte adhesion in the microcirculation. Inhibition of NO production leads to 
increased leukocyte rolling and adhesion in various vascular beds and two adhesion 
molecules, P-selectin and CD11/CD18, have been implicated in these processes.  
Other animal studies have demonstrated the effects of inhaled NO on IL-8 
release[234]. Gomez et al. studied 22 pigs randomly assigned to NO-treated and 
control groups. In NO-treated pigs, NO at 20 ppm was administered 30 min before 
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harvest. Pre-treatment with NO at the time of harvesting showed improvement of 
allograft function in terms of dynamic and static compliance and gas exchange. They 
also demonstrated that in the inhaled NO group there was a significantly diminished 
IL-8 release. Our data did not suggest any difference in cytokine expression between 
our sildenafil group and historical control.  
Several clinical studies involving lung transplant recipients have demonstrated the 
beneficial effects of NO in IRI. Egan et al. reported that the administration of the nitric 
oxide-donor, nitroglycerin to lungs would reduce IRI by activation of cGMP and by 
reducing capillary leak after reperfusion[235]. 
Date et al. demonstrated that nitric oxide improves oxygenation and decreases 
pulmonary artery pressure without systemic circulatory effects in patients with severe 
allograft dysfunction[236]. 
Moreno et al. investigated 32 lung transplant recipients who were randomised to the 
inhaled NO (iNO) treatment or the control group[237]. Patients in the first group were 
given 10 ppm of iNO from the beginning of the lung transplant until 48 hours 
afterwards. The iNO treatment group showed a lower incidence of PGD (29%) in 
comparison with the control group (40%). Significant differences (P <0.05) were 
observed in the iNO group, with lower IL-6 levels at 12 hours in blood and BAL. A 
lower percentage of IL-8 was also detected in the iNO group at 24 hours in BAL and 
12 hours in blood and BAL. They concluded that iNO appeared to modulate the 
inflammatory response by reducing inflammatory cytokine concentrations found 
immediately after re-implantation, and this reduction was related to a lower incidence 
of PGD. 
Nitric oxide itself has been demonstrated to mitigate IRI in many model systems. 
However, studies examining the inhalation delivery of nitric oxide in experimental and 
clinical lung transplantation have shown discrepant results; some show benefits[219] 
others, however, demonstrate detrimental or neutral effects[238]. NO donors have 
been shown to be beneficial during the reperfusion period by augmenting the 
bioavailability of NO after ischaemic injury. They are, however, limited by their rapid 
release and potentially toxic side effects[239]. 
Botha et al. performed a study of 20 bilateral sequential lung transplant recipients 
who were randomised to receive either 20-ppm inhaled NO or a standard anaesthetic 
gas mixture from the onset of ventilation[240]. Bronchoalveolar lavage was 
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performed immediately prior to implantation and after 30 minutes of reperfusion and 
analysed for inflammatory cytokine levels and free radical surrogates. Primary graft 
dysfunction (PGD) scoring was performed prospectively for 72 hours’ post-transplant. 
The study could not demonstrate a significant effect of inhaled NO during the first 30 
minutes of reperfusion in the prevention of neutrophil injury and primary graft 
dysfunction after lung transplantation. 
Ardehali and colleagues have shown that the application of inhaled NO to 28 
consecutive recipients after lung transplantation did not prevent the occurrence of 
primary graft failure[241].  
In a prospective, randomised controlled study involving 30 double lung transplant 
recipients, Perrin et al. illustrated that prophylactic use of iNO failed to decrease 
pulmonary oedema formation and resolution after pulmonary reperfusion[242].  
The presence of NO and simultaneous generation of superoxide during reperfusion 
may lead to the formation of peroxynitrite (ONOO-), a powerful pro-oxidant that may 
enhance graft injury[243-246]. ONOO- catalyses membrane peroxidation and reacts 
to form toxic nitrosylating species. Studies suggest that NO can be either protective 
or toxic to lung grafts depending on dose, timing, duration of NO administration, the 
source of NO and the local re-dox environment and indicate that there is a narrow 
therapeutic window for NO in lung transplant IRI[247]. 
Eppinger et al. demonstrated in a rat lung model that the injury during the first 4 
hours of reperfusion is bimodal in pattern, with significant injury peaks occurring at 30 
minutes and 4 hours, with partial recovery after the 30-minute time point suggesting 
that the two peaks of injury are separate. This group went on to show that the 
delivery of inhaled NO at the start of reperfusion markedly worsened injury at 30 
minutes and that the increase in injury was due to an interaction with endogenously 
produced superoxide. Delaying the delivery of NO for 10 minutes, after the early 
burst of superoxide production had passed, eliminated the increase in injury. This 
group showed that at 4 hours of reperfusion the beneficial effects of inhaled NO 
could be seen with a reduction in lung vascular permeability. They found that the 
neutrophil accumulation in lungs at 4hrs reperfusion was less in the NO treated group 
than controls. NO is known to decrease the adhesive interactions between 
neutrophils and endothelial cells via their expression of the adhesion molecule 
CD11/CD18[201].  
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Our study identified significant differences in the expression of endothelial markers 
shed into perfusate between our sildenafil group and the historical control group. 
Higher levels of thrombomodulin, VE-cadherin and von Willebrand factor were 
detected in the control group. This postulates whether sildenafil has a protective 
effect on the vascular permeability.  
The pulmonary endothelium is formed from a monolayer of mesenchymal-derived 
squamous endothelial cells[192] connected by junctional proteins, forming a semi-
permeable barrier between the circulation and pulmonary interstitium. It prevents 
vascular leak by forming a physical barrier. When the integrity of this barrier is 
compromised, there is increased permeability and fluid shift out of the intravascular 
space. Junctional proteins are vital in maintaining the integrity of the endothelial 
barrier. Adherens junctions are the most populous junctional proteins in the 
endothelium and are predominantly vascular endothelial cadherin (VE-cadherin) 
based. VE-cadherin down-regulation and shedding is induced by thrombin 
presence[248] and oxidative stress[249] and is associated with pulmonary oedema 
formation and respiratory distress[250]. VE-cadherin loss has previously been 
demonstrated in areas where endothelial integrity has been comprised after cold 
ischaemia[251]. 
von Willebrand factor (vWF), a pro-thrombotic, is found in weibel-palade bodies in 
endothelial cells[252]. Activated pulmonary endothelial cells release vWF by two 
independent mechanisms calcium dependent in the presence of thrombin, or cAMP 
dependent in the presence of epinephrine or adenosine[253, 254]. Calcium-
dependent vWF release is activated in the presence of thrombin and results in 
GTPase Rho-associated microtubule dissolution and subsequent redistribution of 
actin and myosin into dense stress fibres. This causes endothelial cell retraction and 
reduced barrier integrity[255]. This process is rapid and can occur within 20 minutes 
of exposure to thrombin[253]. Once released, vWF attaches to platelets via platelet 
glycoprotein 1b, initiating platelet plug formation[252]. vWF increases leukocyte 
extravasation independently of leukocyte adhesion and rolling. This suggests vWF 
has a direct role in increasing endothelial permeability[252, 256], though this has not 
been demonstrated on pulmonary endothelium.  
Evidence on the clinical relevance of vWF release in pulmonary oedema is 
conflicting. Increased serum levels of vWF have been associated with acute lung 
injury and pulmonary oedema[257]. vWF serum levels are a poor prognostic indicator 
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for survival in acute lung injury[258]. Conversely, other work found no significant 
association between serum vWF, e-selectin or thrombomodulin and protein 
accumulation with the lung (a surrogate for pulmonary endothelial permeability)[259]. 
In lung transplantation, serum vWF in recipients was not associated with PGD[260]. 
As described above, thrombin is an oedematogenic agent.  When thrombin is co-
activated by thrombomodulin and endothelial protein kinase C (PKC) receptor from 
the surface of endothelial cells, there is activation and release of PKC, which cleaves 
activated clotting factors V and VIII[261].  
We did not see any significant difference in the staining of eNOS when comparing 
lung tissue at different time points during EVLP, in relation to when sildenafil was 
given. It was expected that eNOS would increase following the drug delivery. We did 
not take a sample immediately before delivery, and the pre biopsy was taken prior to 
EVLP commencing and therefore may only reflect the effect of perfusion itself. In 
future studies, it would be helpful to take a biopsy prior to commencing EVLP and 
immediately before drug delivery.  
It may be that the biopsy taken 30 minutes after drug delivery was too late to see an 
effect on eNOS and that an earlier 5-minute biopsy would be helpful. In future 
studies, it would be helpful to measure iNOS in relation to EVLP and the effect of 
Sildenafil.  
Naka et al. used a rat lung transplantation model showing that inhaled NO treatment 
during reperfusion improved function in only 4 of 12 grafts whereas addition of a 
cGMP analogue to the storage solution was uniformly beneficial[262]. They 
demonstrated that the addition of a membrane permeable cGMP analogue to the 
preservation solution resulted in the stabilsation of pulmonary haemodynamics after 
transplantation and attenuated graft neutrophil infiltration.  The authors concluded 
that the former treatment was more beneficial because it bypassed the reactive 
oxygen species step.  Injury in rat lungs undergoing 90 minutes of warm in situ 
ischemia was significantly worsened when inhaled NO was administered from the 
onset of reperfusion[263]. This effect was reversed by addition of superoxide 
dismutase or by delaying inhaled NO therapy for 10 minutes. The authors 
hypothesised that the interaction of NO with the burst of superoxide generated at 
reperfusion leads to the production of toxic peroxynitrite and hydroxyl radicals and 
may be responsible for these observations. 
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It is therefore believed that distal stimulation of the NO/cGMP pathway at the point of 
cGMP might confer the beneficial vascular effects of NO while avoiding its potential 
toxicities. Inhaled NO facilitates ventilation-perfusion matching as it is inhaled. By 
definition, vasodilation induced by inhaled NO occurs in areas that are being 
ventilated. In contrast, the distal simulation of the NO pathway with soluble mediators 
is independent of ventilation.  
The effects of stimulating the NO/ cGMP pathway at the point of cGMP have been 
investigated. Pinksy et al. showed that NO availability is sharply diminished after 
preservation and reperfusion of the lungs, resulting in a fall in tissue cGMP 
levels[221]. They investigated whether replenishing this intracellular second 
messenger would enhance graft vascular function. Using a rat lung transplant model 
with the addition of 8-Br-cGMP to the preservation solution used during reperfusion. 
Supplemental 8-Br-cGMP increased PA flow, increased P02 and decreased PVR. 
They concluded that augmenting the NO pathway at the level of cGMP provides a 
useful pharmacological approach to normalising vascular function in the early stages 
following pulmonary ischaemia.  
In addition to enhancing levels of cGMP that result in vasodilation and enhanced 
tissue oxygenation, cGMP is also known to facilitate other cellular processes through 
the activation of PKG. This is thought to promote protein phosphorylation, cell 
growth, and survival giving protection against cellular injury[206, 246]. Cyclic GMP is 
also known to inhibit platelet activation, to have anti-apoptotic properties, and to 
reduce production of reactive oxygen species[264]. 
Sandera et al. found that substitution of the NO pathway by administration of 8-Br- 
cGMP, a membrane permeable analogue of cGMP, the second messenger of NO at 
the time of reperfusion improves post-transplant lung allograft function[222].  
In recent years, there has been considerable interest in studying the effect of 
sildenafil and other PDE-5 inhibitors in protection against IRI[265, 266]. 
Das et al. demonstrated activation of protein kinase C could be one of the 
intracellular signal transduction pathways controlling sildenafil dependent cardiac 
protection in the rabbit heart[267]. A direct action of sildenafil on mitochondrial K-ATP 
channels has also been suggested to mediate the sildenafil-induced protection 
against ischemic injury.  
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Lui et al. studied the protective effect of the sildenafil on lung IRI[268]. They studied 
30 rats which were randomly divided into 3 groups of 10: a sham-operated group A, a 
lung ischemia-reperfusion injury group B, and a sildenafil preconditioned group C. 
Compared to group B, the lung wet/dry ratio, malondialdehyde content, 
myeloperoxidase and nitric oxide synthase activity in group C were significantly 
lower, while arterial PO2 and cGMP content in group C were significantly higher. 
They concluded that preconditioning with sildenafil prevented rat lung IRI and 
improved pulmonary function.  
Korom et al. demonstrated that restoring intracellular cGMP and inducing NO-
synthesis attenuates ischemia-associated early pulmonary allograft dysfunction[269]. 
They treated donor pigs with intravenous sildenafil injected directly into the PA before 
experimental lung transplantation. Pigs that received sildenafil had improved short-
term survival. This group concluded that by administering sildenafil during lung 
perfusion, storage and implantation, ischaemic tolerance may be extended and early 
graft function improved. 
Weiss and colleagues demonstrated that pre-treatment with the long-acting PDE-5 
inhibitor, tadalafil, could significantly reduce IRI in a rabbit lung transplantation model. 
This effect was attributed to the increasing tissue content of cGMP and the 
decreasing production of ROS[10]. 
Kiss et al. reported that in a rat pulmonary hypertension model, sildenafil suppressed 
multiple cytokines involved in neutrophil and mononuclear cells recruitment including 
cytokine-induced neutrophil chemoattractant (CINC)-1, CINC-2a/b, tissue inhibitor of 
metalloproteinase (TIMP)-1, interleukin (IL)-1a, lipopolysaccharide induced CXC 
chemokine (LIX), monokine induced by gamma interferon (MIG), macrophage 
inflammatory protein (MIP)-1a, and MIP-3[200]. They suggest a beneficial effect of 
sildenafil on inflammatory mechanisms that substantially contribute to its protective 
effects.  
Shih et al. demonstrated that pre-treatment with sildenafil reduced TNF-α and IL-6 
levels of lung tissue, concluding that sildenafil preconditioning improves lung 
inflammation in early reperfusion injury in a rat model[270]. 
The effect of sildenafil on attenuating ischaemia-reperfusion injury has also been 
demonstrated in other solid organ transplant models. Savvanis et al. evaluated the 
effect of sildenafil in a liver IRI rat model and tested the hypothesis that sildenafil 
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exerts a protective effect on the liver[271]. Serum markers of hepatocellular injury 
were significantly lower in the sildenafil group, which also exhibited lower severity of 
histopathological lesions, decreased scores of necrosis, attenuation of morphological 
liver injury, and anti apoptotic activity, as compared to the control group. The control 
group showed significantly higher leukocyte-endothelial interaction as evidenced by 
MPO activity and higher expression of ICAM-1, as compared to the sildenafil group.  
Lledo-Garcia et al. studied the protective effects of sildenafil on kidney grafts auto 
transplanted after 45 minutes of warm ischaemia by vascular clamping, nephrectomy 
and 60 minutes of isolated hypothermic pump perfusion. They found significantly 
higher renal vascular flow rates and lower renal vascular resistance in the sildenafil 
group.   
The use of sildenafil as a preconditioning agent predominates the evidence in 
treating ischaemic injury. There is evidence that sildenafil is capable of inducing a 
preconditioning-like effect in IRI of various tissues such as the heart, lung, kidney, 
and brain. Botha et al. investigated the use of sildenafil-mediated cardio protection in 
a rat model of heterotopic cardiac transplantation[272]. They concluded that sildenafil 
pre-treatment augments myocardial functional recovery after an ischemic time 
relevant to clinical cardiac transplantation. They linked this with protein kinase C 
activation/translocation and inhibited by 5-hydroxydecanoate. 
 Du Toit et al. reported that the pre administration of sildenafil increased NO levels by 
the stimulation and opening of mitochondrial K+ATP channels[273, 274].  
Kukreja and colleagues[204] reported a myocardial protective effect of sildenafil 
preconditioning. The mechanisms included the opening of the mitochondrial 
adenosine triphosphate-sensitive potassium channel, reducing the intercellular 
calcium overload, and improving endothelial function.  
Hillinger et al. demonstrated that 8-Br-cGMP (a membrane-permeable analogue of 
cGMP) when used as an additive to the flush solution, improves post-transplant lung 
oedema, lipid peroxidation, and neutrophil migration to the allograft[275].  Sildenafil 
as a potent vasodilator may improve the distribution of hypothermic flush solution. 
Pizanis et al. investigated the effect of adding sildenafil to the procurement procedure 
of porcine lungs[276]. They studied 3 groups which allowed for different application 
procedures to be investigated: a control group, a group flushed with Low Potassium 
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Dextran (LPD) with 0.15 mg/kg sildenafil added and a third group which were 
preconditioned with an intravenous bolus of 0.15 mg/kg of sildenafil into the 
pulmonary artery 20 minutes prior to the standard control LDP flush. The group which 
was preconditioned with the sildenafil IV bolus demonstrated lower PAP and PAP, 
superior oxygenation after 6 hours of reperfusion. 
This study has several limitations. The ex vivo reperfusion model allows us to study 
the effect of ischaemia reperfusion injury in the isolated lung pair without an 
immunologic host response. One potential drawback of EVLP, is that we are unable 
to study long-term effects. As we reperfused for less than 4 hours, the effects we 
have observed with PDE-5 inhibition may be short-lived, and the effects of this 
therapy in the longer term are unknown.  
A high dose of sildenafil was chosen for maximum effect and was administered at the 
onset of reperfusion. Adding therapies to the perfusate solution allows a high 
concentration of a drug to be administered without any adverse effects. We based 
our dosage regime on human dosing in the context of pulmonary hypertension and 
literature available, however we do not know whether a more optimal dose could 
have been used, whether an infusion strategy would have been better than a bolus 
dose, the timing of administration could have been improved and whether a bolus 
dose should have been repeated.  
It must be noted that the EVLP protocol used in this study differs from the protocols 
used in DEVELOP-UK, the historical cohort. It is not known what impact the 
differences between protocols, most importantly 40% versus 100% cardiac output, 
open versus closed left atrium and acellular versus cellular, had on the data 
interpretation. One may argue that the acellular study used in our study was 
somewhat less physiological than a cellular perfusate, although literature to support 
this is lacking.  
It is essential to recognise the length and variation in ischaemic times in our study 
cohort. This was a “real-time” research study which was subject to the logistical time 
constraints. In the first three EVLPs, the lungs had ischaemic times greater than 
twenty hours, and this will undoubtedly have an effect on lung function and 
performance. Although human donor lungs being made available for research are a 
scare and precious resource, moving forward into future studies, we would consider 
a twelve-hour ischaemic time to be an upper limit.  
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Animal models predominate the literature when investigating the role of sildenafil in 
attenuating IRI and our study aimed to provide a novel platform, in the context of 
human adult donor lungs. Animal models have certain limitations relating to species 
differences in susceptibility to ischemia-reperfusion injury, inflammatory responses, 
and gene regulation. Our study aimed to demonstrate the effects of sildenafil on 
human donor lungs in the context of EVLP.  
In conclusion, IRI remains a substantial cause of morbidity and mortality after lung 
transplantation. EVLP provides a platform for investigating the effect of novel 
therapeutics to protect and potentially recondition donor lungs. In this study, we have 
examined the effect of sildenafil, a PDE-5 inhibitor on pulmonary performance during 
EVLP and downstream immunological effects. We did not observe any improvements 
in lung physiology following sildenafil however in this group there were lower 
concentrations of endothelial markers in perfusate which could indicate a protective 
effect. Overall, our group concludes that more in-depth investigation should be 
conducted to explore the exact molecular and genetic mechanisms of the effects of 
sildenafil in human donor lungs on EVLP, as well as the feasibility and safety of its 
clinical application.  
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Chapter 6: Discussion  
The research contained within this thesis has been conducted as part of the NIHR 
BTRU-ODT collaboration, a unique strategic partnership between Newcastle and 
Cambridge Universities and NHS-BT. Since my project’s infancy, being part of such a 
structured framework has helped guide and steer project aims and objectives. From 
the outset of the project, there were three clearly defined overarching aims: to 
develop EVLP as a technique for the assessment of lungs turned down for 
transplantation; to identify potential biomarkers that will help us to understand the 
characteristics of human donor lungs and predict the success of EVLP and clinical 
outcomes and thirdly to use EVLP as a therapeutic platform to treat donor lungs.  
Starting my project at Newcastle University in October 2016 marked an important 
time in the timeline of EVLP research in the UK. The results of DEVELOP-UK had 
been recently published and involved all five UK NHS adult lung transplant centres. 
DEVELOP-UK aimed to compare survival during the first 12 months following lung 
transplantation between EVLP and standard groups. At the time of starting my 
project, DEVELOP had demonstrated that EVLP could be used to utilise donor lungs 
unsuitable for standard transplantation with a conversion rate to transplantation of 
18/53 (34%). The main trial outcomes can be summarised below:  
 The Kaplan-Meier estimate of survival at 12 months was 0.67 [95% 
confidence interval (CI) 0.40 to 0.83] for the EVLP arm and 0.80 (95% CI 0.74 
to 0.85) for the standard arm.  
 Patients in the EVLP arm were seen to require a longer period of ventilation 
and intensive therapy unit (ITU) length of stay, than patients in the standard 
arm, but the duration of overall hospital stay was similar in both groups.  
 These differences are most likely explained by the higher rate of early grade 3 
primary graft dysfunction (PGD) in the EVLP arm. Rates of PGD did not differ 
between groups after 72 hours. 
  The requirement for extracorporeal membrane oxygenation (ECMO) support 
was considerably higher in the EVLP arm (7/18, 38.8%) than in the standard 
arm (6/184, 3.2%).  
 DEVELOP-UK reported on the cost of EVLP transplants as approximately 
£35,000 higher than the cost of standard transplants.  
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DEVELOP-UK was a colossal body of work that was an achievement of the UK lung 
transplant community. A number of questions arose from its results, and several of 
these remain unanswered. DEVELOP-UK created a vast number of clinical samples 
which had been collected, processed and stored under the same protocol. This has 
created a unique biobank of EVLP specimens which hold the answers to many 
research questions. My project has benefitted from access to those samples, a 
unique resource.  
I have also benefitted from the local expertise, knowledge and existing equipment 
that followed the trial. DEVELOP-UK did highlight the substantial costs associated 
with EVLP, due to the expense of the equipment and consumables. One of the major 
priorities for my project was to develop a research EVLP model that had been scaled 
down on cost.  
My research project aimed to utilise the knowledge, experience and momentum that 
came from DEVELOP-UK whilst answering new research questions. To carry out this 
project, I used two main work streams. The first was the retrospective processing and 
analysis of DEVELOP-UK samples within my first year. This gave me an introduction 
to the protocols used in the trial and gave me my first experience of laboratory 
techniques such as ELISA. This retrospective work proved essential, given the 
delays that were encountered in finalising approvals for the BTRU lung project.  
Following final approval and training in porcine EVLP, we were able to accept human 
donor lungs which had been turned down for transplantation into the project. This 
prospective work has allowed for the study focussed on sildenafil as a novel 
therapeutic in EVLP. It has also generated a large bank of perfusate, BAL and lung 
tissue samples which are made available to other researchers via the Newcastle 
Institute of Transplantation Tissue Biobank.  
Over the course of this work, a robust, reproducible and cost-effective research 
EVLP model has been developed.  A porcine model was initially developed to 
provide education and hands-on training in dissection, suturing and circuit set-up. 
The porcine model also allowed for optimisation of assessment and sample collection 
protocols. Following the porcine work, we were able to accept human donor lungs 
which were deemed unsuitable for standard transplantation into our study. 
If EVLP is to realise its potential as an innovative platform for the assessment and 
treatment of donor lungs prior to transplantation, it is essential that the cellular and 
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molecular events that occur during EVLP are fully understood. Immune profiling in lung 
transplantation has previously relied on downstream protein production and cellular 
analysis. If the purpose of the biomarker discovery is to detect the onset of ischaemic 
injury before an uncontrollable immune activation takes place, then as a method of 
immune profiling, RNA-Seq transcriptomic analysis illuminates not only individual 
genes, but entire pathways and upstream regulators. RNA sequencing can provide a 
fuller picture of the underlying pathology and allow for identification of potential 
upstream targets to prevent injury before the onset of significant inflammation. Several 
investigators have shown that brain death and ischaemia-reperfusion injury have a 
significant impact on complex gene expression changes [37, 136, 137].  
In Chapter 3, we demonstrated that the process of EVLP itself induces a significant 
effect on the lung tissue transcriptome. This is novel information not previously 
discussed in the literature. Lung transcriptomics, as a method of assessing donor 
lungs that have undergone EVLP, has before now, not been described in the 
literature. Kang et al. used global gene expression profiling to identify differences 
between DBD and DCD donor lungs before transplantation and also analysed 
changes in the gene signature in lung tissue before and after transplantation[139]. 
Kang et al. reported that hundreds of genes and over 30 gene sets were significantly 
altered during transplantation. In our study, EVLP was associated with the significant 
upregulation of 297 and downregulation of 86 specific genes. Our study 
demonstrates that RNA sequencing can be used in the EVLP setting and adds to the 
existing knowledge of how the donor lung gene signature is altered during ex-vivo 
perfusion.  
We found that the gene pathway that was most significantly upregulated was TNFα 
Signalling via NFκB and that those donor lungs which performed poorly and went 
onto fail EVLP assessments had higher upregulation of IFN-γ and TNF-NFκB than 
lungs that passed. This supports the previous literature published by the Newcastle 
team, Andreasson et al. that perfusate IL-1β levels were strongly associated with 
early graft performance and could in the DEVELOP-UK multicentre study with high 
sensitivity and specificity predict both EVLP assessment failure and early post-
transplant mortality. Our study showed that inflammasome activation genes are 
enriched in pre-perfusion biopsies in “fail” lungs shows that in lungs that went on to 
fail, there was clearly upregulation of the IL-1β genetic signal prior to commencing 
perfusion.  
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Following this unbiased approach of identifying genes that were only upregulated in 
fail lungs with poor outcome, we found that there were 5 genes significantly 
upregulated in only fail lungs and that these genes corresponded to pro-inflammatory 
cytokines MIG and MIP-3β; the acute phase proteins PTX3, α1AGp and HSP-70. We 
then investigated the protein expression in perfusate for these specific pro-
inflammatory and tissue injury proteins of interest. We then compared the levels of 
cytokine expression between the clinical outcome and protocol groups to assess if we 
could determine any clinical correlations. 
Surprisingly, although there was a trend throughout all five protein markers of higher 
protein expression in the fail lung group compared with the pass lung group, no time-
points reached statistical significance. We had expected to see significant differences 
in the protein levels of interest between clinical outcome groups as had been 
observed with IL-1β and TNF-α[83].  
We demonstrated that there were higher levels of MIG and MIP-3β concentrations in 
the perfusates of lungs that underwent the Hybrid compared to the Lund EVLP 
protocol. Following DEVELOP-UK, questions had been answered about the impact of 
changing protocols during the trial. Our work shows that there are increased levels of 
these pro-inflammatory cytokines during Hybrid EVLP where a 40% flow rate, open 
left atrium and acellular protocol was used.  Further work is required to identify 
reasons for this, to establish if the higher levels of inflammation seen, are due to the 
open left atrium or the acellular perfusate.  No previous research has focussed on a 
head to head comparison of protocols in human EVLP, and given the significant 
investments from the Steen and Toronto groups in their EVLP machines and 
corresponding protocols, it is unlikely this will ever take place. Linacre et al. 
investigated whether maintaining a physiologic positive LA pressure during EVLP is 
protective to the porcine lung[87]. They reported that using a closed left atrium, 
creates a controlled positive LA during EVLP and leads to significantly less oedema 
and improved lung physiology compared to the open technique. It is likely that our 
findings will influence the protocols used for future EVLP studies. It is well 
documented in the literature that cardiopulmonary bypass and associated equipment, 
namely a pump, oxygenator and artificial plastic circuit can induce a systemic 
inflammatory response (SIRS) by causing cellular activation[277]. One may have 
thought that by having an acellular perfusate as in the Hybrid protocol that there 
would be less of this SIRS response than with a cellular perfusate.  
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We have demonstrated that important information about the donor lung gene 
signature can be deduced from lung tissue prior to commencing EVLP. We showed 
that the RNA counts in tissue taken before EVLP correlated with the concentrations 
of culprit pro-inflammatory cytokines measured in perfusate throughout the perfusion. 
Mapping out the genetic pathways that are upregulated during perfusion adds a new 
dimension to the way in which we could approach biomarker discovery and 
therapeutic targeting. It not only confirms what we may already know from BAL and 
perfusate samples but could also add new information about the molecular events 
occurring in the donor organ.  
Several studies have investigated the impact of donor cytokine levels on recipient 
outcome and demonstrated that there is a direct correlation between increased 
cytokine levels in BAL and perfusate with worsening lung function post 
transplantation[43, 157]. In our study, we demonstrated significantly higher levels of 
MIG and MIP-3β in donor lungs that had undergone EVLP with a Hybrid protocol. 
Both MIG and MIP-3β are chemokines with MIG attracting dendritic and antigen-B 
cells where MIP-3β is a known T-cell chemoattractant. Increased levels of these 
chemokines in donor lungs could result in a heightened recipient T-cell response, 
accumulation post-transplantation and potentially an increased risk of acute cellular 
rejection. It has been shown that depletion of donor immune cells from an organ prior 
to transplantation prevents rejection[278].  
EVLP offers a unique platform to study the effects of depleting donor immune cells 
and leukocytes. Stone et al. demonstrated that the early interactions between donor 
and recipient leukocytes are thought to play a critical role in long-term outcome 
following transplantation. They reported that EVLP-mediated donor leukocyte 
depletion impairs early recipient T cell priming without immunosuppression and 
represents a novel and exciting approach to tackling acute rejection[279]. 
My work on transcriptomics during EVLP has introduced the EVLP community to this 
method of assessing donor lungs and correlating the gene signature to clinical 
outcome. This assessment technique has provided new information about the 
genetic pathways that are induced during perfusion and has the potential to identify 
new therapeutic targets. Transcriptomic studies could be applied to any organ, and 
perfusion platform and comparisons could then be made in future. It would be 
interesting to compare the genetic pathways that are upregulated during lung 
perfusion versus perfusion of the kidneys and liver. It may be, that due to the lungs 
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dual circulation and the ability for alveoli to maintain a degree of oxygenation during 
the period of cold storage that there is an element of protection against the effects of 
hypoxia. It may be that with transcriptomic studies these differences could be 
recognised at a genetic level.  
In Chapter 4, we demonstrated that in extended criteria donor lungs which have been 
turned down for immediate transplantation, there are differential inflammatory and 
tissue injury marker profiles between DBD and DCD lungs. We found that IL-4, IL-6 
and IL-12 were significantly higher in tissue samples from DBD lungs but this was not 
reflected in the perfusate concentrations. We also found that IL-α and IL-1β were 
detected in significantly higher levels in the perfusate of DCD lungs at as early as 15 
minutes and throughout reperfusion. These observations demonstrate differences in 
the cytokine expression between DBD and DCD lungs and also in the compartment 
from which they are released.   
 
Literature comparing the differences between inflammation in DBD and DCD donor 
lungs at a cellular and molecular level is limited. Kang et al.[139] studied the differential 
gene expression profiles in lungs of DCD and DBD patients and interpreted the 
differences using functional pathway analysis. Analysis of gene expression profiles 
showed distinct activation of gene pathways between pre-transplant DBD and DCD 
human lungs. They found that there were 12 gene sets highly enriched in DBD but not 
DCD lungs. 
Our study generates important discussion about the impact of the type of donor on 
donor lung inflammatory burden. We postulate that in the DBD lungs, we missed an 
early peak of production of IL-1α and IL-1β and by the point of organ retrieval this had 
diminished. Instead, we have seen the rise in mediators, IL-4, IL-6 and IL-12 following 
the stimulation of the “early response cytokines” IL-1 and TNF-α. Whereas due to the 
lung insults such as warm ischaemia occurring much closer to the time of retrieval in 
DCD lungs higher levels of the early response cytokines were elevated. We suggest 
that events surrounding death upregulate the early response inflammation in DCD 
donors.  
Our work confirms what has been published by other groups with regards to 
significantly higher levels of IL-6 (p=0.001) being measured in pre-transplant samples 
in DBD compared with DCD lungs[139]. The results from this study are congruent with 
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the theory that DBD lungs carry a higher inflammatory burden due to the insult of brain 
stem death[19].  
This study provides insight into the potential molecular events in the period prior to 
retrieval and differences between the two donor groups. Improved knowledge on when 
and how fast brain death related processes occur and the sequence in which these 
events take place, will help us to understand the primary triggers of DBD-associated 
organ injury. A greater understanding of pre-donation events may inform the creation 
of donor management protocols tailored specifically to the DCD and DBD lung and 
evaluation strategies that identify organs suitable for transplantation. Further 
knowledge of the pathophysiological processes occurring in these groups may identify 
ways to improve donor management and possible therapeutic targets for improving 
outcomes in lung transplantation.  
It is important to highlight that our study did not investigate clinical outcomes in relation 
to the levels of inflammatory and tissue injury profiles. We can therefore not make any 
judgments about whether having higher levels of inflammation at the onset of EVLP 
led to any differences in outcome. Several studies have shown that DBD and DCD 
lung transplantation outcomes do not differ and emphasise that the DCD donor pool is 
an underutilised resource which if used can considerably increase the number of donor 
lungs available for transplantation[16, 145].  
Future studies into the differences between these two donor types are needed. It would 
be interesting to investigate if there are differences between the inflammatory profiles 
in the recipients of DBD versus DCD donor lungs, tested in serum and BAL.   
In theme 1 of the NIHR BTRU-ODT, led by Professors Chris Watson and John Dark, 
PhD student Poppy Aldam is carrying out important research focussing on improving 
the understanding of the physiology of donation after circulatory death (DCD). This 
research will report the physiological changes that occur during the dying process for 
patients having life support treatment withdrawn. This study will also investigate the 
inflammatory profiles measured in the DCD donor during the period leading to the 
withdrawal of treatment and retrieval. It will be important to compare that data with that 
already found in the EVLP setting to make some valuable conclusions about how 
timing impacts inflammatory burden. This period has not been subject to intense study 
and has the potential to have a significant impact on the number and quality of DCD 
organs donated. Research in the DCD population is limited by the sensitive nature of 
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the setting at which samples are required to be taken. It is vital therefore to gain as 
much understanding of pathological processed during DCD donation through means 
available, and EVLP offers a unique opportunity to study this cohort of donors.  
This thesis posed the question of whether there are differences in the inflammatory 
profiles of DBD and DCD lungs. It is only through improving our understanding of 
what is happening prior to donation at a cellular and molecular level can we then 
focus on ways to improve donor management. The lung transplant community is still 
learning about the DCD donor, and in many countries, there is still apprehension and 
reservation about utilising DCD donors. My research aims to generate discussion 
about DCD donation and demonstrating that through the use of EVLP there is much 
to be learnt about the biology of these two donor types. My work highlighted that the 
timing prior to the retrieval of organs might be relevant to the inflammatory insult 
within the organ.  
In Chapter 5 we demonstrated the use of EVLP as a platform for novel therapeutics 
in donor lungs. This is an ever growing area of interest and certainly using EVLP for 
drug therapies in donor lungs is not a new concept. We reported on the first study of 
sildenafil in the context of human EVLP. Several studies have suggested an 
important role for NO signalling pathways mediated by secondary messengers such 
as cGMP in the maintenance of vascular homeostasis and have been implicated in 
IRI. cGMP is an important signalling molecule that stimulates smooth muscle 
relaxation. Models of lung IRI have demonstrated that reduced levels of cGMP[193] 
after lung reperfusion have been associated with the development of pulmonary 
hypertension[194],reduced oxygenation,[195]and increased microvascular 
permeability[189]. PDE-5 inhibitors such as sildenafil prevent the breakdown of NO 
driven cGMP[196]. cGMP has regulatory roles that stimulate neutrophil 
degranulation, inhibit platelet aggregation, regulate intracellular calcium levels, and 
open the mitochondrial K+ATP channels[198, 199]. These mechanisms have a 
beneficial role in reducing the severity of IRI. Previous studies have reported that 
sildenafil can suppress multiple pro-inflammatory cytokines which play an important 
role in neutrophil and monocyte recruitment[200].  It has also been reported that 
through modulation of the NO/cGMP pathway, the interaction between neutrophils 
and endothelial cells via adhesion molecules can be attenuated[201].  
It was surprising that in our study, we did not see the expected changes in lung 
physiology, following the administration of sildenafil to the EVLP circuit. One must 
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consider the relatively normal pulmonary artery pressures of less than 20 mmHg that 
were recorded in our study lungs. It may be that sildenafil requires a certain threshold 
of pulmonary vasoconstriction and therefore pulmonary artery hypertension in order 
to exert its effect. Further studies administrating sildenafil at increasing pulmonary 
artery pressures may help to establish if this threshold exists. Another concern from 
our study is that there may be varying degrees of vasoconstriction and vasodilatation 
at different anatomical sites during EVLP depending on the amount of NO production 
within the vascular system. This could lead to an area of V/Q mismatch whereby 
metabolically active lung tissue which is being under-perfused and over-perfusion of 
metabolically inactive tissue with subsequent shunting, similar to what is seen in 
septic shock[280]. Pulmonary gas exchange is normally preserved and optimised by 
a physiological phenomenon called hypoxic pulmonary vasoconstriction which 
promotes perfusion to areas of ventilated lung instead of under-ventilated areas 
which are considered “physiological dead space”.  One might postulate that 
interruption with the NO pathway could lead to a disturbance in this pulmonary 
regulatory mechanism. 
When considering possible explanations for the lack of hypothesised effects we need 
to consider that the efficacy of sildenafil is dependent on the presence of sufficient 
amounts of endogenous NO to activate soluble guanylyl cyclase (sGC) and generate 
cGMP. Low endogenous NO/cGMP production significantly limits or impairs the 
effects of PDE-5 inhibitors. It could be postulated that endogenous NO levels were 
too low in the donor lung EVLP system for sildenafil to have its desired effects of 
reducing pulmonary artery pressure and pulmonary vascular resistance. Stimulators 
of sGC, such as riociguat could be an alternative therapy as this could increase 
cGMP, independently of NO. Chammaro et al. have reported that riociguat was more 
effective as a vasodilator in isolated rat and human PA than sildenafil[281]. Future 
studies could test the effect of riociguat in the EVLP model, and this could be tested 
next to a control and sildenafil group to compare the effects. Sildenafil has been 
investigated in other clinical areas such as the treatment of pre-eclampsia. Studies in 
this field provide evidence that the effects of sildenafil are independent of NO 
whereby the maternal and feto-placental protective effects with sildenafil treatment 
were not dependent on circulating NO and cGMP levels[282].  
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In future studies, it would be useful to investigate the effect of sildenafil in human 
lungs using a paired experimental model. This would involve paired right and left 
lungs acting as a control and intervention arm. Larger numbers than what was 
available for our study would be required to account for the variability between 
donors and often the individual lungs themselves due to single lung trauma or 
pathology.  
 
Any study focussed on the nitric oxide system needs to consider the delicate balance 
between the beneficial and potentially detrimental effects of this vascular homeostatic 
regulator. NO is generated by NO synthases (NOS) that catalyse the conversion of l-
arginine and O2 into l-citrulline in a complex reaction. There are three isoforms of 
NOS: the neuronal NOS (nNOS), the inducible NOS (iNOS) and the endothelial NOS 
(eNOS)[283]. Endothelial NOS (eNOS), is thought to be cell protective and can be 
found in vascular endothelium where is maintains vascular dilation and permeability. 
Inducible NOS is expressed by inflammatory cells such as neutrophils and 
macrophages and is induced by bacterial lipopolysaccharide, cytokines, and other 
agents. iNOS is constantly active once it is expressed and its regulation is 
independent of intracellular Ca2+ concentrations. The eNOS/iNOS balance may 
have important implications in vascular, pulmonary homeostasis and EVLP could act 
as a platform to study this interaction.  
In any future studies of sildenafil and its role in lung ischaemia reperfusion injury, it 
would be useful to investigate the baseline levels of iNOS and the changes observed 
during perfusion and following an intervention. RNA studies of iNOS and eNOS 
mRNA between pre and post EVLP samples would be interesting, as this has already 
been studied in the rat lung showing that 12 hours of cold preservation had no effect 
on iNOS mRNA expression, however, iNOS was increased significantly 2 hours after 
reperfusion [284, 285]. Increased iNOS expression has also been studied in the 
context of acute lung rejection following transplantation with higher NO production 
being described during the early phases of this severe complication[286, 287]. Worral 
et al. demonstrated in the rat model that inhibition of iNOS prevented impaired gas 
exchange function of the transplanted lung and attenuated the histological changes 
of acute rejection[288]. 
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It is known that overproduction of NO via iNOS and oxidative stress may lead to 
reactive oxygen and nitrogen species formation and vascular dysfunction during 
acute lung injury[289, 290]. Measuring the accumulation of the reactive nitrogen 
species, peroxynitrite via the marker nitrotyrosine could help determine the extent to 
which NO production could be contributing to alveolar capillary damage and 
increased pulmonary vascular permeability. Another area of interest is the concept of 
eNOS uncoupling which has been postulated to contribute to oxidative stress 
generation during lung IRI via a shift towards ROS production. A study by Gielis et al. 
reported that that eNOS uncoupling contributes significantly to pulmonary oxidative 
stress[291]. 
With EVLP it is possible to study the effects of time of administration of a potential 
therapeutic agent. A drug could be administered in the preservation solution with the 
organ flush as a pre-conditioning agent, given during perfusion at various time-points 
or given to the recipient following transplantation. This timing seems to be of 
importance when investigating the NO pathway and further studies could provide 
more clarity on this area of discussion.  
We did not experience the same findings that have been reported in a number of 
animal studies showing beneficial effects of sildenafil in donor lungs [198, 204, 206]. 
This highlights the importance of studies using human tissue in a “real-life” setting 
where the lungs and injury represent what is seen clinically. This study investigated 
lungs that had already been turned down for transplantation and therefore represent 
a very specific cohort of poor quality or very extended criteria donor lungs.  
This work emphasises that EVLP is a therapeutic platform by which a range of cell or 
drug therapies could be applied. There have been several studies focussing on EVLP 
as a therapeutic platform, and our study will add to this collection[82, 102-104, 111, 
292, 293].  EVLP offers a drug delivery platform that avoids systemic toxicity and 
administration via the inhaled or intravenous route. There is huge potential for this 
platform to be used in the future for the reconditioning and recovery of donor lungs 
where their function is sub-optimal.  
EVLP is now considered a valid clinical and research tool, with a vast, yet untapped 
potential to widen the donor pool. EVLP research has taken a new exciting direction 
towards investigating potential therapeutic agents that have immune modulating and 
reconditioning effects. One method of improving the utilisation of research donor lungs, 
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with regards to therapeutic testing, is to develop a Lobar-EVLP model. Our Newcastle 
group have been developing a Lobar EVLP which takes a lung pair, divides them into 
a right and left single lung and subsequent lobes, all of which are perfused as a 
separate system. There are numerous potential advantages to using such a lobar 
model over the whole EVLP system that we currently familiar. When using a lobar 
model as a therapeutic drug platform, multiple dosages of drugs, with only a fraction 
of the total dosage needed for the investigation can be used simultaneously. This both 
increases efficiency and reduces associated costs. This model also addresses inter-
individual variances which can affect datasets. Our experience in EVLP of human 
donor lungs deemed unsuitable for transplantation has been that there is considerable 
variation between each lung pair. Variation can be the result of several factors: the 
cause of death, type of donor (DBD versus DCD), length of ischaemic time and donor 
demographics including age, gender, smoking status and co-morbidities. The lobar 
model circumvents and controls these variables by allowing both the control and 
intervention lobes to be from the same individual. Upon validation of the porcine lobar 
EVLP model, our group has moved onto the development of a human lobar perfusion 
model and internally paired testing of novel therapeutics. To date, our group has 
carried out twelve porcine lobar perfusions and three human lobar perfusions. Moving 
forward, the lobar EVLP model will provide a therapeutic delivery platform which will 
be ideally placed to assess a vast range of donor lung interventions. 
In the last twenty years, EVLP technology has been transformed from an 
experimental method of assessing DCD lungs of unknown quality to a unique 
platform for the evaluation and reconditioning of donor lungs throughout clinical 
centres worldwide. This thesis joins the EVLP literature at a time where the EVLP 
technique itself has been well established and where the focus has been shifted 
towards utilising this platform for assessing donor lung function and treatment with a 
range of therapies.  
My work has demonstrated the importance of maximising the analysis and 
knowledge gained from hugely precious human samples. With each EVLP carried 
out during DEVELOP-UK and sildenafil study, a donor’s family had offered consent 
for samples to be collected and stored. It is vital that as a research team we are 
conducting responsible, sensitive and professional collection and handling of all 
human tissue. My studies have shown that further research questions can be 
answered well beyond the end of the original study period and that by following a 
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precise sampling protocol, the quality of samples does not need to be compromised. 
The samples from my studies will offer answers to future research questions and be 
utilised to aid other members of the BTRU group. I feel it is imperative that as much 
information is gained from each sample to respect the donor from which they 
belonged.  
Over the past two years, along with the BTRU lung perfusion group established a 
reliable and efficient EVLP model for research purposes. We have adapted 
equipment, optimised protocols and modified consumables to ensure a cost-efficient 
model moving forward. This EVLP model will act as the constant when moving into 
future therapeutic studies and we now have confidence in its ability and limitations. 
The sildenafil study has been important in highlighting potential pitfalls in a 
therapeutic study. It emphasised the importance of the experimental design and the 
variability that can be encountered in a human study. It also highlighted that as 
compared to an animal study, the number of experimental repeats is controlled 
externally and therefore project timeframes often need adjusting with a degree of 
flexibility.  
As with all areas of medicine, the future of diagnostics and therapeutics lies in 
personalised medicine. We are naïve to continue to think that “one size fits all” and 
our aim for the next 20 years of EVLP research should be to explore the lengths that 
we can go to in individualising each transplantation. From matching the donor to the 
recipient at a genetic level to assessing the quality of each donor lung pair at a 
cellular and molecular level to treating and reconditioning each lung depending on 
what therapies are required. We should be inspired by the pioneers of this field and 
change the way in which we think about transplantation. We should aspire to days 
where immunosuppression with toxic drug regimens are no longer required because 
the donor immunogenicity has been wiped out completely. We should aim for an era 
where no individual with end-stage lung disease is denied the opportunity to be 
transplanted.  
My work adds to the bank of studies carried out locally and has established a 
research model in Newcastle which will allow for EVLP studies to continue. It is 
important for Newcastle to remain a driver in this area and maintain the respected 
position it holds in this field.  
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One aim of our team is to create an organ perfusion hub for clinical and research 
purposes. A hub which would allow for perfusion spanning lungs, hearts, pancreas, 
kidneys and livers. Through centralising perfusion in a designated perfusion hub, a 
level of expertise would be advanced. In the future, organs deemed unsuitable for 
transplantation could be sent to the Perfusion Hub for evaluation and reconditioning. 
They could then be sent out to other centres for transplantation. A centre for 
excellence would be created by centralising all perfusion activity and developing the 
skills and knowledge of the local team.  
Regardless of the format by which EVLP research and clinical activity takes over the 
next ten years, it is essential that it continues. The overarching aim of the research I 
have carried out is to contribute to the work being done to increase the number of 
lungs available for transplantation. Although not a clinical study, I feel that by 
continuing EVLP research in Newcastle and by answering research questions an 
excitement and interest in this area has been renewed.  
With all research projects involving human tissue, there are hurdles and barriers to 
be encountered. I was naïve to these coming from a clinical background and lacking 
any previous experience in obtaining donor tissue for research studies. The time 
needed to navigate a project from its very beginnings to first recruitment should never 
be underestimated. Despite the bulk of ethical, R&D and RINTAG approval being 
secured by the time of my joining the team, we encountered unexpected delays in 
final approvals. We encountered a 9-month delay in commencing any prospective 
human studies which was understandably frustrating. These barriers are often 
avoided in other countries, for example in Scotland one HTA licence is required for all 
hospitals whereas in England each hospital must have its own licence for the 
removal of human tissue.  
With any project, there are limitations to carrying out the volume of work that was first 
proposed. In our initial proposal, we anticipated 40 human donor lungs to be obtained 
through the specific BRTU consenting by the Northern SNOD team. Within the period 
of study, specific consent led to donor lungs being removed for research purposes on 
one occasion. Generic consent, whereby the lungs had already been removed and 
were turned down for transplantation following removal, accounted for the majority of 
our research activity. It is clear that obtaining specific study consent can be achieved; 
however, the study was then reliant of the mobilisation of the cardiothoracic team 
(attending for the heart) and the donor proceeding for retrieval (often not possible in 
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DCD donors). These factors are out with the control of the research team and despite 
huge support from the Northern Specialist Nurses for Organ Donation (SNOD) team, 
National Organ Retrieval Service (NORS) NORS team, Research, Innovation and 
Novel Technologies Advisory Group (RINTAG), and NHS-BT these factors could not 
be overcome during this period. The research team acknowledged the difficulties 
facing recruitment early on within the project and steps were made in conjunction 
with both NHS-BT and RINTAG to expand into new sites both within the Northern 
region, but also the North West. It is estimated that by adding new sites within this 
region, an extra 70 donor lungs per annum would be available and eligible to be 
entered into the study.  
 
The most important consequence of obtaining lungs via generic consent only was the 
inevitable longer lengths of cold ischaemia. With donors via study specific consent, 
the lungs would be transported from an area up to 60 miles away from the perfusion 
lab, compared to 270 miles when donor lungs via generic consent. Length of cold 
ischaemic time undoubtedly affects the function of donor lungs, and this will need to 
be considered for future studies.  
During my research period, the EVLP perfusion lab was set-up at the Transplant 
Regenerative Medicine Facility at NHS-BT Donor Centre, Holland Drive Newcastle. 
All previous EVLP work, including EVLPs, carried out in Newcastle as part of 
DEVELOP-UK had been performed in the research laboratory in the Institute of 
Transplantation, Freeman Hospital. Moving all EVLP research out with a clinical 
location and environment had both benefits and barriers. The perfusion lab at NHS-
BT was essentially a blank canvas for which we could create the fit for purpose EVLP 
lab that was required. Following all necessary risk assessments and purchasing of 
consumables, it quickly became a space designed solely for the teams’ work. By 
moving from the clinical space at the Freeman, there was far less interruption from 
other research teams and less concern about how those other researchers may feel 
about the nature of our sensitive work with human organs. One downfall of being out 
with the hospital was losing the ability to call upon the expertise of the perfusionists, 
cardiothoracic surgeons and medical physics team whenever needed. We also took 
for granted the systems already in place in a hospital setting that allow for EVLP 
research to be carried out, for example, gas cylinder storage and piped oxygen and 
medical air. By moving to the facility at NHS-BT along with the kidney and pancreas 
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teams, we have been able to consolidate and streamline equipment, consumables 
and storage which should promote more efficient and cost effective ordering in future. 
EVLP research comes with an expensive price tag compared with many other 
projects being carried out locally. In Chapter 2 I laid out the costings breakdown, and 
this highlights that the cost is dictated by the expensive circuit disposables and the 
cost of perfusion fluid. We have developed ways to reduce costs by substituting 
elements of the circuit with cheaper alternatives and making “homemade” perfusate 
solution. There is no doubt that accurate costing will play a crucial part in planning 
any future EVLP research and grant application.  
A major hurdle during the course of my research has been the variability of the 
porcine lungs obtained from Thompsons Meat Ltd. By using lungs procured from pigs 
culled as part of the commercial food chain we gained access to a weekly supply of 
lung pairs that would otherwise be discarded by the meat trade. This gave us an 
important training resource that came from a free of charge, regular and dependable 
supply stream. Porcine lungs were used due to their similarity in physiology and 
organ development to humans. The major downfall with porcine lungs from this 
source was the poor quality and huge variability of the lungs week to week. There 
have been many learning points from repeated procurements at the abattoir. There 
were often lung contusions, lacerations and damage to the pleura visible on being 
presented the lungs; most likely due to the method by which the organs were 
removed from the pig. 
The lungs often showed gross, frank pulmonary oedema from the outset and it is 
thought that this was caused by shear stress from the removal of the lungs from the 
pig thoracic cage, leading to damage to the vasculature and loss of vascular integrity.  
Another problem with porcine abattoir procurements is the variability of the warm 
ischaemic times. Other groups have used the animal model for experimental EVLP 
work using a controlled Schedule 1 termination and utilising an anaesthetic and 
surgical team for procurement. This eliminates variability in procurement method and 
ischaemic times, however, comes at the cost of purchasing and housing animals for 
research. It also raises the ethical issue of culling animals for research versus using 
organs that would be otherwise discarded as part of the food chain. 
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Conclusions 
The major conclusions that can be drawn from the research performed in this thesis 
are as follows: 
1. RNA sequencing analysis is an effective tool that can be utilised to assess 
changes in the gene signature in human donor lungs during perfusion. 
Transcriptomics can be used to generate potential biomarkers that identify 
lungs suitable for transplantation following ex-vivo perfusion. There were more 
than 700 genes were differentially expressed pre- and post-EVLP, and many 
of these are involved in immunological processes. There are differences in the 
transcriptome between lungs that were considered to be transplantable and 
those that were declined in the baseline lung tissue samples obtained prior to 
EVLP. The TNF-α signalling via NFκB pathway is significantly upregulated in 
declined lungs.  
2. In extended criteria donor lungs which have been turned down for immediate 
transplantation, there are differential inflammatory and tissue injury marker 
profiles between DBD and DCD lungs. IL-4, IL-6 and IL-12 were significantly 
higher in tissue samples from DBD lungs. IL-α and IL-1β were detected in 
significantly higher levels in the perfusate of DCD lungs at as early as 15 
minutes and throughout reperfusion. This study also showed significant 
differences in the expression of angiogenic factors between DBD and DCD 
lungs with higher levels of Placental growth factor (PlGF) and soluble Fms-like 
tyrosine kinase receptor 1 (sFlt-1) expression in the perfusate of DBD 
compared with DCD lungs. 
3. EVLP is an effective platform for novel therapeutics aimed at the 
reconditioning of human donor lungs deemed unsuitable for transplantation. 
The vasodilatory agent sildenafil failed to improve lung physiology or attenuate 
pro-inflammatory cytokine expression when given during EVLP.  
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Implications and Future Directions 
The studies contained within this thesis do not stand in insolation and are part of the 
exciting work ongoing within the NIHR BTRU ODT. Below follows a brief summary of 
the major ongoing investigations outlining the future direction of our research: 
Using transcriptomics to generate biomarkers that identify kidneys suitable for 
transplantation following ex-vivo perfusion  
Chapter 3 of this thesis demonstrated the feasibility of using transcriptomics as a 
method for understanding the pro-inflammatory signal from the perfused donor lung 
and investigating potential predictive biomarkers of EVLP performance and post-
transplantation outcomes.  Similar studies are being carried out by Dr Menna 
Clatworthy and Dr John Ferdinand using samples from EVNP of the kidneys. These 
studies will highlight the major differences and similarities between the genetic 
alterations taking place during lung and kidney perfusion.   
Modelling leukocyte-endothelial interactions in ex-vivo organ perfusion  
In a BTRU sponsored PhD project from our group, PhD student Mr Tom Pither, aims 
to further our understanding of the relationship between leukocyte activity and organ 
endothelial status post-perfusion. 
The project at this point has two major aims:  
1. To investigate the microvascular endothelial cells from lung and kidney and 
their response to activation by IL-1β. His work will focus on the microfluidic 
flow assay, Cellix to quantify neutrophil adhesion, rolling, and transmigration to 
the endothelial monolayer when activated with interleukin-1β, as well as 
assessing subsequent extent of neutrophil activation.  
2. Ex-vivo modelling of endothelial/neutrophil interactions, observing the 
migration of labelled neutrophils through sections of lung and kidney tissue 
from animals and human donors in response to IL-1β stimulation and its 
targeted inhibition.  
EVLP is currently being utilised as a platform for studying and investigating leukocyte 
behaviour, activity and final destination when added to perfusate. Tom has been 
successful in demonstrating the adhesion of labelled neutrophils using 
immunofluorescence microscopy and graphically representing the number of labelled 
cells in perfusate across a time course of perfusion. Recent results show that the initial 
infusion of neutrophils into the circulating perfusate results in a spike in cells counted, 
 179 
 
and as expected, the majority of binding can be seen to occur within the first 5 minutes 
of neutrophil infusion. This is then followed by a dramatic fall in the number of 
circulating cells over the following 5 minutes of perfusion. This decrease continues until 
around 20 minutes of perfusion, whereby a plateau is reached with numbers remaining 
relatively static until perfusion is ceased after 120 minutes. This follows the expected 
dynamics of neutrophil adhesion and provides a clear and obvious mechanism which 
can potentially be modulated by the addition of therapeutics. 
Future studies of leukocyte-endothelial interactions in ex-vivo organ perfusion will 
utilise the lobar EVLP model and focus on testing potential therapeutics. Previous 
studies by our group, have demonstrated that perfusate IL-1β levels were strongly 
associated with early graft performance and could in the DEVELOP-UK multicentre 
study, with high sensitivity and specificity, diagnose both EVLP assessment failure 
and early post-transplant mortality[83]. Andreasson et al. demonstrated that by 
inhibiting the action of IL-1β, using an IL-1RA or more potently an IL-1β neutralising 
antibody, both the upregulation of key endothelial surface adhesion molecules and 
neutrophil adhesion to pulmonary endothelial cells could be significantly reduced in-
vitro. Future work will move to using a lobar EVLP model to investigate the effects of 
therapeutic inhibition of IL-1 during EVLP, using the anti-IL-1 receptor antagonist 
Anakinra (Kineret, Swedish Orphan Biovitrum, Stockholm, Sweden). 
 
The use of cell-based therapy in ex vivo reconditioning of lungs prior to 
transplantation  
EVLP allows for perfusion over a prolonged period of time, and this offers a unique 
platform for administering pharmaceuticals, gene and cellular therapies that can 
repair lungs and target the prevention of PGD before transplantation occurs. Human 
Amniotic Epithelial Cells (hAECs) have recently attracted attention in the field of 
regenerative medicine as potential cell therapy, due to their multipotent ability, anti-
inflammatory functions and low immunogenicity[294]. These cells can be isolated 
from the human term placenta following elective caesarean(C)-sections, which would 
usually have been discarded. Human amniotic epithelial cells or their conditioned 
media have the potential to recondition human lungs during ELVP by reducing 
pulmonary vascular endothelial activation and limiting the leukocyte-endothelial 
interactions after organ reperfusion.  
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In a BTRU sponsored PhD project from our group, PhD student Chelsea Griffiths 
aims to:  
1. Establish a robust hAEC isolation technique, fully characterise the isolated cells 
and collect conditioned media. 
2. Investigate the anti-inflammatory and immunomodulatory properties that hAECs  
have on leukocyte-endothelial interactions.  
3. Evaluate the biological and physiological effects of hAECs or their conditioned 
media have on human lungs during EVLP.  
A Near Point of Care Cytokine Test - Evalution™ 
My predecessor Mr Anders Andreasson had established a collaboration with a 
Belgian company to evaluate the feasibility of using their Evalution™ biomarker 
assay platform (MyCartis, Zwijnaarde, Belgium)[295]. One of the obstacles in the 
standard EVLP assessment is the time before a decision on transplant suitability can 
be made, currently around four hours. For any biomarker technology to have real 
impact and clinical relevance it has to be highly accurate and able to deliver a result 
available to the clinical team at the time of decision-making. The previous work on 
predictive biomarkers has been based on MSD, and ELISA techniques which 
although highly sensitive are limited by them both utilising passive binding between 
antigen and antibodies, and therefore requiring incubation times of at least 3-5 hours. 
This is adequate for retrospective analyses, but not applicable for clinical use.  
MyCartis has carried out preliminary feasibility studies focussing on interleukin-1β 
assays. The assay uses the “co-flow” principle of simultaneous incubation of sample, 
detection antibody and reporter molecule to reduce the manual interventions to a few 
pipetting steps, and reduces the assay time to approximately 30 minutes. Further on-
going collaboration involves analysis of perfusate samples from our sildenafil cohort 
with corresponding MSD data available. Further validation of their assay is required, 
and they plan to send a ready-to-use assays and assay kits to Newcastle.  
 
Mitochondrial biology of lungs undergoing ex vivo lung perfusion 
There will be future collaboration with the mitochondrial biology cross-cutting BTRU 
theme, led by Dr Mike Murphy and PhD student Anja Gruszczyk. Utilising EVLP 
perfusate and lung tissue samples future studies will investigate the role of 
mitochondrial oxidative damage in ischaemia reperfusion injury that inevitably 
accompanies organ transplantation[296]. Following on from work on EVNP of 
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kidneys[297], future studies will focus on the protection against mitochondrial 
oxidative damage in the lungs by the mitochondria-targeted anti-oxidant Mitoquinone 
or MitoQ™. Future collaborative work will involve investigating the role of succinate 
accumulation in lungs during storage and subsequent damage on reperfusion.  
Summary 
Lung transplantation can be a life changing procedure for selected patients with end-
stage lung disease. It is, however, currently limited by low donor and poor donor lung 
utilisation rates.  EVLP demonstrates promise as a method to better evaluate lungs 
during the ex vivo phase of transplantation.  Moreover, drug delivery to lungs during 
EVLP offers new therapeutic potential with the ambition of reconditioning lungs 
initially turned down for transplantation. There is huge scope for EVLP’s potential for 
reconditioning lungs in the future as EVLP offers a unique platform tailored to this 
clinical and investigative work, aiming to find novel ways to increase the donor pool 
and to make lung transplantation a reality for more waiting list patients with life 
threatening lung disease. The next chapter in the history of EVLP is an exciting and 
ambitious one with future goals focussed on the development of specialised national 
organ perfusion centres to facilitate ex vivo perfusion of organs; the reconditioning of 
ex vivo organs with cell and regenerative therapies and personalised medicine 
whereby donor lungs are somehow programmed for each individual recipient. It 
would the naïve and foolish to consider EVLP as the only method of increasing the 
donor lung utilisation rate as this will continue to be dependent on a number of 
important factors.  There will continue to be an ongoing drive to increase the number 
of people registered on organ donor registries worldwide, with the impact of the “opt 
out” schemes eagerly anticipated. Donor management within intensive care units is 
an important area of ongoing research along with the utilisation of DCD donor lungs. 
The next 20 years poses huge potential to better our understanding of the 
fundamental pathophysiology of ischaemia reperfusion injury and investigating 
therapeutic targets. This ongoing research is vital to those patients waiting on the 
lung transplant waiting list becoming more unwell as time passes and to patients 
following lung transplantation who suffer primary graft dysfunction with its associated 
morbidity and mortality.  
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Medtronic EVLP circuit design  
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APPENDIX C 
- 
EVLP costings 
Total cost per EVLP £4668 
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Consumable Supplier Catalogue Number Amount per isolation (g/ml/item) Cost per EVLP (£) 
Perfusion     
Lung perfusion Set up kit Medtronic 444426C 1 680 
Steen solution XVIVO PERFUSION 19004 2500 3504 
Cannulae XVIVO PERFUSION 19022 3 266 
Scalpel no10 Brosch Direct NS1010 2 0.55 
Suture 4.0 prolene Medisave SKU:W8020T 2 6.324167 
Prolene 5.0 Suture Medisave SKU:W8010T 2 7.3575 
Ventilation     
Ventilation Tubing Intersurgical 1528000 2 3.9 
Ventilation Y piece Intersurgical 190000 1 1.813333 
Ventilator Catheter Mount Intersurgical 3508000 1 0.7 
Ventilator Filters Teleflex 19402T 1 0.42 
Suction tubing Medisave ASP010/SET 1 0.446 
Medical Air size J BOC 191-J 0.25 4.64 
Oxygen Size W BOC 1-W 0.5 2.38 
Special Mixed Gas CO2/N2 (7% CO2) BOC 152295-L-C 0.5 72.585 
Sample collection     
ISTAT cartridges  CG4+ Abbot Laboratories 03P8525 15 63 
50ml Luer Lock Syringe Brosch Direct NS3666 1 0.462 
Woven Swabs Brosch Direct DW6412 4 0.022667 
Sterile Containers 30ml SLS CON7502 4 1.09 
Syringe 10ml Luer lock Medisave SKU:SYR912 15 2.2485 
Needle 21gage Green Terumo Medisave SKU:8N-2138R 15 0.3525 
Cryobox Starlab E2383-5004 1 7.573333 
20ml syringe BD plastipack Medisave SKU:SYR213 7 0.874417 
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APPENDIX D 
- 
Study logistics flowchart
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APPENDIX E 
- 
DEVELOP-UK EVLP standard operating 
procedure 
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DEVELOP-UK EVLP Set- SOP  
Location 
EVLP was performed in an operating theatre, a suitably designated clinical area 
that fulfils the necessary infection control precautions.  
Equipment 
• Vivoline LS1 evaluation unit: An integrated roller pump (Jostra), heater 
cooler unit, gas system, monitor and control unit with associated software 
package.  
• Vivoline LS1 disposable lung set: Includes an oxygenator (Capiox), LDF 
leukocyte filter, pressure sensors and temperature probes. 
• 93% Nitrogen and 7% CO2 gas mixture cylinder on a trolley:  A full 
cylinder contains 10000 litres and each EVLP run requires at least 2000 litres 
of gas mixture (3 hours).  
• Oxygen supply:  From the wall outlet. 
• ICU standard ventilator: Model that measures minute and tidal volumes, lung 
compliance / resistance and airway pressure. 
• Arterial blood gas machine. 
• Standard thoracic surgical instrument tray. 
• Sterilised bronchoscope: With suction tubing and lavage traps, 5, 10 and 
20ml syringes. 
• Sample collection disposables: Includes Duet-stapler devices for lung 
biopsies, specimen pots for tissue, test tubes for perfusate and ice bucket or 
refrigerator for sample storage. 
Medications 
• Saline 0.9%: 240 ml for 2xBAL and additional 100 ml for flushing pressure 
transducers. 
• Steen Solution: At least 4 x 500 ml bottles. 
• Packed Red Blood Cells: Request 3 packs of red blood cells from the blood 
bank, either universal donor (O negative) if >1 potential recipient identified or 
cross matched to the single known recipient.  
• THAM/TRIS solution: Use a preparation containing Trometamol 3.0 mmol/ml 
in a quantity as directed by base deficit to a Base Excess +/- 3 and pH of 7.35 
– 7.45  
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• THAM is available in various dilutions (ranging from 3.6% (Abbott, Köhler) to 
36.5% (Braun) or 40% (Fresenius-Kabi or Addex-THAM) so caution is advised 
in measuring the correct amount. A 3.6% solution of THAM contains a 
concentration of Trometamol (active ingredient) of 0.33mmol/ml. A 40% 
solution of THAM contains a concentration of Trometamol (active ingredient) 
of 3.0mmol/ml. When buffering Steen solution in the circuit use 3mmol of 
THAM per minus unit in base deficit. This will be 1ml per minus unit base 
deficit for the 40% THAM preparations and 10ml per minus unit base deficit if 
the 3.6% THAM preparation is used. A THAM preparation of between 3.0 – 
3.3 mmol/ml is strongly recommended and use of lower concentrations 
strongly discouraged due to the dilutional effects on Steen Solution of adding 
large volumes of a lower concentration THAM. 
• Heparin: 10,000IU unfractionated. 
• Methylprednisolone: 500mg. 
• Antibiotics: Meropenem 500mg is the default antibiotic if there is no 
documented recipient allergy to ß-lactams. If donor airway cultures known, 
other antibiotics can be used after discussion with microbiology. 
• Amphotericin B: 10 mg for injection (Amphocin, Fungizone or equivalent). 
• Actrapid Insulin and 10% Glucose Solution: Possible requirement for 10ml 
of 10% Glucose solution and 20 IU Actrapid Insulin but not routinely used. 
Priming the Circuit 
• Connect the disposable kit to the evaluation unit according to user manual 
instructions.  
• Flush the pressure transducers. 
• Connect the water to the heater-cooler unit, open the water bag. 
• Start the priming phase on the screen. Check the oxygenator for leakage. 
• Calibrate the pressure transducers. 
• Fill the system with 2.0L Steen solution (4 x 500ml bottles). 
• Calibrate the pump occlusion by following the screen instructions.  
• Recirculate perfusate at 15°C set flow to 2.0 L/minute and maximum perfusion 
pressure at 10 mmHg.  
• Connect the gases. 
• Add 10,000IU of unfractionated Heparin to circulating Steen solution. 
• Add 1-2 units of Packed Red Blood Cells.  
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• Prepare 500mg dose of Methylprednisolone.  
• Make up Antibiotics and Amphotericin B according to manufacturers’ 
instructions. 
• Add Methylprednisolone, Antibiotics and Amphotericin B to the circulating 
perfusate. 
• Do a perfusate blood gas analysis and correct the base deficit with THAM to a 
Base Excess +/- 3 and pH of 7.35 – 7.45. Add 3 mmol THAM per minus unit in 
base deficit. The blood gas needs to be temperature corrected for 15oC. 
• Note haematocrit of perfusate on blood gas. Target is 10-15% so add more 
red cells if needed.  
• Check perfusate glucose and potassium concentration via blood gas analysis; 
if glucose <5 or >20 mmol or potassium >7mmol correct with Insulin. 
• Repeat the perfusate gas prior to connecting the lung for any further 
corrections. 
• The perfusate, pharmaceuticals and gases should be circulated for ≥15 
minutes before connecting the lung.  
• If satisfactory, start the reconditioning phase. 
 
Reconditioning Phase 
• Surgical dissection is performed to allow placement of the donor lung onto the 
Vivoline EVLP circuit in the covered organ bath to maintain humidity. 
• Before connecting the lung to the circuit, take Lung Biopsy #1 from the RML 
or Lingula and collect Perfusate Sample P0 (See separate Sample collection 
SOP). 
• Cannulate the main pulmonary artery with the quick-fix pre-fashioned cannula 
and open the shunt to the inflow cannula. 
• The left atrium is left open and visualised to ensure a smooth flow of 
perfusate. 
• The LA temperature probe and sampling line is secured in place equal 
distance from the 4 pulmonary veins. 
• Where possible the trachea remains clamped with lungs partially inflated with 
50% FiO2 while the quick-fix ventilation tube is secured in place. This prevents 
collapse of the lungs and development of atelectasis prior to the ventilation. 
• Set the pulmonary artery (PA) pressure to a maximum of 15 mmHg. 
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• Perform de-airing of the circuit with the shunt open at a flow of 0.5L / minute 
for approximately 2 minutes until fully de-aired. Leave the shunt open. 
• Set temperature to 32oC. The system will warm up the lung automatically with 
a maximum delta temperature of less than 8°C. 
• If initial perfusion is uneventful, increase the PA pressure limit to 20 mmHg 
and flow to maximum.  
The recommended max flow is 70 ml/kg IBW /minute. With a cold lung the 
pressure will limit the flow, when the resistance in the lung goes down the flow 
will increase over time. 
• When temperature has reached 25oC close the shunt.  
• At 32oC remove the clamp on the trachea and before commencing ventilation, 
perform a bronchoscopy and collect BAL sample #1 from either RLL or LLL 
using 120 ml 0.9% NaCl with the bronchoscope in a wedged position (See 
separate Sample collection SOP). 
• Commence mechanical volume-controlled ventilation at 32oC with a protective 
ventilation strategy:  
• Set inspired oxygen (FiO2) to 0.5 (50%)  
• Set respiratory rate (RR) initially to 5 or 8 breaths/min according to 
donor IBW 
• The ideal body weight calculation formulae used to determine the tidal 
volumes in protective lung ventilation are: 
IBW (kg) for men = [(height (cm) -154) x 0.9] + 50  
IBW (kg) for women = [(height (cm) -154) x 0.9] + 45.5 
• Set Minute volume (mV) initially to 1 L/min 
• Set PEEP at 5 cmH2O  
• Set I:E ratio 1:2 and inspiratory pause at 10% 
• Keep peak airway pressure <20 cmH2O 
• Increase temperature from 32oC to 37oC. 
• Increase the mV in 1 L/min increments gradually as lung warms to 37oC; mV 
should not exceed 1.5X the flow. Continue to keep peak airway pressure 
(Paw) < 20 cmH2O. Increase the RR, as mV increases, up to a maximum of 
15 breaths/min to keep tidal volume <7ml/kg IBW. 
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• At 32°C the perfusate flow is usually lower than the set value, please note the 
flow as the lungs warm to 37°C as the minute volume should not exceed 
1.5X the flow.  
• If uneventful and once 37°C reached, mV can be increased gradually up to a 
maximum of 100 ml/kg IBW/ min but the tidal volume should not exceed 7 
ml/kg IBW.  
• If persistent atelectasis present, perform a recruitment manoeuvre by 
transiently increasing PEEP from 5 cm H2O in increments of 1 cm H2O for a 
few breaths to a max of 12 cm H2O while always keeping Paw <25 cm H2O. 
Note flow will fall significantly during increase in PEEP. After recruitment return 
PEEP to 5 cm H2O. 
• Flow, PVR, Lung Compliance and PA pressure to be documented once lungs 
reach 37°C and flow stabilised. 
• After lungs have reached 37°C and flow and ventilation stabilised, shift to the 
evaluation phase.  
Evaluation Phase 
• Once re-warming is complete and target perfusion established, the function of 
the donor lungs undergoing EVLP can be assessed as specified in the study 
protocol. 
• Disconnect the oxygen from the perfusion system prior to evaluation. 
• Once the perfusate is deoxygenated and confirmed on blood gas analysis, 
perform recruitment manoeuvres as above and set the ventilator for evaluation 
as below: 
• Increase FiO2 via the ventilator from 50% to 100%.  
• PEEP can be increased to 8 cm H2O for a short period. 
• Maximum mV should not exceed 100 ml/kg/min (donor IBW)  
• Keep peak airway pressure Paw <25 cm H2O  
• RR can be adjusted between 12 and 15 breaths/min to maintain VT up to a 
maximum of 7 ml/kg (donor IBW) 
• Perform blood gas analysis 15 minutes after FiO2 is increased to 100% to 
assess venous and arterial pO2 values. Blood gas analyses should be 
performed from each pulmonary vein as well as a mixed LA sample. 
• Flow, PVR, Lung Compliance and PA pressure should be carefully 
documented on the data sheets.  
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• Perform a lung deflation test by disconnecting the tracheal tube at the end of 
inspiration. Remember to first reduce perfusate flow to maximum of 
1.5L/min to avoid alveolar oedema. Recoil of the lungs is evaluated 
subjectively; global collapse of the lungs is defined as normal. 
• If transplant suitability criteria have been achieved, move immediately to 
cooling phase for organ preservation. 
• If transplant suitability criteria have not been achieved, return to the 
reconditioning phase. 
• Perform hourly clinical assessments as documented in the protocol until a 
decision on suitability of the lungs for transplantation or 240 minutes of EVLP 
perfusion has been reached (from the time of reaching 37°C). 
• During perfusion if pH <7.35 administer additional THAM to the Steen 
Solution™.  
• During perfusion do not automatically replace Steen Solution™.  
 
Cooling Phase 
• Reduce mV by a 30% reduction in tidal volume and lowering respiratory rate 
to 8 breaths/min 
• Set temperature to 32°C 
• Reconnect the oxygen to the perfusate. 
• Before discontinuing ventilation, perform a bronchoscopy and collect BAL 
sample #2 from the same lobe, but from a different segment than BAL sample 
#1, using 120 ml 0.9% NaCl with the bronchoscope in a wedged position (See 
separate Sample collection SOP). 
• Stop ventilation at 32°C, clamp trachea with lungs partially inflated with 50% 
FiO2.  
• Set temperature to 12°C and continue to cool lungs until perfusate 
temperature 12°C. 
• Collect Perfusate Sample PX. 
• Disconnect PA cannula and plug PA with special bung. 
• Once perfusion has stopped and the lung is disconnected, take Lung Biopsy 
#2 from the same lobe as Lung Biopsy #1 (See separate Sample collection 
SOP). 
• Commence topical cooling. 
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• Place mat under lungs and wrap towels over lungs so that they touch the mat 
all around lungs. 
• Connect the Y shaped hose from the cooling assembly to the lung perfusion 
quick connection and cover the highest point of each lung. 
• Connect the remaining hose from the cooling assembly to the shunt quick 
connection and place over the trachea and PA.  
• In the preservation phase set pump to 2.5 L/ min. Check fluid level and add 
more Steen Solution if necessary. 
• Maintain the lungs in topical Steen solution at 6 - 8 °C on the circuit 
(preservation phase) until ready for transplant. 
Adaption for Single Lung Reconditioning 
 For cannulation, if feasible staple the contralateral PA (right PA if it is a left 
lung transplant or vice versa) at least 2 cm above its first branch to facilitate as 
much length as possible. If the pulmonary artery is too short and/or the 
surgeon is unable to fit the quick-fix pre-fashioned cannula, use a part of the 
donor’s aorta to augment the cuff. 
 For connection of the bronchus, please note there are 3 sizes of connection 
available in the disposable kit to aid achieving an effective connection. If it is a 
right lung EVLP, staple the left main bronchus at the level of the carina and 
cannulate the trachea. If it is a left lung EVLP, the left main bronchus from the 
level of the carina should be long enough to facilitate attachment. Ensure a 
seal that prevents either ineffective ventilation of fluid entering the airway. 
 Set to 50% target flow i.e. 35 ml/kg body weight/minute. 
 When starting ventilation, start at a minute volume of 0.5 L/min and increase 
to a maximum of 1.5 times the perfusate flow. 
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Protocol for alternative STEEEN Solution  
List of equipment/consumables needed:  
 Fisher Glass Bottles – 2 litre capacity  
 Scales  
 Funnel  
 Filter paper  
 Sterile filters  
 Labels 
 Dextran 40 BioChemica from VWR international cat ref #A2249.0500 
 Bovine Serum Albumin Insight Biotechnology catalogue numbers: sc-2323A 
 Sodium Bicarbonate Sol. 7.5% Sigma Aldrich S8761 
 Calcium Chloride Dihydrate Sigma Aldrich 000020 C7902  
 Krebs-Henseleit Buffer with 2000 mg/L Glucose, Without Calcium Chloride 
and Sodium Bicarbonate Product Number Sigma Aldrich K3753 
To make 2 litres of stock:  
1. Fill Glass Jar (2 litre capacity) to 1800 ml with distilled water, and then mix in 2 
bottles of powdered Krebs Buffer. 
2.  Mix gently on magnetic stirrer plate until liquid clear and no visible fragments 
3. Add 56 ml of 7.5% Sodium Bicarbonate Solution 
4. Add 10 g of Dextran 40 (0.5% concentration) 
5. Add 140 g of BSA (7% concentration) 
6. Top up to 2 litres with distilled water  
7. Mix on magnetic plate  
8. Add Calcium Chloride  
9. Filter through filter paper into sterile jar  
10. Label with “Homemade Steen”, date and initials  
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 Constituents of Alternative Perfusate Solution 
 Mol 
weight 
(g/mol) 
Stock 
conc 
(mmol/L) 
Weight 
(g) into 
stock 
Vol 
stock 
(L) 
Conc 
req 
(mmol/L) 
Vol 
stock 
(ml) for 
1L 
Steen 
Dry 
weight 
to add 
(g) 
NaCl 58.44 1560 182.33 2 114 73 0 
NaHCO3 84.01 250 42.01 2 25 100 0 
KCl 74.55 92 13.72 2 4.6 50 0 
NaH2PO4 137.99 120 16.56 1 1.2 10 0 
MgCl2 203.3 120 24.4 1 1.2 10 0 
CaCl2 147.02 30 8.82 2 1.5 50 0 
Glucose 180.16 NA NA NA 11 NA 1.9818 
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APPENDIX G 
- 
ELISA protocol 
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Solid Phase Sandwich ELISA protocol  
1. Coating with Capture  
1a. Dilute the Capture Antibody in PBS 1:100 
1b. Add 25μl/well of the diluted Capture Antibody. 96-well microplates (R&D 
systems) were coated with capture antibody/PBS (1:100) 
1c. Seal the plate and incubate overnight at Room Temperature on a rocker.  
2. Blocking  
2a. Wash all plates using the ThermoScientific Washer primed with Buffer A – 
1000 ml Distilled Water with 5 tablets of PBS and 0.5 ml Tween)  
2b. Add 150 μl/well of Reagent Diluent (1% BSA and PBS – 100 ml: 1g BSA + 
100 ml PBS)  
2c. Seal the plates and incubate at room temperature on the rocker for 2 
hours.  
3. Standard and Sample preparation  
3a. Defrost from -80°C freezer aliquoted Eppendorf’s of the appropriate standard 
for marker kit   
3b. Prepare standard in Reagent Diluent 1:100 
3c. Take sample transfer plates from -80°C freezer and defrost on ice  
3d. Wash all plates  
3e. Add 25 μl/well of samples and standards in duplicate.  
3f. Seal the plates and incubate at room temperature on a rocker for 2 hours. 
4. Detection  
4a. Dilute the Detection Antibody (defrost aliquoted Eppendorf’s for 
appropriate kit from -80°C freezer) in Reagent Diluent 1:100. 
4b. Wash all plates  
4c. Add 25μl/well of the diluted Detection Antibody.  
4d. Seal the plates and incubate at room temperature on the rocker for 2 
hours. 
5. Streptavidin-HRP  
5a. Dilute Streptavidin-HRP in Reagent Diluent 1:40 
5b. Wash all plates  
5c. Add 25μl/well of the diluted Streptavidin-HRP.  
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5d. Seal the plates and incubate at room temperature, in the cupboard, 
avoiding direct light, no rocker, for 20 minutes only.  
6. Substrate Solution  
6a. Prepare Substrate Solution (stored at 4°C) at a ratio of 1:1 of Substrate A: 
Substrate B 
6b. Wash all plates  
6c. Add 25μl/well of Substrate Solution.  
6d. Incubate at room temperature, in the cupboard, avoiding direct light, no 
rocker, for a maximum period of 20 minutes.  
6e. Observe standard columns and samples for yellow colour change. 
Observe for dynamic changes and variation. Ensure standards show 
progressive colour change.  
7. Stop Solution  
7a. Do not wash plates at this step 
7b. Make up Stop Solution (pre-prepared 1M H2 SO4. 26.7ml H2 S04 + 473.3 
ml H20) 
7c. Add 25μl/well of Stop Solution. Gently tap the plate to ensure thorough 
mixing.  
7d. By adding Stop Solution there will be a second colour change to blue.  
8. The absorbance was read on the plates using a microplate reader set to 
450nm. 
9. Mean optical densities were corrected for background signals using blank 
wells as controls then divided by the gradient the standard curve and 
multiplied by the dilution factor to give an estimate of protein volume. 
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- 
Immunohistochemistry protocol 
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Immunohistochemistry protocol  
 Pre heat sections to 60°C for 1 hour. 
 De wax in xylene for 2 x 5 minutes. 
 Re hydrate through graded alcohols: 1 minute each 99% IMS, 99% IMS, 95% 
IMS 
 Block endogenous peroxidase in 0.3% Hydrogen peroxide in Methanol for 30 
minutes. 
 Wash well for at least 10 minutes in gently running tap water. 
Antigen retrieval: 
eNOS 
 Place 600 ml Retrieval buffer in a white plastic bucket with vented lid, bring to 
boiling point. 
 Using forceps carefully add the rack of slides to the boiling buffer, replace lid 
and return container to the microwave oven. 
 Set the power control on MAX, set timer and press start 
 At the end of the time period, remove from microwave and allow to cool for 15 
minutes. 
 Remove the rack of slides and transfer to Tris Buffered Solution (TBS) 
Neutrophil Elastase (NE) 
 Antigen retrieval using trypsin (pH7.6) – use water bath at 37.5°C for 20 
minutes 
Antibody steps: 
eNOS 
 Dilute the primary antibody to final concentration 1:50 
 In a bioassay incubating tray containing moist tissue, apply 100μl of diluted 
antibody to the appropriate section. 
 Incubate for optimised time period - room temperature for 1 hour and then 
overnight at 4°C, in the fridge for 18hours. 
Neutrophil Elastase (NE) 
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 Dilute the primary antibody to final concentration 1:100 
 In a bioassay incubating tray containing moist tissue, apply 100μl of diluted 
antibody to the appropriate section. 
 Incubate for optimised time period - room temperature for 90 minutes 
To finish:  
 Use wash bottle to gently rinse the slides in TBS. Place in a metal rack in a 
staining trough containing 300 ml fresh TBS. Wash gently for 5 minutes. 
 Repeat wash in TBS 5 minutes 
 Remove excess buffer but do not allow section to dry out and apply 100 μl of 
the secondary antibody and incubate for 30 minutes at room temperature. 
 Gently rinse slides with TBS and place in a trough of 300 ml of TBS. Wash 5 
minutes. 
 Gently remove excess buffer and treat sections with DAB 5-10 minutes. Mix 
Dako Buffer (K4010) 1 ml/1 drop DAB concentrate well immediately before 
use. 
 Wash sections in running tap water. 
 Counterstain with Carrazzi’s Haematoxylin for 1 minute. Wash gently in tap 
water until blue. 
 Dehydrate through 95%IMS, 99% IMS, 99% IMS for 1 minute each 
 Clear sections in xylene 
 Mount in DPX/Perfex 
 Read on microscope 
 
 
 
 
 
 
 
 
